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Denys-Drash syndrome, which is characterised by genitourinary
abnormalities, a type of progressive nephropathy known as mesangial sclerosis and
the development ofWilms' tumours, results from mutations in the zinc finger-coding
region of one copy of the WT1 gene. Murine ES cells from the CGR8 line with DDS-
type mutations in both Wtl alleles (compound heterozygotes) were produced by gene
targeting and their properties compared with wild-type and DDS heterozygous cells.
To distinguish between effects of the Wtl mutations and of alterations elsewhere in
the genome, cells of the E14 ES cell line and their DDS heterozygous and
homozygous derivatives were also studied. While attempting to characterise the
mutant cells in terms of RNA and protein expression, it was discovered that
undifferentiated ES cells do not express Wtl. To enable the detection ofmutant and
wild-type Wtl RNA transcripts and proteins, a previously published method of ES
cell differentiation using all trans-retinoic acid was adapted to optimise Wtl
expression. Examination of Wtl expression levels in differentiated cells of the
different DDS genotypes revealed a reduction in the level of mutant protein in the
DDS heterozygotes and compound heterozygotes compared with that predicted from
the relative levels ofRNA transcripts.
Embryoid bodies were produced using cells of the above genotypes. Some of
these were grown in suspension, others were allowed to attach to the surface of a
flask and form outgrowths. A comparison of these embryoid bodies revealed no
obvious differences between the differentiation capabilities of wild-type and DDS
mutant ES cells. As abnormalites of Wtl have been found in leukaemia, including
expression of DDS-type mutations, more embryoid bodies were produced, and their
potential to differentiate along haematopoietic lineages was assessed using the CFU-
A assay. This revealed a delay in the production of haematopoietic cells in Wtl
mutant embryoid bodies relative to those produced from wild-type cells, which was
consistent between the two cell lines examined. Further evidence for this delay was
obtained by the examination of the expression patterns of several genes known to be
involved in haematopoiesis, using RT-PCR.
X
To try to identify possible transcriptional targets of the WT1 protein, a
comparison of gene expression in retinoic acid-differentiated wild-type and DDS
mutant ES cells was performed using expression macro-arrays. Many genes were
seen to be expressed at significantly different levels in wild-type and mutant cells,
and several of these results were found to be consistent between the CGR8 and El4
cell lines. The differential expression in mutant and wild-type cells of some of these
genes was confirmed using RT-PCR analysis. Cyclin Gl, heat shock protein 90 alpha
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Gene targeting is the introduction of planned alterations into the genome by
homologous recombination of DNA sequences residing in the chromosome with
newly introduced DNA sequences (Thomas and Capecchi, 1987). Techniques
developed in recent years have enabled researchers to mutate genes of interest in this
way and introduce these mutations into mice. Analysis of the phenotypes of these
mice has provided insight into the biological roles of a number ofgenes.
In 1981, embryonic stem (ES) cells were first derived from the inner cell
mass of a mouse blastocyst (Martin, 1981, Evans and Kaufman, 1981). These
resemble teratocarcinoma cell lines in that they can be cultured in an undifferentiated
state indefinitely. When ES cells are reintroduced to a blastocyst, they can contribute
to germline, as well as somatic, tissues (Bradley et al., 1984).
At the same time, it was shown that homologous recombination could be used
to target mutations into mammalian cells. In 1987, mutations were first targeted into
ES cells (Thomas and Capecchi, 1987), and such mutations were passed through the
germline in 1989 (Thompson et al., 1989). ES cells are useful in gene targeting for a
number of reasons. Not only are they easy to culture and manipulate by homologous
recombination in vitro, but they are amenable to a range of selection and screening
techniques (Bronson and Smithies, 1994).
The most common strategies for targeted mutagenesis use vectors containing
a selectable marker gene, for example neomycin phosphotransferase (neor), which
confers resistance to geneticin (G418). This is used to disrupt the gene of interest in
a targeting vector in vitro. There are two main types of targeting vector, insertion and
replacement vectors (Bronson and Smithies, 1994). Insertion (O-type) vectors lead to
the duplication of regions of homology contained in the vector. Replacement (Q-
type) vectors insert in place of the DNA segment contained within the regions of
homology. These are used for simple gene disruptions (see figure 1.1).
Use of a selectable marker gene enables identification of cells containing the
targeting vector, but in the majority of these, the vector will have inserted by non¬
homologous recombination at random positions in the genome. A positive-negative
selection procedure can be used to enrich for targeted events. Mansour et al. (1988)
described a 2000-fold enrichment for targeted cells, using neor and the Herpes
simplex virus thymidine kinase gene (HSV-tk), but more recent studies have obtained
enrichment in the range 2-20 fold (Hooper, 1992). When the vector replaces the
endogenous sequence by homologous recombination, the HSV-tk gene will not be
transferred. Positive selection for cells containing the vector is by addition of G418.
Cells expressing HSV-tk, the ones that contain the vector at a non-homologous site,
will be killed by the addition of gancyclovir, thus enriching for targeted cells.
Presence of the targeted vector is confirmed using PCR and/or Southern analysis.
Efficiency of homologous recombination can be increased by increasing the
length of the region of homology between the vector and target sequences (Thomas
and Capecchi, 1987), and also by using an isogenic vector, derived from the same
mouse strain as the ES cells (te Riele et al., 1992). This may increase the targeting
efficiency enough to dispense with the use ofpositive-negative selection.
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Many germline mutations have been generated which produce a null mutation
in the gene of interest. Methods to generate more subtle mutations have been
developed, which are useful to increase knowledge of gene function, for example,
mutations to determine the function of specific domains within a protein, mutations
in sequences controlling gene expression, or mutations mimicking those found in
clinical disorders of interest.
The use of selectable marker genes to disrupt the target gene is a limitation, as
this gene must be active, and so may affect the mutant phenotype in some way. 'Hit
and run' (Hasty et al., 1991) and 'in-out' strategies (Valancius and Smithies, 1991)
are similar methods to introduce specific sequence changes to genes without insertion
of a selectable marker gene. These involve selection against the marker gene to retain
cells out of which the vector has recombined, leaving subtle mutations behind (see
figure 1.2). The Cre-lox system uses the bacteriophage PI enzyme Cre, a member of
a family of recombinases (Rajewsky et al., 1996). Cre recognises a 34bp sequence
called loxP and will excise a DNA segment flanked by two loxP sites, leaving just
one of the loxP sites behind. (Cre will invert a DNA sequence if it is flanked by loxP
sites in opposite orientations). A selectable marker gene can be flanked by loxP sites,
then removed after selection, by transient transfection of Cre-expression vector into
the cell. This system can be used to produce deletions, gene replacements, insertions
and point mutations. It also means that once the original marker has been removed,
the second allele can be targeted using the same vector.
The Cre-lox system can also be used for conditional (cell-type specific or
inducible) gene targeting. This allows the development of models of somatically
acquired genetic diseases. If a region of the gene of interest is flanked by loxP sites,







Homologous recombination between vector and
genomic sequences
( ▼ indicates position of slight mutation to be
added.)
Selection for neo shows presence of vector.
Gene conversion, or branch migration plus
heteroduplex repair, leading to interchanging
of copies, results in either two wildtype or
two mutant copies.
Selection against HSVtk enriches for cells without
the vector, which have undergone intrachromosomal
homologous recombination between the repeated
segments. This either reverses the original insertion,
or may excise the wildtype sequence, retaining the
mutant sequence.
The result is a gene containing no selectable
marker, that differs from the wildtype only in the
slight mutation.
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this portion of the gene can be deleted in specific cell-types or developmental stages
by the induction of Cre recombinase at the appropriate developmental stage or cell
type.
Chimaeric mice made by introduction of targeted ES cells into a blastocyst
are useful to study the fate of mutant cells in different lineages, and therefore the
importance of the gene of interest in development of a particular lineage. The use of
chimaeras to study gene function during embryogenesis and postnatal development
can have several advantages over constitutional homozygotes or heterozygotes.
'Chimaeric rescue' approaches enable the effects of embryonic lethal mutations to be
studied in later development, as rescue by wild-type cells allows development to
proceed. In chimaeras consisting ofmutant and wild-type cells, competition between
the two cell types can be studied, also whether a mutation acts in a cell-autonomous
manner, by determining in which cell types the mutation is required in order to
produce a given phenotype. Such studies on the Rb gene (Maandag et al., 1994,
Williams et al., 1994) and the Pax6 gene (Quinn et al., 1996) have revealed the
inability ofmutant cells to contribute to tissues in which cell autonomous expression
of the particular gene is required during development.
Recessive mutations can often be more effectively studied by creating ES
cells which are homozygous for the targeted sequence. There are two main ways of
achieving this. Cells can be retargeted using a second vector similar to the first, but
containing a different selectable marker, for example a hygromycin resistance gene
instead ofneo'.
Alternatively, if an increased concentration of G418 is added, many of the
survivors will be cells that contain two copies of neor, in other words, have become
6
homozygous for the mutation. This is believed to occur through either chromosome
loss followed by duplication, or mitotic recombination (Mortensen et al., 1992).
Although high G418 selection is much simpler, as it does not involve the
construction of a second targeting vector, a drawback is that the duplication of either
the maternal or paternal allele may be accompanied by homozygosity over a
substantial chromosome segment, which may in itself produce a phenotype in a gene
where imprinting is involved.
1.2 Kidney and Genital System Development
The kidney is the major excretory and osmoregulatory homeostatic organ in
the mammalian body. The mammalian kidney develops from the intermediate
mesoderm via three successive structures, the pronephros, mesonephros and
metanephros (Saxen, 1987).
The first stage of kidney development is the formation of the Wolffian duct,
followed by induction of the pronephric tubules from the nephrogenic cord by the
Wolffian duct which occurs at embryonic day 22 in humans, E8 in the mouse. The
pronephros is transient, and has no function in mammals. The mesonephroi are
induced by the Wolffian duct around embryonic day 22 in humans, E9.5 in the
mouse.
The ureteric bud forms as an outgrowth of the Wolffian duct, and reciprocal
inductive interactions occur between this and the metanephric mesenchyme, during
week 5/ Ell (see figure 1.3a). This leads to branching of the ureteric bud and
7








e) elongation 2 f) maturation
Figure 1.3 Development of the metanephros (from Williamson and Van
Heyningen, 1994)
a. Induction U- ureteric bud, M= metanephric mesenchyme
b. Condensation B= metanephric blastema
c. Vesiculation RV= renal vesicle
d. Elongation 1 C/S= comma-/s-shaped body
e. Elongation 2 GB= glomeruloid body
f. Maturation G= glomerulus, PT= proximal tubule, DT= distal tubule
condensation of the mesenchyme into metanephric blastema at the end of each branch
(week 5/ E11.5)(figure 1.3b). The metanephric blastema then differentiates into renal
vesicles (figure 1.3c), which become comma- and s-shaped bodies (week 7/ E13)
(figure 1.3d) then glomeruloid bodies (figure 1.3e) as intermediates in the formation
of the mature glomerulus (figure 1.3f). The glomeruli contain mesangial cells and
podocytes, which are needed in the mature kidney to maintain glomerular pressure
and the flow of filtrate through the kidney.
Gonadal structures develop from the mesonephroi and gonadal ridges. Cells
from the degenerating mesonephroi migrate to the gonadal ridge, forming primary
sex cords with the germinal epithelium. Primordial germ cells migrate to the gonadal
ridge at week 6/E12.
In the male, the Wolffian duct develops into the epididymis, vas deferens and
seminal vesicle, with the mesonephric structures incorporated into the testis and other
genital tissues. The male genital system is maintained by Leydig and Sertoli cells in
the testis. The Mullerian duct in the female forms the fallopian tubes, uterus and
upper vagina, with the Wolffian duct and most of the mesonephros degenerating. The
remaining mesonephros contributes to the developing ovaries, along with the
coelomic epithelium. Granulosa cells in the ovary are responsible for maintenance of
the ova. The renal and gonadal systems appear to be far more independent of one
another in the female than in the male.
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1.3 Haematopoiesis and development of the haematopoietic system
The cells of the haematopoietic system consist of three populations,
multipotent haematopoietic stem cells (HSCs), committed progenitor cells, and cells
which are mature or maturing.
HSCs are extremely rare, believed to occur at a frequency of 1 per 105
nucleated cells in adult murine bone marrow. When haematopoiesis is at a normal,
steady state, the vast majority of HSCs are believed to be metabolically inactive, in
Go, with only a few clones responsible for the day to day maintenance of the blood
cell population by clonogenic expansion (Lajtha, 1979). The blood system consists of
eight cell lineages: platelets, lymphocytes, erythrocytes, macrophages, neutrophils,
eosinophils, basophils and mast cells (figure 1.4). These must be replaced by the
HSCs throughout an animal's life, as they have finite life-spans. The assay for the
ability of HSCs to achieve long-term repopulation of the haematopoietic system is
carried out by using the cells to repopulate the haematopoietic system of a lethally
irradiated animal (Moore and Metcalf, 1970).
There are two main models for the commitment and self-renewal of HSCs.
One sees these as stochastic processes, with very little input from external regulators,
such as cytokines, until cells are already committed to a particular lineage or lineages
(Ogawa, 1993a). The other is deterministic, with the haematopoietic
microenvironment influencing not only the proliferation and survival of committed
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Figure 1.4 The hierarchy of haematopoietic development
Representation of development of the different blood cell lineages from the
pluripotent haematopoietic stem cell. Development occurs via intermediate
progenitor stages, with cells becoming progressively more differentiated reading
down the diagram, until the final, fully differentiated progeny.
Also represented on the diagram are the various cytokines believed to be
involved in each stage of the differentiation process.
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The immediate progeny of HSCs are called haematopoietic progenitors, or
lineage-restricted/committed progenitors. It has been demonstrated that multipotential
haematopoietic cells activate several different lineage-specific gene expression
programmes simultaneously before lineage commitment actually occurs (Hu et al.,
1997). These have more limited potential for further differentiation, and undergo
much clonal expansion. The differentiation process from progenitors to mature,
terminally-differentiated cells is seen as an irreversible descending hierarchy of
differentiation. Cytokines have been demonstrated in vitro to be necessary for
survival and proliferation ofprogenitor cells (Han and Caen, 1994).
All haematopoietic cells, including HSCs, are highly influenced by the
haematopoietic microenvironment. The bone marrow contains a network of stromal
cells, consisting of endothelial cells, macrophages, adipocytes, fibroblasts and
extracellular matrix proteins such as collagen, laminin and fibronectin (Lichtman,
1981). The close physical and developmental association between haematopoietic
and endothelial lineages within the bone marrow and, earlier, in the yolk sac blood
islands, and their common mesodermal origin has led to the suggestion that they arise
from a common precursor, which has been named the haemangioblast (Choi et al,
1998).
Non-haematopoietic cells have a role in the regulation of proliferation and
maturation of haematopoietic cells via both cell-cell contact and secreted molecules
(Clark et al., 1992). Both adhesion proteins and membrane-bound cytokines are
involved in binding haematopoietic cells to stromal cells (Ohneda and Bautch, 1997).
The cells of the haematopoietic microenvironment are the major source of
predominantly stimulatory (eg. GM-CSF, G-CSF, M-CSF, SCF, IL-3) and inhibitory
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(eg. TNF-a, TGF-P, IFN, MlPla) cytokines. It is a complex equilibrium of these
factors within the haematopoietic microenvironment that controls haematopoiesis,
including stem cell self-renewal, proliferation, commitment, differentiation and
maturation, in a manner that is responsive to changing conditions. Cytokines have
been shown to prevent cells from undergoing death by apoptosis (Koury, 1992).
Colony stimulating factors induce clonal proliferation and differentiation.
They are characterised by the different types of colonies they induce bone marrow
cells to form in assays. Cytokines have pleiotrophic activity, and will work at more
than one stage of differentiation, or in more than one lineage. Generally, cytokines
acting at later stages of development are more lineage-specific than those acting
earlier. For example, erythropoietin is responsible for the maintenance and control of
erythropoiesis (Spivak, 1989) and M-CSF only acts in specific macrophage/monocyte
lineages (Bajorin et al., 1991). Cytokines such as IL-6, IL-3, SCF and GM-CSF are
relatively non-specific (Rapoport et al., 1992; Williams et al., 1990).
Cytokines bind to glycoprotein receptors on the cell surface, activating a
signal-transduction pathway which ends with a haematopoietic transcription factor in
the cell nucleus. It is suggested that a hierarchical relationship exists among
haematopoietic transcription factors (Orkin, 1995), with some, relatively non¬
specific, acting early in differentiation pathways, eg. SCL/tal-1, Rbtn 2, and others
acting later, in a more specific manner, eg. GATA-1, Ikaros, Pu.l. GATA-2 and c-
myb are believed to act on HSCs and early haematopoietic progenitors (Tsai et al.,
1994; Weston, 1990). In general, most haematopoietic transcription factors seem to
act on several different lineages, and it is the combination of transcription factors
activated that characterises the lineage (Ness and Engel, 1994). Particular
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transcription factors may also play more than one role within a specific lineage, for
example, GATA-1 has been found to be responsible for suppressing apoptosis in red
cell precursors, as well as regulating the genes that define the erythroid phenotype
(Weiss and Orkin, 1995). The first haematopoietic activity is seen at day 7 of murine
development. This consists of the differentiation of extraembryonic mesodermal yolk
sac cells into primitive erythrocytes (Moore and Metcalf, 1970). At midgestation,
haematopoietic activity is found in the foetal liver (E9), thymus (El0.5) and spleen
(El5), and does not occur in the bone marrow until just prior to birth (Johnson and
Moore, 1975). Movement of the site of haematopoietic activity from the yolk sac to
the intraembryonic tissue is not solely due to migration ofHSCs from the yolk sac, as
haematopoietic cells arise independently in both sets of tissues (Godin et al., 1993;
Medvinsky etal., 1993).
Formation of the yolk sac from extraembryonic endodermal and mesodermal
derivatives begins around E6.5. Primitive nucleated erythrocytes aggregate in blood
islands with endothelial cells from day 7 (Tavassoli, 1991). Evidence for a common
precursor to the endothelial and blood cell lineages in blood islands comes from
mouse knockouts (Shalaby et al., 1995; 1997).
The primitive haematopoiesis occurring in the yolk sac produces a limited
range of blood cell types, confined to erythrocytes and a small proportion of
macrophages (Gordon et al., 1992). The erythrocytes present differ from those
produced in definitive haematopoiesis in that they are larger, remain nucleated, and
express embryonic, rather than adult, haemoglobins.
Formation of the liver begins at late E9, and definitive haematopoiesis is
established within it by day 10.5 (Johnson and Jones, 1973). This definitive
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haematopoiesis does not actually originate in the liver, but comes from colonising
cells via the circulation. The modified model for mammalian haematopoiesis
(Dzierzak and Medvinsky, 1995) postulates that colonisation of the foetal liver
happens as two separate waves. The first wave comes from the yolk sac at around
day 9, and consists of CFU-C (colony-forming unit-culture) cells, that are already
committed. The second wave, at day 10, comes from the AGM region (adjacent to
the dorsal Aorta, Gonads and Mesonephros) (Godin et al. 1993; Medvinsky et al.,
1993), and contains primitive CFU-S (see below) and long-term repopulating HSCs.
This forms a stable population of definitive HSCs, which replaces the
extraembiyonically-derived progenitors (Zon, 1995).
Definitive haematopoiesis, which begins in the yolk sac (Palis et al., 1999),
then continues in the foetal liver and bone marrow, produces cells of all
haematopoietic lineages, with nucleated erythrocytes containing adult globins. The
cells responsible for definitive haematopoiesis originate from the dorsal mesoderm of
the AGM region, although blood cells from the yolk sac have been shown to be
capable of reconstituting the haematopoietic system of lethally-irradiated mice
(Moore and Metcalf, 1970; Toles et al., 1989).
The liver never entirely loses its potential for haematopoiesis, and can regain
this activity in an emergency, but its haematopoietic activity declines after birth.
Colonisation of the thymus by haematopoietic precursors occurs from day 10.5, but
this activity again declines around birth (Moore and Owen, 1967). Haematopoiesis in
the spleen begins at day 15 and continues until a few weeks post-natal. In mice, the
spleen continues to be the site of eiythropoiesis. Lymphoid cells are first seen after
the development of the thymus and spleen.
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The CFU-S assay is used to measure the haematopoietic potential of cells
(Till and McCulloch, 1961). The cells are injected into lethally-irradiated recipient
mice, and macroscopic colonies on the surface of the spleen are counted 8-15 days
later. CFU-S cells themselves, although fairly immature, are not HSCs (Jones et al.,
1990). At mouse E10, CFU-S activity is found in both the dorsal aorta and urogenital
ridges (Medvinsky et al., 1996).
The bone marrow is the last part of the haematopoietic system to be colonised
by haematopoietic precursors, at day 16 (Ogawa et al., 1988). Although responsible
for the production of all haematopoietic lineages in adult life, the bone marrow does
not gain full haematopoietic potential until after birth, and before that is limited to
granulopoiesis (Tavassoli, 1991).
1.4Wilms' tumour
Wilms' tumour (WT) is also known as nephroblastoma. It is one of the most
common solid tumours of childhood, with an incidence of 1 in 10,000, and was first
described in 1899 by Max Wilms. 90% of affected individuals are under the age of
seven years (Greenwood et al., 1984).
WTs are derived from the metanephric blastema (Machin et al., 1984), and
classically display "triphasic" histology, which means that they consist of persistent
blastemal cells (undifferentiated), dysplastic tubules (epithelial elements) and
supporting stroma. These are found in different proportions and reflect phases of
normal kidney development, suggesting that tumour development may be due to an
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abnormal differentiation program. WTs may also contain focal areas ofmesodermal
derivatives, such as smooth/striated muscle, adipose tissue, cartilage or bone (Coppes
et al., 1993a).
Most cases of Wilms' are unilateral and sporadic, but bilateral and familial
cases also occur. 3% of WT cases present with genitourinary abnormalities
(Williamson and van Heyningen 1994), often as part of a recognised clinical
syndrome, such as WAGR (Wilms' tumour, Aniridia, Genitourinary malformations
and mental Retardation) or Denys-Drash syndrome.
In 1971, Knudson published his two-hit model of tumorigenesis, based on his
study of retinoblastoma, another childhood tumour. He observed that the age-
dependence of diagnosis of bilateral retinoblastoma was consistent with the
hypothesis that a single somatic event was required for tumour onset, while that for
unilateral retinoblastoma fitted a model in which two somatic events were required.
In 1973, Comings hypothesised that these two events were affecting a single gene in
retinoblastoma.
Knudson and Strong (1972) found a similar result from a statistical analysis
ofWT cases, supporting a two-hit model. The isolation of the WT1 gene in 1990 and
its loss in many WTs suggested that the two hits required are loss or mutation of both
alleles of WT1. However, as described below, the situation is more complex than in
retinoblastoma.
The WT1 gene was located in 1990 by three different groups. The region
1 lpl3 was associated with WT through deletions found in WAGR syndrome. Call et
al. (1990) and Bonetta et al. (1990) constructed a cosmid and a YAC library
respectively and isolated fragments missing in sporadic tumours containing small
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deletions. These fragments were both found to contain the same coding region.
Gessler et al. (1990) found the same locus by chromosome jumping from a CpG
island in the region of interest. Soon after, a sporadic unilateral WT was reported
containing a mutation in this gene (Haber et al., 1993).
1.4.1 WT1 mutations in Wilms' tumour
WT1 mutations found in WTs include gross deletions, small insertions or
deletions, point mutations, deletions or insertions associated with di- or tri¬
nucleotide repeats and splicing defects. Some WT1 mutations lead to a change in
WT1 transcriptional function, for example, leading to activation rather than
repression from a particular promoter (Park et al., 1993a). Some WTs have been
found to overexpress WT1.
WT1 is not imprinted in normal foetal kidney or WTs (Little et al., 1992a).
However, in sporadic WTs with loss of heterozygosity at lip13, only the maternal
allele is lost (Pal et al., 1990). Germline and sporadic deletions and point mutations
generally arise in the paternal allele (Little et al., 1992b), which may be more
susceptible to mutation, perhaps due to a higher mutation frequency during
spermatogenesis. Loss of the maternal allele then uncovers the mutation, leading to
loss of function.
Nephrogenic rests are non-neoplastic lesions present in 30-40% of kidneys
containing sporadic tumours, and nearly all with bilateral tumours (Beckwith et al.,
1990). When nephrogenic rests were screened for WT1 mutations the same somatic
mutations were found in the nephrogenic rest as in the tumour in the same kidney.
Inactivation of WT1 may be an early genetic event, leading to the production of
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nephrogenic rests, followed by additional genetic hits causing the WT (Park et al.,
1993b).
1.4.2 Other loci implicated in WT
WT1 mutations are found in only around 10% of WTs (Hastie, 1994).
Tumorigenesis may involve interaction between WT1 and other, as yet unidentified,
loci. One of these, WT2, is believed to be associated with Beckwith-Wiedemann
Syndrome (BWS), a clinical syndrome involving WT, which is caused by non-
random loss of the 1 lpl 5 region. Markers found in this region include H-RAS, IGF2,
INS (insulin), H19, a maternally-expressed growth suppressor, which may interact
with IGF2 (Leighton et al., 1995a & b), and p57KIP2, a CDK inhibitor, which is
expressed from the maternal allele and induces Gi arrest (Matsuoka et al., 1995).
IGF-2 is a potent mitogen for mesenchymal cells and is involved in kidney
development in vitro (Yun et al., 1993). It is downregulated in the transition from
mesenchyme to epithelium in the kidney and is overexpressed in -95% of WTs
(Ogawa et al., 1993b). It is located at 1 lpl5, making it a possible candidate for WT2
and is maternally imprinted in most tissues, although this imprinting is relaxed in
many WTs (Ogawa et al., 1993b). WT1 regulates expression of IGF2 in vitro, via
promoter binding (Little & Wells, 1996). IGF2 overexpression and loss of imprinting
have been found in WTs (Ogawa et al., 1993b), as have repression ofp5 J™2 and
H19 (Thompson et al., 1996; Hatada et al., 1996). Hatada et al. found that the
reduced expression of p57KIP2 in WTs was due to either loss of the maternal allele or
aberrant imprinting. BWS patients with uniparental disomy of the paternal lip 15
region have a higher incidence ofWT, plus increased levels of IGF-2 and no HI 9 or
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p57KIP2 (Henry et al., 1991). It could be the combination of IGF-2 overexpression
and lack ofHI 9 and p57KIP2 that causes tumours in these patients (Menke and Hastie,
2000). However, as WTs are also found in other overgrowth disorders, e.g. isolated
hemihypertrophy, Sotos syndrome (Clericuzio, 1993), Simpson-Golabi-Behemel
syndrome (Pilia et al., 1996) and Perlman syndrome (Neri et al., 1984), the
overgrowth itself could favour tumour production by increasing the chance of
disruption during kidney development (Menke and Hastie, 2000).
WIT-1 is a transcribed DNA sequence which colocalises with WT1 (2kb
upstream) (Huang et al., 1990). It is transcribed in the opposite direction, and is
reminiscent of sequences upstream of some proto-oncogenes. WIT-1 mutations could
lead to deregulation of WT1 expression. So far, it is not known whether WIT-1
encodes a functional polypeptide. Some WIT-1 transcripts include exon 1 of WT1
(Campbell et al., 1994). This suggests that heteroduplex formation between WT1 and
WIT-1 transcripts may regulate WT1 protein expression. Therefore, mutation or
deregulation of WIT-1 could lead to changes in WT1 expression without WT1
mutations (Campbell et al., 1994).
Mutation of the p53 gene may be another mechanism for alteration of WT1
function in the absence of WT1 mutations, as p53 may be required for WT1
transcriptional repression. (Maheswaran et al., 1993). One study found that all of 34
WTs assayed overexpressed p53 (Lemoine et al., 1992). Mutations in p53 were also
found in 8 of 11 anaplastic tumours. Progression to anaplasia may be associated with
loss ofp53 function.
LOH for 16q markers is found in almost 20% ofWTs (Coppes and Williams,
1994). This may be a secondary event in tumourigenesis, and is often associated with
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poor prognosis (Grundy et al., 1994). It is also associated with hepatocellular
carcinomas. WT1 mutations may interact with other WT genes, including ones at
lip15 (WT2), and 16q, other tumour suppressor genes or oncogenes, leading to
tumour development.
1% ofWTs occur in a familial form, as an autosomal dominant trait, showing
incomplete penetrance (Matsunaga, 1981). As no WT kindred has yet been found
with constitutional mutation of lip 13, 1 lpl5, or 16q, another locus, or loci, are
believed to be involved in familial cases, with recent evidence pointing to 17q 12-21
as the location of a familial WT gene (FWT1) (Rahman et al., 1996). A good
candidate gene located in this region is that for Insulin-like Growth Factor Binding
Protein 4 (IGFBP-4), which is known to bind IGF-2 (Tonin et al., 1993). However,
many WT families show no linkage to 17ql2-21. Other regions of possible
importance in these families have been identified, including 3q and 20p (Altura et al.,
1996) and 19q (McDonald et al., 1998).
1.5 WT1
1.5.1 WT1 gene and protein
The human WT1 gene spans of 50kb of genomic DNA, and consists of 10
exons, which produce a main mRNA transcript of approximately 3.0kb (Buckler et
al., 1991, Call et al., 1990)(figure 1.5). Other WT1 mRNAs of 1.8 and 2.5 kb are also



















Alternative splicing of WT1 mRNA transcripts produces 4 different species.
These differ in the presence or absence of exon 5 (encoding 17 amino acids), and the
presence or absence of a region encoding amino acids lysine, threonine and serine
(KTS), in the 3' region of exon 9.
Further different isoforms ofWT1 are produced from an upstream non-AUG
alternative translational initiation site, which leads to the production ofWT1 proteins
of higher molecular weights (Bruening and Pelletier, 1996).
RNA editing occurs in WT1 transcripts in rats and humans. WT1 cDNAs have
either a T or a C at codon 280, whereas genomic DNA only has a T. The change
means that a leucine residue is replaced by a proline (Sharma et al., 1994). This
region is not conserved in chickens or alligators, so probably has a mammalian-
specific function (Hastie, 1994). Alternative splicing, alternative initiation of
translation and RNA editing together produce 16 different isoforms ofWT1.
WT1 encodes a nuclear protein, of molecular weight 49-54 kDa, with 4
Kruppel C2-H2 class zinc fingers. It consists of an N terminal proline- and
glutamine-rich region and C-terminal zinc fingers. This suggests a role for the WT1
protein as a transcription factor, which is strengthened by the resemblance of 3 of the
4 WT1 zinc fingers to the 3 zinc fingers of transcription factor EGR-1. It is believed
that the two proteins may have overlapping sequence specificities, and may be
involved in the control of the same genes, possibly in an opposing manner. The N-
terminal region and alternatively-spliced exon 5 are not conserved in chicken or
alligator, suggesting that either these have a mammalian-specific function, or are not
important for WT1 function. The KTS alternative splice is conserved (Hastie, 1994).
The signals responsible for localising WT1 to the cell nucleus are believed to be
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located in the zinc finger region, but their sequence has not yet been identified fully
(Bruening et al., 1996).
Evidence suggests that WT1 expression is controlled at the level of
transcription (Grubb et al., 1994). The WTl upstream regulatory region consists of a
TATA-less promoter, similar to those ofp53 and RB (Hofmann et al., 1993). Unlike
these, however, WTl has highly tissue-specific expression, which suggests that other
regulatory elements must be involved. A silencer region has been found in intron
three, which does not function in cells of renal origin (Hewitt et al., 1995a). There is
a 350bp enhancer 500bp downstream of exon 10 (Fraizer et al., 1994, Wu et al,
1995). This is cell type specific, and contains two GATA motifs, which bind GATA
transcription factors. It may also be controlled by a transcriptional silencer, which
prevents expression in cell types not normally expressing WTl. A 5' cis-regulatory
element has been located 15 kb upstream of the WTl transcriptional start site, this is
conserved between mouse and human, and is necessary, but not sufficient, for
transcription of mouse Wtl in human cells (Scholz et al., 1997). It remains to be
determined which other elements are required for correct temporal and spatial
expression of WTl.
In vitro experiments have shown that WTl transcription is activated by Sp-1
transcription factor (Hofmann et al., 1993). The WTl promoter contains binding sites
for EGR-1, WTl and Sp-1 (Fraizer et al., 1994), also NFkB (Dehbi et al., 1998),
PAX2 (Dehbi et al., 1996) and PAX8 (Fraizer et al., 1997). There is strong evidence
for activation ofWTl by PAX8 in vivo in the kidney. Colocalisation, both temporal
and spatial, ofWTl and PAX8 is seen, including in WTs. The PAX8 binding site
found 250 bp 5' of the minimal human WTl promoter is not conserved in the mouse,
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but PAX8 was shown to activate WT1 expression in vitro via this site (Fraizer et al.,
1997). WT1 represses transcription of its own promoter in transient co-transfection
experiments, so may be controlled by a negative feedback loop. (Campbell et al.,
1994).
Evidence also exists for regulation of WT1 by antisense transcripts, which
have been detected in 293 cells (Eccles et al., 1994). An 'antisense promoter' was
found within intron 1, which is activated by expression ofWT1 itself, in a possible
feedback mechanism (Malik et al., 1995). The expression of antisense WT1 RNA in
293 cells has been shown to lead to a 50% decrease in WT1 at the protein level.
1.5.2 WT1 protein function
1.5.2.1 WT1 as a transcription factor
The structure of the WT1 protein suggests a role as a DNA-binding
transcription factor (Grubb et al., 1994). It is predicted that the WT1 protein should
bind to a 12 nucleotide sequence, of the form GNGNGGGNGNGN, where N
represents any nucleotide, (Pavletich and Pabo, 1991). Such sequences are found in
the promoter regions of many genes that have CpG islands, including some house¬
keeping genes. As will be seen later, WT1 is expressed at very specific times in very
specific locations, and is therefore unlikely to be a regulator of all these genes. Many
studies have identified possible transcriptional targets for WT1 in vitro (see table
1.1), but as more studies were performed, it became obvious that WT1 transcriptional
regulatory activity varies according to the cell system used (Menke, 1998) and type of
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expression vector (Reddy et al., 1995a; Wang et al., 1995). Thus, exactly which
genes are affected by endogenous WT1 activity remains to be determined.
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Table 1.1: Putative WT1 target genes
Gene Reference
Insulin-like growth factor 1 receptor (IGF1-R) Werner et al., 1994
Epidermal growth factor receptor (EGR1-R) Englert et al., 1995a
Retinoic acid receptor a subunit Goodyer etal., 1996
Insulin receptor (IR) Webster et al., 1997
WT1 Hewitt and Saunders, 1996
Early growth response 1 (EGR1) Wang et al., 1993
Pax2 Ryan etal., 1995
c-myb McCann et al., 1995
c-myc Hewitt et al., 1995b
Bcl-2 Hewitt et al., 1995b
MyoD Miyagawa et al., 1998
Insulin-like growth factor 2 (IGF2) Ward et al., 1995
Platelet-derived growth factor A (PDGF-A) Wang et al., 1992
Transforming growth factor pi (TGF-pi) Dey etal., 1994
Colony stimulating factor 1 (CSF-1) Harrington et al., 1993
Inhibin-a Hsu et al., 1995
Syndecan Cook etal., 1996
Midkine Adachi et al., 1996
Ornithine decarboxylase Moshier etal., 1996
novH Martinerie et al., 1996
G protein ai-2 Kinane et al., 1996
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WT1 has been shown to act as both an activator and repressor of transcription
(Madden et al., 1991; Wang et al., 1993). It is believed that WT1 functions as an
activator on its own (Reddy and Licht, 1996), but as a repressor when bound to other
factors, including p53 (Maheswaran et al., 1993). Which transcriptional function is
needed for tumour-suppressor activity has not yet been determined (Reddy and Licht,
1996).
WT1 binds to the same DNA recognition sequence as a related protein, EGR-
1, but with less affinity than EGR-1 (30-40 times less). When bound to the EGR-1
consensus sequence, WT1 causes repression of transcription, not activation,
suggesting that WT1 has opposite activity to that of EGR-1 (Madden et al., 1991).
WT1 has one more zinc finger than EGR-1 does, suggesting that WT1 has its own
recognition sequence (Hastie, 1992). Zinc finger 1 (ZF1) may destabilise WT1
binding to the EGR-1 sequence (Rauscher, 1993). WT1 has been shown to repress
transcription through a response element in the IGF2 P4 promoter. EGR-1 activates
transcription through the same element (Lee & Kim, 1996). WT1 and EGR-1 have
also both been shown to bind to overlapping regions of the IGF2 promoter 3 (Duarte
etal., 1998).
The -KTS form ofWT1 can bind to the EGR-1 sequence, but +KTS cannot.
The two forms may regulate different genes in vivo (Hastie, 1992), with ZF1 playing
a role in the different DNA-binding specificities of -/+ KTS isoforms.
-KTS and +KTS DNA binding sequences may have overlapping binding
specificities. The -KTS isoforms are believed to bind with high affinity to a 9
nucleotide motif, whereas the +KTS isoforms bind with low affinity to a 12
nucleotide motif (Drummond et al., 1994). The IGF2 P3 promoter contains a 12bp
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sequence that can bind to both isoforms (Drummond et al., 1994). However, in
primary embryonic fibroblasts, but not NIH3T3 cells, the + and -KTS isoforms have
opposite effects on IGF2 expression (Duarte et al., 1998). Both isoforms can also
bind to the promoters of PDGF-A (Wang et al., 1995), PAX-2 (Ryan et al., 1995)
and WT1 itself, causing negative autoregulation (Rupprecht et al., 1994). In +KTS
isoforms, all four zinc fingers may be involved in DNA binding, whereas in -KTS
isoforms, only zinc fingers 2,3 and 4 are involved (Drummond et al., 1994). All WT1
+KTS binding sites contain a site that can also bind -KTS.
Recent evidence suggests that the presence of the WT1 zinc finger region is
not actually necessary for transcriptional repression. A study examining the effect of
various forms of WT1 on the IGF1 receptor promoter found that more repression
from this promoter was produced by the N-terminal region (including exon 5) alone
than the +KTS form of the C-terminus (Tajinda et al., 1999). This may be due to
some kind of protein-protein interaction by the WT1 N-terminus. Normal
transcriptional repression by WT1 may therefore be due to a combination ofDNA-
binding by the C-terminal zinc fingers and protein-protein interaction via the N-
terminal region.
1.5.2.2 WT1 and splicing
The WT1 protein has been seen to associate with components of the cellular
splicing machinery in vivo in kidney cell lines, foetal tissue and transfected Cos cells
(Charlieu et al., 1995). This is most typical of the +KTS forms, whereas the -KTS
forms are mainly found in the transcriptional domains (Larsson et al., 1995). -KTS
forms primarily bind DNA, but they can associate with splicing complexes, and will
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ifDNA targets are unavailable. Does WT1 actually play a role in splicing, or is there
just a sequestration of isoforms with lower DNA-binding affinity and non-DNA-
binding mutants in sub-nuclear clusters which are separate from those of the cellular
splicing machinery? The +KTS isoforms have been shown not to colocalise with
SC35, a spliceosome assembly factor (Englert et al., 1995b), but on the other hand,
WT1 does interact with U2AF65, a splicing factor (Davies et al., 1998). Disruption
of splicing causes the redistribution of WT1 (Larsson et al., 1995), and treatment
with RNase changes the subnuclear localisation ofWT1, while treatment with DNase
does not (Caricasole et al., 1996). A highly conserved RNA recognition motif (RRM)
has been located in the N-terminal region of the WT1 protein (Kennedy et al., 1996).
Isoforms of WT1 both with and without the KTS insert have been demonstrated to
bind RNA from exon 2 of IGF2, this may produce downregulation of IGF2
expression (Caricasole et al., 1996). DNA and RNA binding by WT1 are mutually
exclusive, as the binding sites overlap (Bardeesy and Pelletier, 1998). WT1 is not the
only Cys2-His2 zinc finger protein to bind to RNA, others, including MOK2, have
also been seen to do so (Bardeesy and Pelletier, 1998).
1.5.2.3 Functions of the second alternative splice site
The other alternatively spliced region, exon 5, does not have an effect on
DNA binding, but may be important for transcriptional repression functions ofWT1
(Madden et al., 1991; 1993). The isoform of WT1 containing both alternatively
spliced regions was shown to repress transcription from the WT1 promoter itself 25
times better than the isoform with the KTS insert, but not exon 5 (Rupprecht et al.,
1994). The presence or absence of the 17 amino acid sequence has also been found to
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produce proteins having opposite effects. The isoform with both alternatively spliced
regions repressed transcription of a PDGF-A promoter construct, whereas the
isoform with KTS, but not exon 5, was seen to activate transcription from this
construct (Wang et al., 1995). Use of cell proliferation assays revealed that isoforms
of WT1 without exon 5 repressed cell growth, isoforms with exon 5 slowed cell
growth less, but led to altered cell morphology (Hewitt and Saunders, 1996).
1.5.2.4 Disruption ofWT1 isoform ratios and Frasier syndrome
There is evidence to suggest that a disruption of the normal relative
proportions of the different WT1 splice variants may itself cause tumorigenicity. One
study found an increase in the ratio between transcripts without and with exon 5
when compared with normal kidney in 7 out of 10 WTs (Simms et al., 1995). A
similar increase was seen in 4 out of 7 sporadic unilateral tumours (Liu et al., 1999).
This could indicate the presence of higher than normal levels of the WT1 isoform
lacking both inserts, and, if so, may explain why high expression of IGF2 has been
detected in WTs. This particular WT1 isoform has been shown to induce expression
from the endogenous IGF2 gene in both RM1 (Nichols et al., 1995) and NIH3T3
cells (Hosono et al., 1999).
It has been suggested that an imbalance in the ratios of the + and - KTS WT1
isoforms produces a condition known as Frasier Syndrome (FS). This is characterised
by male pseudohermaphroditism and progressive glomerular nephropathy (Frasier et
al., 1964). Mutations in intron 9 of WT1 have been found in FS patients, which
prevent formation of + KTS isoforms (Barbaux et al., 1997; Klamt et al., 1998). It
was thought that this upset of the normal ratio of the WT1 isoforms somehow
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produced the observed pathology. However, two cases of FS have recently been
reported with exon 9 mutations which had no effect on the +/- KTS ratio, and another
patient was found with no intronic or exonic mutations at all (Kohsaka et al., 1999).
This calls into question the role of the imbalanced isoform ratio in the pathology of
FS and raises the issue of whether FS is actually a distinct disease from Denys-Drash
Syndrome (DDS), which will be described in section 1.6, particularly considering
that the exon 9 mutation seen in one of the FS patients had previously been reported
in a case ofDDS (Ogawa et al., 1993c). However, although the fact remains that this
mutation is in exon 9, and is therefore not expected to interfere with splicing of the
KTS insert, the patient reported by Ogawa et al. (1993) did not exhibit Wilms'
tumour, and may in fact have been a misdiagnosed case of FS.
1.5.2.5 Protein-protein interactions ofWT1
The WT1 protein is capable of self-association. This occurs via two self-
association domains that are located in the N-terminal region of the protein (Holmes
etal., 1997).
The WT1 protein has been observed binding to other proteins. It has been
found occurring in complexes ranging from 100-669 kDa in size (Maheswaran et al.,
1993). The transcriptional activity ofWT1 has been found to be affected by physical
interaction with p53. WT1 (-KTS) isoforms produce transcriptional repression in
NIH3T3 cells, but transcriptional activation in Saos-2 cells, which are p53-null.
When wild-type p53 is co-transfected, the observed transcriptional activation is
suppressed. However, no difference is seen in the ability ofWT1 to bind to the IGF2
promoter, whatever the p53 status of the cell (Duarte et al., 1998). Other proteins
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known to bind WT1 include par-4 (Prostate Apoptosis Response protein 4)
(Johnstone et al., 1996), UBC9 (Wang et al., 1996), Ciao 1 (Johnstone et al., 1998)
and SF-1. Transient transfection assays revealed that WT1 -KTS isoforms increased
transcription of SF-1 more than 20-fold (Nachtigal et al., 1998). par-4 has been
shown to increase levels of transcriptional repression controlled by WT1, but reduce
levels of transcriptional activation (Johnstone et al., 1996). WT1 also binds to heat
shock protein hsp70, via the WT1 N-terminal domain, in embryonic rat kidney cells
and cultured cells with inducible WT1, releasing it from complexes with another
protein, HSF, which enables HSF-mediated transcription of the hsp70 gene
(Maheswaran et al., 1998). Hsp70 has been shown to be induced during
haematopoietic differentiation (Sistonen et al., 1992). Interestingly, protein-protein
interaction between WT1 and par-4 occurs via the WT1 DNA-binding domain
(Johnstone et al., 1996).
1.5.2.6 WT1 in cell proliferation, differentiation and death
WT1 also inhibits DNA replication (Anant et al., 1994), which has been
shown to occur through a direct, although as yet unknown, mechanism, as well as
indirectly through induction of cell death (Basu et al., 1999). This suggests a direct
role in the control of cellular proliferation. It may also play a role in the control of
programmed cell death, through a p53-independent mechanism involving suppression
of the epidermal growth factor receptor (EGFR) gene (Englert et al., 1995a).
Apparently opposite effects of WT1 on cellular proliferation have been
observed when studying different cell lines. IfWT (+17 aa) isoforms are injected into
synchronised NIH3T3 cells, an inhibition of serum-induced cell cycle progression is
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observed (Kudoh et al., 1995). Isoforms both with and without exon 5 have been
shown to suppress proliferation in a rat carcinoma cell line (Hewitt and Saunders,
1996), although a stronger suppressive effect was observed with the -17 aa isoforms,
with a higher proportion of -17 aa-expressing cells found in Go/Gi.
WT1 (-17 aa) has been shown to induce expression of p21, a cyclin-
dependent kinase inhibitor, in several cell lines (Englert et al., 1997). p21 is
expressed in differentiating glomerular podocytes, along with WT1 (Englert et al.,
1997). As p21 induces cell-cycle arrest, its induction may be the mechanism by
which WT1 prolongs Gi. It has been shown that interaction between WT1 and hsp70
is required for p21 induction in Saos-2 cells (Maheswaran et al., 1998). In a
leukaemic cell line, K562, use of WT1 antisense oligonucleotides to suppress
endogenous WT1 expression leads to G2/M arrest (Yamagami et al., 1996; 1998).
This means that evidence exists to connect WT1 with two cell-cycle checkpoints,
with overexpression of WT1 causing Gi/S arrest, and lack of WT1 leading to G2/M
arrest.
Upregulation of endogenous WT1 expression has been observed when both
embryonic stem cells and embryonal carcinoma cells are induced to differentiate
using retinoic acid (Scharnhorst et al., 1997). Growth suppression by WT1 requires
WT1 to act as an activator, rather than a repressor, of transcription. Three mutant
forms of WT1 from WTs, all of which had N-terminal missense mutations, were
incapable of suppressing cell growth. These were shown to be capable of
transcriptional activation, but not repression (English and Licht, 1999).
In some cell lines, there is an observed downregulation of WT1 when
differentiation is induced. For example, HL60 cells will differentiate into
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granulocytes when DMSO or retinoic acid is added, into macrophages when TPA is
added and into monocytes when vitamin D3 is added. Induction of each of these
differentiation programmes is accompanied by a drop in WT1 levels (Sekiya et al.,
1994). K652 leukaemia cells can be induced to differentiate into erythroid cells by
the addition of sodium butyrate, or megakaryocyte cells by the addition of TPA.
Downregulation ofWT1 is observed in both these cases (Phelan et al., 1994). Use of
antisense WT1 oligonucleotides established that WT1 downregulation is not
sufficient for differentiation to occur, but cells stopped growing and underwent
apoptosis, suggesting that WT1 expression is important for survival, as well as
proliferation (Algar et al., 1996).
In WT1 null mice, the metanephric mesenchyme fails to develop and
undergoes apoptosis (Kreidberg et al., 1993). This offers additional evidence for
WT1 having a role in cell survival and prevention of apoptosis. However, as in
proliferation, the role of WT1 in apoptosis is confusing. As already mentioned,
expression ofWT1 antisense oligonucleotides in K562 cells led to apoptosis. WT1 is
known to suppress p53-mediated apoptosis (Maheswaran et al., 1995), but
expression of different WT1 isoforms in Saos-2 and U20S cells was seen to induce
apoptosis (Englert et al., 1995a). Only WT1 (-KTS) isoforms caused apoptosis in
HepG2 and Hep3B cells (Menke et al., 1997).
The situation is further confused by the fact that many putative target genes of
WT1 are involved in apoptosis, both in its inhibition, eg. bcl-2, IGF2, and in its
promotion, eg. c-myc, c-myb, TGF-(3. These opposing effects of WT1 may turn out
to be cell-type specific, with WT1 required for survival in some cell types, but
involved in switching on genes for apoptosis in others. It is known that the cellular
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environment is important in the control of apoptosis, so in some cell types, WT1 may
exert an effect on apoptosis by transcriptional control of cell-surface receptors, for
example RAR-a, EGF-R, IR.
1.5.2.7 Roles for WT1 in other types of tumour
Abnormal expression of WT1 has been reported in other varieties of tumour
(Reddy and Licht, 1996), for example melanoma, leukaemia, mesothelioma, also
desmoplastic small round cell tumour, in which reciprocal translocation between the
WT1 and EWS genes leads to the production of a fused protein (Karnieli et al., 1996).
It is not clear whether WT1 is involved in other tumours of the urogenital system.
WT1 is expressed by 75% of ovarian tumours (Bruening et al, 1993), but, to date,
only silent, intronic mutations have been found. There may be an effect of p53
mutation in these tumours (Viel et al., 1994). Polymorphism in WT1 is associated
with testicular germ cell tumours. The WT1 gene is grossly normal in testicular
cancers with LOH at 1 lpl3 (Smith and Rukstalis, 1995). No WT1 mutations have
been found in sex-cord stromal tumours (Coppes et al., 1993b). LOH of WT1 has
been found in some cases ofbladder carcinoma (Shipman et al., 1993).
1.5.3 The role of WT1 in kidney development
Studies of WT1 expression during development provided strong evidence for
involvement of this gene in genitourinary development (Pritchard-Jones et al., 1990;
Armstrong et al., 1992). WT1 is expressed at many stages of kidney development,
from its onset, right through to the adult kidney (Rackley et al., 1993). In situ
hybridisation has revealed the presence of WT1 mRNA in the uninduced metanephric
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mesenchyme, then a stronger signal is seen in the induced metanephric blastema and
condensations (Armstrong et al., 1992). Presence ofWT1 protein is detected in the
cell nuclei of the comma- and s-shaped bodies, then later in the podocytes (Grubb et
al., 1994).
WT1 expression is also seen in the developing gonad, particularly in the
gonadal ridge at the very beginning of gonadal system development. Later,
expression is restricted to the Sertoli cells of the testes and granulosa and epithelium
of the ovary (Pelletier et al., 1991a).
Other tissues also express WT1 during development, including the CNS,
abdominal wall musculature and mesothelial linings of thoracic and abdominal
organs, including the heart (Armstrong et al., 1992). The timing and pattern of
expression is consistent with a role for WT1 in the control of expression of genes
involved in mesenchymal differentiation, particularly in the mesenchyme to epithelial
transition (Rackley et al., 1993). Expression of WT1 (-/-) in NIH3T3 cells led to
induction of epithelial differentiation (Hosono et al., 1999).
During adulthood, WT1 expression appears to be confined to tumours
(Mundlos et al., 1993), supporting cells in the testis and ovary, and the podocytes of
the glomerulus. This suggests a role for WT1 in the maintenance, as well as
development of these structures (Reddy and Licht, 1996).
Kreidberg et al. (1993) studied Wtl function in development by deleting the
first exon of Wtl plus 0.5kb of upstream sequences. Mice heterozygous for this
mutation had no abnormal genital or renal phenotype, and no tumours had appeared
by 10 months. When crossed, the resulting live born offspring showed a 2:1 ratio of
heterozygotes to wild-types, and no viable homozygotes were found. Homozygous
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embryos died between days 13 and 15 of development. On autopsy, these revealed
complete failure of kidney development, with no ureteric bud present, indicating a
requirement for WT1 in its development, despite WT1 not being expressed in the
ureteric epithelial cells (Grubb et al., 1994). The requirement for WT1 must then be
in the metanephric mesenchyme. Metanephric blastema was present, but 10-50% of
cells showed apoptosis. This subsequently degenerated, and no mesenchymal cells
were detectable by day 12. These cells cannot be induced to differentiate by
embryonic spinal cord tissue, a strong inducer ofmesenchyme into kidney tubules, so
the failure of the metanephric blastema to develop is not merely due to the lack of the
ureteric duct (Kreidberg et al., 1993). Later, only remnants of the urogenital system
were found, consisting of Wolffian ducts in a small ridge along the posterior
abdomen. No development of the urogenital ridge occurred after day 11, but
migration of the germ cells to the urogenital ridge occurred as normal. The kidney
phenotype of WTl-null embryos can be partially rescued by the introduction of the
human WT1 gene on a YAC. In some cases nephrogenesis proceeded as far as the s-
shaped body stage (Moore et al., 1999a).
During nephrogenesis, WT1 may act on the genes PAX-2 and Wnt-4,
expression of both of which is seen in the condensing metanephric mesenchyme just
after induction by the ureteric bud. Their expression is down-regulated after the s-
shaped body stage of nephrogenesis (Stark et al., 1994; Dressier et al., 1992). PAX-2
null mice develop no kidneys, ureters or genital tracts (Torres et al., 1995). In the
Wnt-4 null mouse, no tubular epithelium forms, due to developmental arrest of the
metanephric mesenchyme (Stark et al., 1994). It is known that Wtl and Pax-2 can
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each regulate the expression of the other, in a possible feedback loop (Ryan et al.,
1995; Dehbi et al., 1996).
Death of homozygous Wtl null embryos was believed to be due to heart
abnormalities, although this was not proven. A generally smaller heart was seen, with
a small left ventricle and thin right ventricular walls. The mesothelium was also
affected, with incomplete development of the diaphragm, leading to herniation of
lung tissue into the abdominal cavity (Kreidberg et al., 1993). Kreidberg et al. (1993)
suggested that WT1 may be required for the signal from the metanephric blastema to
the ureteric epithelium which determines the time and location of ureteric bud
outgrowth.
The observation that 5-10% ofWTs contain ectopic components, frequently
skeletal muscle, led to the suggestion that loss of WT1 expression may lead to the
activation of myogenesis (Miyagawa et al., 1998). Five out of seven WTs studied
were expressing myogenic genes at high levels, and expression of wild-type WT1 in
C2 myoblasts prevented myogenesis on treatment with dexamethasone.
1.6 Denys-Drash syndrome
Denys-Drash syndrome is a congenital nephrotic syndrome, usually leading to
end-stage renal failure. Other features are XY pseudohermaphroditism and/or WT.
There is evidence for a direct role of WT1 mutations in DDS, patients being
constitutionally heterozygous for WT1 point mutations. Mutations in the WT1 gene
found in DDS fall into distinct categories, all of which disrupt DNA binding in vitro.
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Some patients have missense mutations altering amino acids that directly interact
with the DNA target. Other affected individuals show substitutions of amino acids
involved in zinc complexing, or nonsense mutations leading to the removal of at least
two zinc fingers (Little and Wells, 1997). Approximately 60% ofDDS patients carry
missense mutations in exon 9, the most common of which is a C—»T transition,
leading to Arg394 being replaced by tryptophan in zinc finger 3. This is a mutation
hotspot, found in 40% of patients. Such mutations may act by disrupting DNA
sequence recognition by the WT1 protein, preventing transcription factor activity.
Duarte et al. (1998), introduced DDS-type point mutations into both + and -KTS
WT1 isoforms and showed that this completely abolished all binding to IGF-2
promoter 3. A patient with the exon 9 mutation inherited it from an apparently
unaffected father, suggesting that this mutation exhibits incomplete penetrance
(Coppes et al, 1993a). Tumours from DDS patients show loss of heterozygosity
(LOH) of WT1 (Pelletier et al., 1991b).
There is no apparent relationship between the DDS mutation present and the
severity of the phenotype seen in the patient. This may be due to plasticity of
development in the gonad, or differences in genetic background between patients
(Hastie, 1992). Genetic females with DDS are less likely to have genitourinary
abnormalities, suggesting that WT1 may play a more important role in male
genitourinary development (Coppes et al., 1993a).
Patek et al. (1999) used gene targeting to generate a WT1 allele with
termination of translation within zinc finger 3, producing a truncated protein. In
heterozygous ES cells, mutant transcripts are as abundant as the wild-type, but only
5% of WT1 protein found in the nucleus is truncated, suggesting that some form of
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post-transcriptional regulation occurs. Mice heterozygous for Wtl null mutations
develop no obvious kidney pathology (Kreidberg et al., 1993). In contrast, mice
heterozygous for the allele truncated in zinc finger 3 exhibit nephropathy
characteristic of DDS. (Patek et al., 1999). 90% of DDS patients have WT, but the
single Wtl DDS heterozygous mouse did not exhibit Wilms'tumour. However, 1 out
of 29 DDS chimaeras did. This may reflect the higher risk of WT associated with
DDS, compared with WAGR in humans, as the SeyDey mouse model ofWAGR has
produced no WTs (Glaser et al., 1990).
WT1 proteins without zinc fingers, and other proteins produced by DDS
mutations, can inhibit transcriptional action of wild-type protein. Some of these
mutant proteins are completely incapable of DNA binding through the zinc finger
region, so most likely do not act in a dominant manner by binding to inappropriate
target genes (Little et al., 1993). A dominant-negative mechanism is believed to
occur, through protein-protein interaction between mutant and wild-type forms
(Reddy et al., 1995b). WT1 has been shown to self-associate, and oligomers between
truncated DDS proteins and wild-type proteins form more efficiently or more stably
than wild-type oligomers (Moffett et al., 1995). The parts of the WT1 N-terminal
domain believed to be involved in self-association have also been shown to be
required for the dominant-negative activity of DDS mutant forms (Holmes et al.,
1997). Although only 5% ofWT1 protein was found to be truncated in the targeted
ES cells, the nephropathy observed could be the result of preferential formation of
complexes containing mutant and wild-type protein, or to formation of multimers
(Patek et al., 1999). DDS proteins bind to RNA with 10-fold less affinity than wild-
type WT1 (Bardeesy and Pelletier, 1998).
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DDS dominant-negative mutations lead to less than 50% WT1 dosage, but
this is enough to allow kidney development (Reddy et al., 1995b). The genitourinary
malformations are fairly severe, including streak gonads and pseudohermaphroditism.
Patients show progressive nephropathy leading to renal failure, and abnormalities of
the podocytes. It has been hypothesised that dominant-negative DDS mutations in the
podocytes may inhibit glomerular maintenance and somehow be responsible for the
mesangial sclerosis seen in DDS patients. This may occur in association with lack of
transcriptional repression of the PAX-2 gene by mutant WT1. Yang et al. (1999)
found a distinct lack of nuclear WT1 protein in the podocytes of DDS patients with
diffuse mesangial sclerosis and an associated rise in PAX-2 protein, which is
normally only expressed up to the S-shaped body stage of kidney development. Mice
with dominant gain-of-fimction Pax-2 mutations exhibit congenital nephrotic
syndrome, with some features resembling the kidney pathology present in DDS
(Dressier et al., 1993), so deregulation of the expression ofPAX-2 could be a means
by which WT1 mutations lead to podocyte dysfunction.
It has recently been suggested that at least some DDS mutations may act in a
dominant, gain of function, manner, rather than by a dominant-negative mechanism.
Tajinda et al. (1999) performed transient transfection assays to measure the amount
of repression of the IGF-1 receptor promoter produced by various WT1 mutants. One
construct contained the most common, R394W, DDS mutation. Both + and - KTS
forms of this protein were observed to repress this promoter in a dosage-dependent
manner. Additionally, when the DDS mutant was co-transfected along with wild-type
WT1, instead of the mutant inhibiting the action of the wild-type, an additive effect
on repression was observed, which is the opposite to that which would be expected if
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a dominant-negative mechanism were at work. This suggests the possibility that DDS
mutants may result in DDS pathology by acting on novel target genes. Alternatively,
maybe DDS point mutations have no effect on the ability of WT1 to repress
transcription, but only affect its transcriptional activation function.
Another study using PDGF-A and TGF-f3 reporter constructs in cell lines
stably transfected with different WT1 mutations showed that a different DDS
mutation (Cys356Ser) produced less repression than wild-type WT1, but significantly
more than mutants lacking some or all of the zinc finger region (Jin et al., 1999).
1.7 WT1 and leukaemia
Leukaemias are defined as neoplastic proliferations of leucocyte precursors in
the bone marrow (Anderson, 1985). These are traditionally divided into acute and
chronic classes according to the life-expectancy of sufferers, with chronic leukaemia
patients surviving for far longer than those with acute leukaemia. Modem methods of
therapy mean that this definition no longer applies, but the distinction remains and
the two classes can be separated by aetiology, pathogenesis and clinical features.
Each class is further divided according to the type of leukaemic cell predominating.
Acute leukaemias can be divided into two main groups: acute lymphoblastic (ALL)
and acute non-lymphoblastic (ANLL) or acute myeloid (AML). Chronic leukaemias
consist of leukaemic cells at more differentiated stages than acute leukaemias, and
can be divided into chronic lymphocytic (CLL) and chronic myeloid/granulocytic
(CM/GL).
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As previously mentioned, WT1 mutations have been found in several cases of
leukaemia. King-Underwood et al. (1996) found such mutations in acute leukaemias
of both myeloid and biphenotypic types, and discovered that these mutations were
associated with a poor response to chemotherapy. A further study by the same group
examined 67 cases of leukaemia, finding WT1 mutations in 14% ofAML and 20% of
biphenotypic leukaemia patients (King-Underwood and Pritchard-Jones, 1998).
However, WT1 mutations were much rarer in patients with ALL.
Interestingly, seven out of eight WT1 mutations looked at were found to be in
a heterozygous form in leukaemic cells. This suggests either a dominant or dominant-
negative mode of action for WT1 mutations in leukaemogenesis. As well as their
heterozygous nature, the mutations found appear to bear a functional resemblance to
the mutations found in Denys-Drash syndrome, affecting the zinc finger region, and
therefore the DNA-binding ability, of the WT1 protein (King-Underwood and
Pritchard-Jones, 1998). DDS patients, however, are constitutional heterozygotes for
such mutations, but their tumours almost invariably show loss of the second allele of
WT1. This increased significance of heterozygous mutations in leukaemic patients
suggests that the normal WT1 function in this case is much more easily disrupted by
dominant/ dominant-negative mutations than the function which is disrupted to
produce WTs. Specific proteins which interact with WT1 in normal haematopoiesis
may be prevented from this interaction by the binding of the mutant form to wild-type
WT1.
Whatever the function of WT1 in normal haematopoiesis, this evidence
suggests that it occurs fairly early on in haematopoietic differentiation, before the
splitting of the lymphoid and myeloid lines, as leukaemias of both types contain WT1
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mutations. WT1 must have some functional redundancy in haematopoiesis, however,
as no obvious haematopoietic defects were found in Wtl null mice (Kreidberg et al.,
1993), and a patient homozygous for a WT1 missense mutation had WT, but no
apparent haematopoietic defects. (Kikuchi etal., 1995).
More studies, however, have found overexpression of normal WT1 in
leukaemias. An early study found WT1 expression by Northern analysis in more than
50% of both ALL and AML patients, 80% of CML patients in blast crisis, but no
detectable WT1 RNA in other chronic leukaemias, including CML in chronic phase
(Miwa et al., 1992). Later, using a more sensitive, RT-PCR, technique, another group
found that when patients with leukaemia and with non-Hodgkin's lymphoma were
examined, all the leukaemias, including both acute and chronic cases, were found to
express high levels of WT1 mRNA, but no, or very low, WT1 expression was found
in the non-Hodgkin's lymphoma patients (Inoue et al., 1994). It was also found that
in CML, WT1 levels increased as clinical phase progressed, and, in acute leukaemias,
the level of WT1 expression correlated strongly with the prognosis for the patient,
with higher WT1 levels corresponding to a poorer prognosis (Inoue et al., 1994). No
mutations in the WT1 gene were found when these were looked for. Similar
overexpression of wild-type WT1 has since been found in children with leukaemia
(Niegemann et al., 1999).
Further studies, involving long-term follow-up of leukaemia patients who had
achieved complete remission (CR), showed that in patients who later suffered clinical
relapse, WT1 levels had either never returned to the levels found in normal
individuals, or that WT1 expression had decreased to normal levels then risen again
1-18 months before relapse became apparent (Inoue et al., 1996). Patients who did
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not relapse during the course of the study had either no or very low expression of
WT1 in their peripheral blood (Inoue et al., 1996). It was later found that WT1 levels
in the relapsed patients were, on average, 4.5 times higher than on initial diagnosis
(Tamaki et al., 1996).
Inoue et al. concluded that WT1 levels in peripheral blood were such a good
indicator of possible relapse and effectiveness of treatment that they could be used in
patients to monitor minimal residual disease, having the advantage over existing
methods of being independent of leukaemia lineage and not relying on the presence
of tumour-specific DNA markers.
Efforts have been made to determine which, if any, cells within the
haematopoietic system normally express WT1. Bone marrow mononuclear cells
(MNCs) were sorted by FACS, according to cell surface antigen expression. Two cell
populations were isolated, a more primitive CD34+ population, and a maturer CD34"
population. WT1 expression was examined using RT-PCR, and was found in the
more primitive population, but not the more mature (Baird and Simmons, 1997). This
corresponds to the fact that more differentiated leukaemias express lower levels of
WT1 than less differentiated ones (Inoue et al., 1997). Moreover, when this
population was further divided, WT1 expression was seen to be confined to those
cells which were CD34+/CD38"'°, the population believed to contain the
haematopoietic stem cell (Baird and Simmons, 1997). This indicates that the role of
WT1 occurs very early in haematopoiesis, before much differentiation or lineage
commitment has taken place. This would explain why both lymphoid and myeloid
tumours are affected by WT1 mutations. It should be pointed out, however, that
several previous studies which had detected WT1 expression in leukaemic cells had
failed to detect any WT1 in normal bone marrow (Brieger et al., 1994), or normal
peripheral CD34+ haematopoietic precursors (Mensenn et al., 1995). This could be
due in both cases to lower sensitivity of the analysis used.
It is suggested that the downregulation of WT1 is an important step in the
differentiation of early haematopoietic precursors, and may even be a prerequisite for
this to occur. It has been seen that the induction of neutrophil and monocyte
differentiation in the human promyelocytic cell line HL60 and of
erythroid/megakaryocytic differentiation of a chronic myelogenous line, K562, are
both accompanied by a fall in WT1 expression (Sekiya et al., 1994; Phelan et al.,
1994).
MNCs from patients with solid cancers underwent clonal growth assays for
various cell lineages. Colonies from these assays were picked after 14, 21 and 28
days, and the WT1 expression was measured by RT-PCR. Expression of WT1 was
found only at day 14, not at the later time points, indicating that is a transient
phenomenon, occurring only at early stages of haematopoietic differentiation
(Mensenn et al., 1997).
If WT1 expression in a certain subset of cells at a specific stage of
haematopoiesis is normal, could WT1 expression, rather than being an important part
of leukaemogenesis, just reflect normal expression for the cell types present in the
leukaemia? This believed not to be the case, as a study found ten times less WT1
expression in normal haematopoietic progenitors than in leukaemic cells (Inoue et al.,
1997). The mechanism by which this overexpression occurs is as yet undetermined,
but could conceivably function through the action of GATA-1 on the 3' WT1
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enhancer, although the expression of GATA-1 is not as widespread in leukaemias as
WT1 (Inoue et al., 1997).
Several studies point to the functional significance ofWT1 downregulation in
the haematopoietic differentiation program and its role in the choice between
proliferation and differentiation in early haematopoietic progenitors. Constitutive
expression of either + or - KTS isoforms ofWT1 in the monoblastic cell line U937
prevented induction of differentiation by retinoic acid or vitamin D3 (Svedberg et al.,
1998). This cell line does not normally express WT1. Upon closer examination, some
differentiation was seen to have occurred, with the cells arresting in Gi/Go upon
addition of the inductive reagent, and some changes taking place in cell surface
antigens. However, morphological changes did not occur, as seen in untransfected
cells, leading to the suggestion that WT1 expression acts as a block to differentiation,
not at the beginning of the process, but at a later stage (Svedberg et al., 1998).
A similar result was seen in cell line 32Dcl3, an IL-3 dependent myeloid
progenitor line, which will differentiate into neutrophils upon addition of G-CSF.
Constitutive expression ofWT1 led to cells continuing to proliferate in the presence
of G-CSF (Inoue et al., 1998). Again, some differentiation was detected by
examination of cell surface antigens, but this was blocked at an early stage (Inoue et
al., 1998). WT1 was seen to affect expression of Stat 3a and P, preventing
transduction of the G-CSF-R-mediated differentiation signal, but allowing
transduction of the proliferation signal (Inoue et al., 1998).
The opposite study was carried out on K562 cells, which do express WT1.
Transfection with four out of twenty WT1 antisense oligonucleotides suppressed cell
growth in comparison to WT1 sense and random oligonucleotides (Yamagami et al.,
48
1996). These antisense oligonucleotides were also found to have a growth
suppressive effect on fresh leukaemic cells from 6/14 AML and 1/2 CML patients,
but no effect on the growth of CFU-GM colonies (Yamagami et al., 1996). It was
shown that the K562 cells inhibited by WT1 antisense were accumulating in G2/M,
suggesting that WT1 expression is important to enable haematopoietic cells to get
past this cell cycle checkpoint (Yamagami et al., 1998).
Baird and Simmons (1997) examined WTl expression in bone marrow
mononuclear cells. Using RT-PCR analysis on single cells, they found that +/- exon 5
isoforms were being differentially expressed within this population. Some cells
expressed both isoforms, others only one. In general, the CD34+/CD38" lo population
expressed more + exon 5 isoforms, whereas the CD34+/CD38+ population expressed
more - exon 5 isoforms. It was hypothesised that exon 5 isoform usage depends on
differentiation status of the cell, as the CD34+/ CD38~/k) population is believed to be
less committed that the CD34+/ CD38+ population. This finding was called into
question, however, by Pritchard-Jones and Renshaw (1997), who suggested that the
extreme dilutions of WTl RNA used for the PCR may have caused arbitrary
amplification of one isoform over the other. Renshaw et al. (1997) found an excess of
transcripts containing the exon 5 alternatively spliced region in tissues of the
haematopoietic system compared with all other human tissues apart from the testis.
This excess appears to also be present in the leukaemias and leukaemic cell lines also
examined, suggesting that, although the splicing ratios in leukaemic cells differ from
those found in other tissues, this is merely a reflection of the pattern of splicing in
their cell type of origin, not a novel, tumour-associated phenomenon (Renshaw et al.,
1997). This is consistent with findings in the same paper which suggest that the
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abnormal splice ratios in Wilms' tumours, as compared with adjacent normal kidney
found by Simms et al. (1995) are due to the developmentally immature cells from
which the tumour originates (Renshaw et al., 1997).
The role played by WT1 in leukaemogenesis is confusing, with WT1
mutations in some leukaemias suggesting that WT1 is playing its traditional role as a
tumour suppressor, whereas the link between WT1 expression and proliferation in
some leukaemias and cell lines implying an oncogenic function. It is not known
whether WT1 mutation or expression plays a part in leukaemic initiation or
progression.
It seems probable that WT1 expression is necessary for proliferation to occur
in some cell lines, but the role of WT1 mutations in leukaemia remains to be
determined, and may be affecting a completely different function ofWT1 altogether.
1.8 Summary
Evidence from the phenotype ofWtl null mice (Kreidberg et al., 1993) indicates that
the Wtl gene product is vital for the development of the genitourinary system. The
precise role of this transcription factor in this process, and the target genes through
which its function is effected, remain unknown. To help elucidate these functions,
this project examines the role of Wtl in early developmental processes using
embryoid bodies (Martin and Evans, 1975), in which these early stages of
development are simulated in vitro. Gene targeting was used to produce murine ES
cells with mutations of a type found in Denys-Drash syndrome (DDS) in both alleles
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of Wtl. The resultant mutant proteins are incapable of binding to DNA through the
WT1 zinc finger region, and are therefore presumed to have no transcription factor
function. As mutations in Wtl (King-Underwood et al., 1996), of a similar type to
those studied here, and overexpression of WT1 (Miwa et al., 1992) have both been
detected in human leukaemias, the CFU-A assay (Pragnell et al., 1988), a technique
for examining early haematopoietic development in vitro, was utilised to compare
Wtl mutant and wild-type cells. The mutant ES cells also provided a system for the
examination of transcriptional regulation by the WT1 protein without the use of
tranfected constructs, with Wtl expression under the control of its own promoter.
cDNA expression arrays (Kelly and Rizzino, 2000) were utilised to compare
expression of 588 different genes in wild-type and Wtl mutant cells. As well as
allowing the study of many different genes simultaneously, this technique enabled
WT1 function to be studied under more physiological conditions than had previously
been attempted, producing a more accurate picture of which genes are affected by
WT1.
2. Aims and objectives
■ To continue the work begun by Patek et al. (1999) by generating ES cells
with mutations producing DDS-type truncations in both alleles of the Wtl
gene.
■ To use an in vitro differentiation approach to examine the role of WT1 in
early embryogenesis through production of wild-type and DDS mutant
embryoid bodies. This enables development of all three primitive germ
layers to be studied at once and assessment of the importance of WT1 in
these processes to be made.
■ To study in more detail the role of WT1 in haematopoietic development
using a specific in vitro assay which assesses the potential of embryoid
bodies to differentiate along haematopoietic lineages (Hole et al., 1996).
This can be used to compare this potential in wild-type and Wtl mutant
embryoid bodies, and help to define the role of WT1 in haematopoiesis and
possibly also leukaemogenesis.
■ To identify possible target genes of WT1 using cDNA expression array
technology to compare gene expression in wild-type, DDS heterozygous and
DDS compound heterozygous ES cells. This has the advantage over previous
studies that it employs endogenous expression of both Wtl and target genes,
and all splice isoforms of WT1 are present. DDS heterozygous cells had
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previously been demonstrated to cause mesangial sclerosis in chimaeric mice
(Patek et al., 1999), making examination of gene expression in these and the
DDS compound heterozygous cells relevant to determining the molecular
basis ofDDS.
■ To use the DDS compound heterozygous cells to produce chimaeric mice,
utilising a 'chimaeric rescue' strategy to gain insight into the role ofWT1 in
mouse development. This exploits the fact that the presence of sufficient
wild-type cells in a chimaera allow development to proceed, but information
can still be obtained on the effects of the mutation due to the contribution of
mutant cells to the chimaera.
■ To generate experimental teratomas in vivo using wild-type and Wtl mutant
ES cells. This is an established method for determining the early
developmental potential ofmutant ES cells (Bloch et al., 1997; Moore et al.,
1999b) particularly in cases where the null mutation has been found to be
embryonic lethal (Kreidberg et al., 1993). It is assumed that the DDS
truncation would be lethal if present in both alleles, as it leads to disruption
of the WT1 zinc finger region, but this has not yet been demonstrated.
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3. Materials and methods
3.1 Cell culture methods
3.1.1 ES cell lines
The murine embryonic stem cells used were either from the CGR8
(Mountford et al., 1994) or El4 (Hooper et al., 1987) lines. These included wild-
type, DDS heterozygous (Wtl/Wtl'mT396 - CGR8 clones 10 and 15; E14 clones 75 and
261) and DDS homozygous (WtltmT396/Wtl'mT396 - E14 clones DK3A and 75/28)
(Patek et al., 1999).
3.1.2 Routine maintenance of ES cells
All tissue culture procedures, unless stated otherwise, were carried out in a
Class 2 biological safety cabinet. The medium used was standard tissue culture
medium (see appendix I) unless otherwise specified.
ES cell stocks were stored in medium containing 10% DMSO above liquid
nitrogen. Freezing vials were removed from the liquid nitrogen canister and thawed
briefly using water taken from a 37°C water bath. The cells were then centrifuged
using a MSE Mistral 1000 hanging bucket centrifuge at lOOOrpm for 5 minutes.
Unless stated otherwise, this type of centrifuge was used for all ES cell culture
procedures. The supernatant was removed by aspiration, then the cells resuspended in
fresh medium and transferred into a prepared 25cm2 flask (Corning Costar) using a
plugged pasteur pipette.
Flasks were prepared for ES cell culture by adding 3ml of cold, filter-
sterilised 0.1% gelatine (Sigma), and then leaving at 4°C for at least 1 hour. Before
use, the gelatine was removed and 7ml of tissue culture medium, prewarmed to 37°C,
was added.
After the thawed cells had been placed into the flask, it was left in a 37°C, 5%
CO2 incubator for 2 hours to allow the cells to stick down to the surface of the flask.
The medium was then removed by aspiration, to remove dead cells and any
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remaining DMSO, and replaced with fresh prewarmed medium. Used medium was
removed in this manner at least every second day and replaced with fresh, prewarmed
medium.
When the cells became confluent, they were passaged using TVP (see
appendix I). The used medium was first removed by aspiration, and the cells washed
with approximately 8ml of prewarmed PBS, which was also removed by aspiration,
lml of TVP was then added to the flask, ensuring that the cells were completely
covered. The flask was then placed back into a 37°C incubator for 5 minutes, or as
long as was required to detach the cells from the base of the flask. 4ml of tissue
culture medium was then added to take up the cell suspension. Approximately 0.5ml
of cell suspension was placed into a fresh 25cm2 flask, prepared as described earlier.
The remaining cells were pelleted at lOOOrpm for 5 minutes. The supernatant was
removed by aspiration, and the cells were resuspended in 3ml of filter-sterilised
medium CM (see appendix I), with 10% DMSO. lml of suspension was then placed
into each of three Nunc CryoTubes (Life Technologies). The vials were put into
Nunc cooling racks (Life Technologies) and immediately placed into a -70°C freezer
and left there overnight before being placed above liquid nitrogen until required.
3.1.3 Maintenance of M15 cells
Cells from the Ml5 mouse mesonephric cell line (Larsson et al., 1995) were
used as a positive control for Wtl expression in RNA and protein applications. These
were cultured in the same manner as ES cells, although plasticware did not require
gelatinisation, as these cells are able to attach to the plastic itself. The cells were
grown in medium CM(3 (appendix I), as LIF was not required to inhibit
differentiation. Cells were harvested in the same manner as ES cells, and RNA and
protein preparation was carried out using the same method (see section 3.1.9).
3.1.4 Preparation of metaphase spreads
A medium sized (75cm2) flask of cells to be used in the production ofmetaphase
spreads were split approximately 1:20 several days before use. The medium was then
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left unchanged until approximately 24 hours before they would reach 60%
confluence. The following day, the used medium was removed by aspiration, and
10ml of fresh medium, to which had been added lOOpl of KaryoMax® Colcemid®
lOpg/ml solution (Life Technologies), was placed into the flask. The flask was then
replaced in the incubator for two hours.
After this time, the medium was removed by aspiration, and 2ml of TVP added.
After incubation at 37°C for approximately 5min, the flask was shaken gently to
create a single cell suspension. 8ml of medium was then added, and the total 10ml
was centrifuged at lOOOrpm for 5 min, to pellet the cells. The supernatant was
removed, then the cells resuspended in 10ml 75mM KC1, and left at room
temperature for 15min. At this point, the cells were again centrifuged at lOOOrpm for
10 min. The KC1 was removed by aspiration, and approximately 1ml ice cold fixative
(appendix I) added, drop by drop, using a pasteur pipette with shaking in between
each drop to prevent clumping of the cells. A further 9ml of ice cold fixative was
then added slowly, after which the cells were left to fix at room temperature for 10
min, before being pelleted by centrifugation at lOOOrpm for 5 min. The fixative was
removed by aspiration, and the cell pellet resuspended in a further 10ml of ice cold
fixative. The cells were then pelleted again, as above, but this time 1ml of fixative
was left behind after aspiration. The cells were gently resuspended, then dropped
onto cold microscope slides, which had been stored at 4°C in 100% ethanol. The
slides were left to dry for a few minutes, then labelled with a diamond pen and
stained for 15 min with 5% Giemsa in PBS. After staining, the slides were rinsed in
water to remove excess stain. They were then left until dry, when cover slips were
attached using DPX (Merck).
3.1.5 Electroporation of ES cells
Cells to be transformed by electroshock were grown to confluence in a
162cm flask, as described in section 3.1.1. These were then washed in PBS and
detached from the flask using 3ml of TVP. The resulting single cell suspension was
taken up in a further 7ml of warmed tissue culture medium, after which the cell
concentration was measured using an Improved Neubauer haemacytometer (Fisher).
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A volume calculated to contain approximately 1 x 108 cells was centrifuged in a
hanging bucket centrifuge at lOOOrpm for 5min, then the supernatant removed by
aspiration.
In the meantime, the DNA with which the cells were to be transformed was
prepared. 150pl of the WTV2 plasmid had been linearised by digestion with
restriction enzyme Notl (see section 3.2.4), then precipitated for 1 hour at -70°C with
Zi volume of 7.5M ammonium acetate and 2 volumes of absolute ethanol. The DNA
pellet was obtained by centrifugation in a microfuge at 13,000rpm for 10 min. After a
wash with 80% ethanol, the pellet was air dried, then resuspended in 0.6ml of sterile
PBS in the tissue culture safety cabinet.
The DNA suspension was used to resuspend the ES cell pellet. The cell and
DNA suspension was then transferred into a 1ml cuvette (BioRad, path length
0.4cm), which was inserted into the Bio-Rad gene pulser, and an electric pulse of
800mV with a capacitance of 3pF was applied. The cuvette was then left at room
temperature for lOmin before being added to 100ml of tissue culture medium which
was then divided between ten 100mm tissue culture dishes. The cells were placed
into a 5% CO2 incubator at 37°C overnight before the selection procedure was
started.
3.1.6 Selection of targeted ES cells
The day following electroporation with the WTV2 plasmid, the medium was
replaced with medium containing 100pg/ml G418 (Life Technologies) and 100pg/ml
hygromycin B (Sigma) which had been prewarmed to 37°C. After a further two days
of incubation, the selective medium was replaced with fresh selective medium. After
a further two days, the medium was removed again and replaced with selective
medium with the addition of 2 x 10~6M ganciclovir (Roche)(Mansour et al., 1988).
This medium was then replaced after three days, then, after a further two days, it was
replaced with medium containing just G418 and hygromycin.
When ES cell clones growing on the plates were seen to be large enough, they
were picked under a light microscope in a still air hood, then each placed into a drop
of TVP in a petri dish for a few minutes to dissociate the cells. The drops of TVP
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were each then added to 3ml of selection medium in one well of a gelatinised 24 well
plate (Corning Costar). The selection medium in the wells was changed every two
days until the well became confluent. At this point, the cells were trypsinised and
transferred into 2 wells of a gelatinised 24 well plate in selective medium, which was
changed every second day until the wells became confluent. At this point, the cells
were again removed from the well using TVP. One third of the cells were frozen
down, as described in section 3.1.2. The remaining two thirds of the cells were
transferred in medium into a 1.5ml microfuge tube, centrifuged in a microfuge at
4000rpm for 5min, then stored at -20°C after the supernatant was removed using a
pasteur pipette. DNA extraction was then carried out as described in section 3.3.1.
3.1.7 Preparation of ES cell pellets for DNA extraction
A confluent 25cm2 flask of ES cells was trypsinised as described in section
3.1.2 to obtain a single cell suspension. This was taken up with 4ml of tissue culture
medium and then centrifuged for 5 minutes at lOOOrpm. The supernatant was
removed, then the cells were resuspended in 1.5ml of tissue culture medium and
transferred into a 1.5ml microcentrifuge tube. This was then microfuged at 4000rpm
for 5 minutes to pellet the cells. The supernatant was removed, and the pellet stored
at -20°C until required for DNA preparation, as described in section 3.3.1.
3.1.8 In vitro differentiation with retinoic acid
Cells to be differentiated with retinoic acid were grown to confluence in
162cm2 flasks, then split 1:50 into 162cm2 flasks. These were then grown in normal
tissue culture medium for 2 days, after which the medium was replaced with medium
containing 5pM all-trans retinoic acid (Sigma) and (3-mercaptoethanol, but no LIF.
The retinoic acid was dissolved in DMSO, which had a final concentration in the
medium of 0.05%. The medium was removed and replaced with freshly made up
medium every day for four days. After this time, the cells were harvested for either
RNA or protein preparation, as described in section 3.1.9.
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3.1.9 Preparation of cell pellets for RNA and protein extraction
Cell harvesting for RNA extraction was carried out using disposable cell
scrapers (Greiner). The medium was removed from the cells, and the cell scraper
used to detach all the cells from the base of the flask. Approximately 10ml (for a
162cm2 flask) of tissue culture medium was then used to take up the cells, which
were then centrifuged at lOOOrpm for 5 minutes to produce a pellet. The supernatant
was removed by aspiration and 5ml of ice-cold PBS used to wash the cell pellet,
which was then centrifuged again at lOOOrpm for 5 minutes.
Cells for immediate use were then resuspended in a further 1.5ml of ice-cold
PBS and transferred into a 1.5ml microfuge tube. This was then centrifuged at
5000rpm at 4°C in a Heraeus Biofuge Fresco (Fisher) for 5min, after which the
supernatant was removed by aspiration and the extraction procedure begun.
Pellets for RNA extraction which were to be stored for a time were first
resuspended in 1ml of ice-cold PBS and transferred into a freezing vial. This was
centrifuged at lOOOrpm for 5min, then the medium was removed and the pellet
immediately snap-frozen in liquid nitrogen. Pellets were stored over liquid nitrogen
until RNA extraction was performed as described in section 3.4.1.
Pellets to be stored for protein extraction were transferred into 1.5ml tubes, as
for fresh pellets, then the supernatant was removed by aspiration and the pellets
stored at -70°C until required. Protein extraction was then carried out as described in
section 3.5.1.
3.1.10 In vitro differentiation into embryoid bodies - cell aggregation method
Single cell suspensions of ES cells were seeded into 60mm tissue culture
dishes (Corning Costar) at 3 x 106 cells per dish in medium EFN(3. The medium was
changed every day for approximately 4 days, until the cells were very confluent. At
this point, the used medium was removed using a sterile wide bore pipette tip and
transferred into a sterile 20ml universal tube. 5ml of fresh EFNp was used to
dislodge clumps of cells from the surface of the dish by squirting through a narrow-
bore pipette. The cell clumps were taken up gently using a wide bore pipette tip and
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transferred into the same universal tube as the spent medium. This was repeated
using two more 5ml volumes of fresh medium. The universal tube was left
undisturbed for approximately 5min, until the cell clumps were seen to sediment
under gravity, then all but approximately 1ml of the medium was carefully removed
by aspiration. A wide bore pipette tip was used to resuspend the clumps in 10ml of
fresh medium EFNp.
The cell clumps were then placed into dishes that had been prepared on the
previous day, one 100mm dish (Corning Costar) per previous 60mm dish. Solutions
of 1% and 2% low melting point agarose (Sigma) were made up in PBS and melted
by autoclaving. These were kept at 65°C in a water bath until required. 100mm tissue
culture dishes were coated with 2% agarose by adding 10ml ofmelted agarose and
swirling to cover the entire surface, then removing 7ml. The agarose remaining in the
dish was left to set at room temperature. A layer of 1% agarose was then added on
top of the first layer in the same manner. After the second layer of agarose had set,
10ml of EFNP was placed into the dish, which was incubated at 37°C overnight to
equilibrate. The equilibration medium was then removed and replaced with the
medium containing the cell clumps. The dishes were then incubated at 37°C in a
tissue culture incubator, with medium changes every two days. This was achieved by
removing the used medium containing the cell aggregates with a wide-bore Gilson tip
into a sterile 20ml universal tube, and allowing the aggregates to precipitate under
gravity. The supernatant was carefully removed and replaced with fresh medium, and
the cell aggregates were then returned to the agarose-coated dish.
Cell aggregates were either left to differentiate in suspension in agarose-
coated dishes for up to 28 days, or were transferred into non-coated dishes to attach,
after approximately four days in suspension culture. Aggregates which remained in
suspension were harvested by removing from the dishes into universal tubes,
allowing to sediment, removing the supernatant, washing twice in PBS and fixing in
Bouin's fluid (see appendix I). Cell aggregates for attachment were transferred into
universal tubes as described above, then resuspended in 16 ml ofmedium CMp. This
was divided between four 60mm non-gelatinised tissue culture dishes. The dishes
were placed into a 37°C incubator and left undisturbed for 48 hours to allow the
60
aggregates to attach to the dishes. The medium was changed by aspiration and
replaced with fresh CM(3 every 2 days.
3.1.11 In vitro differentiation into embryoid bodies - hanging drop method
Medium used for the production and differentiation of hanging drop embryoid
bodies was the same as standard tissue culture medium (appendix I), except that 10%
foetal calf serum was used instead of 5% foetal/ 5% newborn calf serum.
Approximately 10ml of sterile water was placed into each of a quantity of
90mm square petri dishes (Life Technologies) (approximately 6 dishes per 10ml of
drops to be produced). The cells, which had been grown in a 25cm2 flask, were
trypsinised with 1ml of TVP to obtain a single-cell suspension, then 4ml of medium
was added, and the cells were pelleted by centrifugation at lOOOrpm for 5min before
being resuspended in 5ml of fresh medium. The cell concentration was determined
using an Improved Neubauer haemacytometer (Fisher), and 2 x 106 cells added to a
gelatinised 25cm2 flask, with fresh medium. 3 xlO5 cells per 10ml of drops to be
made were put into a fresh tube, and the volume made up to the required amount with
medium including LIF and mixed well to produce an even suspension of cells. Cell
suspensions were placed into a 37°C incubator until required.
lOp.1 drops were pipetted onto the underside of the lids of the prepared square
petri dishes using an electronic multipipettor (Wolf Laboratories) until all the cell
suspension was used. Petri dish lids were replaced, and the dishes placed in a 5%
CO2 incubator at 37°C for 2 days before harvesting by removing the lid and tapping
one corner on the floor of the tissue culture hood. Drops were collected from the
corner of the lid using a sterile plugged pasteur pipette and transferred into a 20ml
universal tube, then centrifuged at 800rpm for 3 minutes. The supernatant was
removed, and the embryoid bodies resuspended in 10ml of differentiation medium
per original 10ml of hanging drops. Penicillin/ streptomycin (Life Technologies -
penicillin 10,000U, streptomycin 10,000pg/ml) was added at a dilution of 1:100, but
no LIF was added to the medium. The embryoid bodies were then transferred into
60mm bacteriological grade petri dishes, with a maximum of 10ml of embryoid body
suspension going into each dish. Every 2 days, the medium in the dishes was changed
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by removing the used medium and embryoid bodies into a 20ml universal tube,
leaving them to sediment by gravity for a few minutes, then the old medium was
removed and the embryoid bodies resuspended in fresh differentiation medium,
without LIF. The embryoid body suspension was then placed into a fresh 60mm
bacteriological grade petri dish for the next 2 days.
When harvesting embryoid bodies for analysis, they were removed from the
petri dish into a 20ml universal tube in the manner described above. Embryoid bodies
to be used in RNA extraction were washed in cold PBS before being transferred into
an RNase-free 1.5ml microfuge tube, then treated in the same manner as ES cells (see
section 3.4.1).
3.1.12 Staining of embryoid bodies for the presence of haem
Embiyoid bodies produced by hanging drop culture were stained for the
presence of haem using o-dianisidine using a method adapted from Huber et al.,
1998. Embryoid bodies were placed into 0.14% o-dianisidine (Sigma) in a 20:25:1
(by volume) mixture of 100% ethanol, 0.2M sodium acetate and 30% hydrogen
peroxide in a 20ml universal tube and left for approximately 15 minutes until a red
colouring was seen to appear. The embryoid bodies were then washed twice in PBS
before being fixed in 4% paraformaldehyde in PBS.
Scoring was carried out by phase contrast microscopy, with the proportion of
embryoid bodies with any red staining counted for 5 fields of view.
3.1.13 CFU-A assay
Embryoid bodies were prepared using the hanging drop method, as described
in section 3.1.10. After differentiation in suspension culture in the absence of LIF for
the required length of time, embryoid bodies were harvested into universal tubes in
the manner described above. The supernatant was removed, leaving the embiyoid
bodies in approximately 1ml of medium. A lOpl aliquot of the embiyoid body
suspension was placed on a glass slide, and the number of embryoid bodies present
counted under a microscope. CFU-A assays were prepared in triplicate, and 50
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embryoid bodies were placed into each dish, so a volume of embryoid body
suspension containing approximately 150 embryoid bodies was transferred into a
fresh tube and were returned to an incubator until required.
Dishes were prepared as described in Pragnell et al., 1988. A layer of agar
containing growth supplements was poured into 35mm suspension culture dishes
(Corning). To 20ml of 2x stock (see appendix I) was added 20ml of molten 1.2%
Noble agar (Difco)(kept at 55°C in a water bath), 4ml (1/10 volume) L929
conditioned medium and 2ml (1/20 volume) AF1 conditioned medium (preparation
described in Pragnell et al., 1988). These were quickly mixed, then 1ml was placed
into the bottom of each of the required number of 35mm dishes, which were then left
at room temperature until the agar had set. In the meantime, the top layer of agar was
prepared. This contained 20ml of 2x stock, 10ml of 1.2% agar at 55°C and 10ml of
sterile distilled water. After mixing, 3ml was used to resuspend the embryoid bodies,
then 1ml of agar and embryoid bodies was placed into each of 3 prepared dishes. The
dishes were left at room temperature until the top layer of agar had set, then placed
into a 37°C incubator with 5% O2 and 10% CO2 for 8-10 days.
CFU-A assay dishes were scored using phase contrast microscopy, and an
acetate 1mm2 grid used to estimate of the size of the colonies. Colonies were scored
as being CFU-A positive if they showed the characteristic 'halo' appearance (see
figure 5.4) and had a diameter greater than or equal to 1mm. All other colonies and
embryoid bodies were scored as negatives.
3.1.14 Secondary replating of CFU-A colonies
Replating of the colonies produced in the CFU-A assay was performed after
the colonies had been growing in the assay for 8 days. Whole colonies were picked
out, dissociated, and each plated out in a separate new dish. The bottom layer of agar
was prepared as described for the original CFU-A assay. While this was setting,
CFU-A positive colonies were located under a light microscope and picked out of the
agar. The pipette tip containing the colony was placed into a sterile universal tube.
The top agar was then prepared as described in section 3.1.13, and 1ml used
to produce a single cell suspension of the CFU-A colony. This agar was then placed
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into a prepared 35mm dish, containing a bottom layer of agar. When the top layer had
set, the dish was placed in a 37°C incubator with 5% O2 and 10% CO2 and left for 10
days.
3.2Vector and probe preparation
3.2.1 Plasmid mini-prep
Plasmids used during the course of this project were:
1. WTV2 - constructed by Sheila Christie and Anthony Brookes (see figure 4.3).
Used for targeting of DDS heterozygous ES cells and also for preparation of the
WTV2 hygro probe, used in Southern analysis. This was prepared by restriction
digestion ofWTV2 with enzymes EcoKl and HindiII, followed by recovery of a
1.2kb fragment, as described in section 3.2.6.
2. pUHD172-lneo (Gossen et al., 1995) - a 2.7kb fragment (neo) was prepared
from this plasmid by digestion with Xhoi and used for Southern analysis.
3. pJ5QWTl (Miyagawa et al., 1998) - contains Wtl cDNA possessing both
alternatively spliced regions. Used as the probe for Wtl for Northern analysis. A
1,8kb fragment was recovered after digestion withHindlll and Xbal.
4. pBIuescript® SKM13(-) (Stratagene; Leader et al., 1986) - contains mouse
skeletal muscle actin cDNA. Used to make probe for Northern analysis.
Digestion with Xhoi and EcoHA excises 1,5kb insert.
Preparation of small quantities of plasmid was carried out using a Wizard™ Plus
Minipreps DNA purification System (Promega), according to the manufacturer's
instructions. Bacteria containing the plasmid of interest were inoculated into 10ml of
L-Amp broth (see Appendix I) and grown overnight in a 37°C Gallenkamp orbital
shaker at 220rpm. 3ml of this culture was then centrifuged at 10,000 x g for 2
minutes in a Sorvall RT 6000D centrifuge (Fisher) to pellet the cells. The cells were
then completely resuspended in 200pl of Cell Resuspension Solution and transferred
into a 1.5ml microfuge tube. 200pi of Cell Lysis Solution was then added, followed
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by 200pl of Neutralising Solution. The lysate was then microfuged in a MSE
MicroCentaur at 10,000 x g for 5 minutes.
Plasmid purification was performed using a Vac-Man® Laboratory vacuum
manifold (Promega) and the minicolumns provided with the DNA purification kit.
The cell lysate was placed into the column, along with DNA Purification Resin, then
washed with Column Wash Solution. The syringe barrel was then removed, and the
minicolumn inserted into a 1.5ml microfuge tube, into which the DNA was eluted
with TE buffer by microfugation. The eluted DNA was then stored at -20°C until
required.
3.2.2 Transformation of competent bacteria
The cells used for transformation were Library Efficiency DH5a™ Competent
Cells (Life Technologies). 20pl of cells was aliquoted into a chilled microfuge tube,
lpl (1-1Ong) ofDNA was added and gently mixed. The tube was then placed on ice
for 30 minutes before being heat-shocked for 40 seconds in a 42°C water bath, then
replaced on ice. 80pl of S.O.C. medium (see appendix 1) was added, then the tube
was placed into an orbital shaker and shaken at 225 rpm at 37°C for 1 hour. All the
cells were applied to one LB-Amp plate (appendix I), then incubated overnight at
37°C.
3.2.3 Qiagen plasmid maxi-prep
Large scale production of plasmid was performed using a Qiagen Maxi
plasmid kit. lOOpl of bacteria glycerol stock was inoculated into 8ml of L-Amp
broth. This was placed in an orbital shaker at 220rpm at 37°C overnight. This was
then added into 500ml ofL-Amp broth, which was incubated at 37°C at 180rpm in an
orbital shaker overnight.
The bacterial culture was transferred into two 250ml centrifuge beakers then
centrifuged at 3200rpm in a Sorvall centrifuge for 30 minutes. The supernatant was
tipped away, and the bacterial pellet resuspended in 10ml of buffer Pl. The bacterial
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suspension was then transferred into a 30ml Sorvall centrifuge tube, 10ml of buffer
P2 were then added and mixed in, before being incubated at room temperature for 5
minutes. 10ml of chilled buffer P3 was then added, and mixed in immediately. The
bacterial suspension was then placed on ice for 20 minutes. After this, the suspension
was mixed, then centrifuged at 4,000rpm in a Sorvall centrifuge for 30 minutes at
4°C. In the meantime, a Qiagen-tip 500 column was equilibrated by applying 10ml of
buffer QBT, and allowing the column to empty by gravity flow. The supernatant from
the bacterial suspension was removed immediately after centrifugation, and applied,
through a metal tea strainer, to the Qiagen column. After the supernatant had entered
the resin of the column, the column was washed twice with 30ml of buffer QC. The
DNA was then eluted from the column into a fresh Sorvall centrifuge tube, using
15ml ofbuffer QF.
0.7 volumes of room temperature isopropanol was mixed with the eluted
DNA, which was immediately centrifuged at 6,000rpm for 1 hour in a Sorvall
centrifuge at 4°C. After removal of the supernatant, the DNA pellet was then taken
up in 1ml of 70% ethanol and transferred into a microfuge tube. The DNA was then
microfuged at 13,000rpm for 5 minutes, after which time the ethanol was removed
and the pellet left to dry at room temperature for approximately 15 minutes before
being resuspended in 300pi ofTE buffer (appendix I) and stored at -20°C.
3.2.4 Restriction enzyme digestion of plasmid DNA
Restriction enzyme digests were performed according to the manufacturer's
instructions, using the restriction buffer supplied with the enzyme. The required
amount of plasmid suspension, usually l-4pl, was placed into a 0.5ml microfuge
tube, along with lpl of lOx restriction buffer and lpl of enzyme. The volume was
made up to lOpl using ddw. The tube was then placed into a 37°C water bath for 1-2
hours for the digestion to occur. If a larger quantity of plasmid was being digested,
volumes of the reagents used were increased accordingly.
For double digests, using two restriction enzymes, 0.5pl of each enzyme was
used. If the two enzymes required different restriction buffers, the manufacturer's
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guidelines were consulted to determine which buffer to use to obtain maximum
performance from both enzymes.
3.2.5 Minigel DNA electrophoresis
Minigels were used to examine the products of restriction enzyme digests
quickly and easily. A 0.8% agarose gel was made up in lx TBE (see appendix I),
with the addition of 5pi lOmg/ml ethidium bromide (Sigma) per 100ml of gel. A
BioRad Wide Mini-Sub® gel GT system, connected to an EPS 300 power supply
(Amersham Pharmacia), was used to separate the restriction products. 2pi of
electrophoresis loading buffer (see appendix I) was added to each sample before
loading. Gels were run in lx TBE buffer, and a molecular weight marker appropriate
to the expected size of the fragments was included, for example X/Hindlll (Life
Technologies). After the blue loading dye had reached an appropriate distance along
the gel, the gel was removed from the tank and examined under ultraviolet light to
reveal the positions of the ethidium bromide-stained bands. A photograph could then
be taken to record the image.
3.2.6 Extraction of DNA from an agarose gel (GlassMax method)
The required amount of plasmid DNA was digested and electrophoresed on a
minigel as described above. The band containing the restriction product of interest
was excised from the agarose on a UV light box. Extraction of DNA was performed
using a GlassMax DNA Isolation Spin Cartridge System (Life Technologies),
according to the manufacturer's instructions. 0.45ml Nal binding solution per O.lg
gel was added to the agarose piece in a 1.5ml microfuge tube, along with 20pl TBE-
enhancing buffer per O.lg gel. The microfuge tube was then placed in a 50°C water
bath for approximately 5-7 min, until the agarose dissolved. The solution containing
the dissolved agarose and DNA was placed into a spin column/ collection tube
assembly, and centrifuged for 20 sec at 13,000rpm. 0.4ml wash buffer, at 4°C, was
then placed into the column, and centrifuged for 20 sec, as before. This step was
repeated twice more, with the collection tube being emptied after each spin. After
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centrifuging at 13,000rpm for lmin, to remove any excess wash buffer, the spin
column was removed to a sample recovery tube, and 40pl of TE buffer at 65 °C was
added. The column was again centrifuged at 13,000rpm for 20sec, during which time
the DNA was eluted with the TE buffer into the recovery tube.
3.3 DNA analysis
3.3.1 DNA preparation from ES cell pellets
ES cell pellets for DNA extraction were prepared as described in section 3.1.7.
750pl ofDNA lysis buffer (see appendix I) was added to each pellet, along with 40pi
of 20mg/ml proteinase K. This was incubated overnight at 37°C. 750pl ofphenol was
then added to each tube, and mixed thoroughly. Tubes were then microcentrifuged at
13,000rpm for 2min, then the upper, aqueous, phase was immediately removed into a
fresh tube, and the remaining phase discarded. This process was then repeated with a
further 750pl of phenol, and then 750pl of chloroform. The aqueous phase was
removed after the chloroform stage into a fresh tube, as before, then the DNA was
precipitated using an equal volume of isopropanol, and then microcentrifuged at
13,000rpm for lOmin to obtain a DNA pellet. The supernatant was then removed, and
the pellets left for approximately 15min to air dry. Pellets were resuspended in 20-
lOOpl TE buffer, then stored at 4°C.
3.3.2 Restriction enzyme digestion of genomic DNA
Restriction enzyme digestion of genomic DNA was performed using Hindlll
(Life Technologies) with the supplied REact II buffer. Digestions were performed in
a 50pl volume, using 5pl of 10X buffer, 4pl of enzyme, lpl of 50mM spermidine
(Sigma) and the required volume of DNA suspension. The volume was made up to
50pl using deionised distilled water (ddw). The reagents were combined in a 1.5ml
microfuge tube, then incubated in a 37°C water bath overnight. Agarose gel
electrophoresis was then performed on the digested samples, as described in section
3.3.3.
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3.3.3 Agarose gel electrophoresis of DNA
DNA electrophoresis was performed using a 0.7% agarose gel, made up in lx
TBE buffer, with 5pi of lOmg/ml ethidium bromide per 100ml of gel in a horizontal
electrophoresis tank (H4 SET, Anachem). 10 pi of loading buffer was added to each
sample before loading on to the gel. 30pl of XIHindWl size marker were run
alongside the samples for sizing reference. The electrophoresis tank was connected to
a power supply, and the gel run at 40-50mA overnight, or until the dye front
approached the end of the gel. The gel tray was then removed from the
electrophoresis tank, and photographed under ultraviolet light.
3.3.4 Southern transfer
The gel was then removed from the gel tray, placed in denaturing solution
(see appendix I) and rocked on a 3D rocking platform for 30-40min. Southern
transfer was then carried out using a Blot Transfer System (Life Technologies), in
denaturing solution with Whatman 3MM paper as a wick. A Hybond filter was then
soaked in denaturing solution and placed on top of the gel, followed by two further
pieces of 3MM paper, which had been cut to the size of the gel and filter. Two
approximately 20cm high stacks of green paper towels were placed side by side on
the top, covering the whole surface of the pile. The DNA was left to transfer
overnight, after which time the filter was removed and placed inside a 3MM paper
folder to dry for approximately an hour. The filter was then placed in a plastic bag
and stored at room temperature until required.
3.3.5 Radio-labelling of DNA probe
Radioactive labelling ofprobes was performed using a Stratagene RmT probe
labelling kit. A tube of reaction mixture was used for each probe to be labelled. To
this tube was added 25-50ng of probe DNA, and ddw to a final volume of 42pl. The
reaction tube was then placed in a boiling water bath for 5min, then 3pi ofmagenta
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polymerase was then added. 5pi (50 pCi) of a-32P dCTP (ICN) were added to each
tube in a safety cabinet, behind a perspex shield. Tubes containing radioactive
material were always handled with forceps, behind shields. The reaction tubes were
then placed in a shielded water bath at 37°C for 1V2- 2 hours.
Unincorporated P was removed from the labelled probe using a Nick
translation column (Amersham Pharmacia). The reaction tube was removed from the
water bath and 20pl of lOmg/ml salmon sperm DNA was added. The Nick column
was clamped above a fresh 1.5ml microfuge tube, and the entire 70pi contents of the
reaction tube were added, followed by 400pl of TE. When this had run through, the
collection tube was replaced with a screw-capped 1.5ml tube. A further 400pl of TE
was added to the column. The resulting run-through contained the labelled probe.
The amount of radioactivity present was compared with that retained in the column,
using a Geiger counter, and the probe only used to label a filter if the reading from
the eluate was greater that that from the column. The labelled probe was either used
immediately to label a filter, or stored in a lead pot at -20°C until required.
3.3.6 Hybridisation of labelled probe to filter
The filter was dampened with 2x SSC (see appendix I), rolled up with the
gauze from a Hybaid hybridisation bottle, then placed into the bottle. 0.5ml of
lOmg/ml sonicated salmon sperm DNA was placed into a microfuge tube, and heated
in a boiling water bath for 5min, before being added to 25 ml of hybridisation
solution (see appendix I), which had been prewarmed to 65°C. The resulting
hybridisation mix was added to the hybridisation bottle with the filter, and then left to
prehybridise while rotating in the hybridisation oven at 65 °C for 3 hours. The
labelled probe was then heated in a boiling water bath for 5min, then added to the
hybridisation solution in the hybridisation bottle. The bottle was then returned to the
hybridisation oven and left to rotate at 65°C overnight.
The liquid contents of the hybridisation bottle were flushed away with an
excess ofwater down a drain suitable for the disposal of small amounts of radioactive
isotopes. The filter was then rinsed with 2x SSC, before being washed once with
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100ml of washing solution (see appendix I) that had been prewarmed to 65°C, at
65°C for 30min. This washing solution was then discarded, and a further 100ml of
prewarmed washing solution added to the bottle, which was returned to the
hybridisation oven for another 30min. The filter and gauze were removed from the
bottle using forceps, and the filter was blotted between two sheets of Whatman 3MM
paper, before being wrapped in Saran wrap, placed into an autoradiography cassette,
and exposed to Fuji Medical X-ray film at -70°C for 24 hours. The film was then
removed and developed using a hyperprocessor (Amersham Pharmacia), and the
strength of the signal obtained used to determine the length of any further exposures,
ifnecessary.
3.3.7 Polymerase chain reaction
PCR reactions were performed in 0.5ml microfuge tubes using a Hybaid
Omnigene thermal cycler. The reaction consisted of lpl of 1:1000 dilution ofWTV2
plasmid stock, ImM MgCL (Life Technologies), 125pM each primer (Genosys),
200pM each dATP, dCTP, dGTP, dTTP (Pharmacia Biotech), 1 unit of Taq DNA
polymerase (Life Technologies) and lx PCR buffer (Life Technologies). The volume
was made up to 50pl with ddw, then the reaction mixture was overlaid with 50pl of
paraffin oil to prevent evaporation.
The PCR reaction was carried out for 30 cycles of amplification under the
conditions described in appendix II. 10pi of reaction was then removed and
electrophoresed on a 2% agarose minigel (see section 3.2.5), with the addition of 2pl
ofDNA loading buffer.
3.3.8 DNA sequence analysis
Sequencing of the PCR product was performed using a Thermo Sequenase
Cycle Sequencing Kit (Amersham Pharmacia). 5pl of the WTV2 PCR product was
incubated at 37° for 15min in a heating block with lpl shrimp alkaline phosphatase
and 1 pi exonuclease I, to clean away elements from the PCR reaction mix, such as
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primers and excess dNTPs. The tube was then heated to 80°C in a heating block for
15min to stop the reaction and kept on ice until used.
Two reaction mixtures were then made up, one for each of the forward and
reverse primers. These consisted of lpl of the prepared PCR product, 125pM of the
primer, and 2pl of reaction buffer, made up to 20pl with ddw. Eight termination
mixtures were made up, one set of each of the 4 ddNTPs for each primer. These
consisted of 2pl of dGTP termination master mix plus 0.5pl of the (a-33P)ddNTP
(0.45pCi/pl, Amersham). 4.5pi of the reaction mix was added to each termination
mix, one set of four for the forward primer mix, one set for the reverse primer mix.
The contents of the tubes were mixed by vortexing, then overlaid with 50pl of
paraffin oil. The reactions were then placed in the thermal cycler and amplified under
the same PCR conditions as were originally used with the WTV2 primers (see
appendix II). After the reactions were complete, 4pl of stop mix was added to each
tube. The tubes were stored at 4°C until used.
The products of the sequencing reactions were separated using a 6%
denaturing polyacrylamide gel. This was carried out using BRL S2 sequencing
apparatus (Life Technologies). 65ml of 6% denaturing gel solution (see appendix I)
was polymerised by the addition of 700pl 10% ammonium persulphate (Life
Technologies) and 75pl TEMED (Sigma). This was immediately poured between the
two glass plates, which were laid horizontally, fastened by bulldog clips, and
separated by 0.4mm spacers. A shark's tooth comb was inserted into the end of the
gel before polymerisation had occurred. After the gel had polymerised, it was fitted
into the sequencing apparatus, and IX TBE buffer placed in the upper and lower
reservoirs. The gel was pre-run at 80W for half an hour before loading.
The reaction product was added to lOpl of sequencing gel loading dye
(appendix I) and denatured in a heating block at 95°C for 2-3min. The wells were
flushed out using running buffer from the upper reservoir before the samples were
loaded. The gel was run at 80W for 2 hours, after which the gel was transferred on to
a piece of 3MM paper. This was overlaid with Saran wrap and then dried for 2 hours
using a vacuum dryer (BioRad). The Saran wrap was then removed and the gel
exposed to Kodak Biomax MR-1 film (Sigma) overnight at room temperature.
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3.4 RNA analysis
Before commencing RNA work, the bench surface was cleaned using RNase
Away reagent (Life Technologies). All pipetting was carried out using filter tips
which were racked into clean boxes using clean gloves and autoclaved before use. A
separate bag of microfuge tubes was set aside for RNA work, and these were only
handled using clean gloves. Solutions for RNA analysis were made up using DEPC-
treated water (see appendix I) in glass bottles which had been baked at 180°C for 4
hours, or in sterile disposable tubes. Stocks of reagents such as chloroform,
isopropanol and ethanol were set aside for RNA use only. All tubes and reagents
were only handled using gloves. Gel tanks were cleaned using RNase Away reagent
before each use, as were the flasks in which the gels were made.
3.4.1 Total RNA preparation from ES cell pellets
RNA was extracted from either freshly prepared or quick frozen (see section
3.1.9) ES cell pellets. Pellets had been prepared such that each contained
approximately 1 x 107 cells. 1ml of TRIzol reagent (Life Technologies) was added to
the cell pellet, which was then vortexed to resuspend the cells. At this point, cells
which had been stored in liquid nitrogen were transferred into an RNase-free 1.5ml
microfuge tube. The cell suspension was then left at room temperature for 5 minutes.
0.2ml chloroform and 0.3ml DEPC-treated water (see appendix I) were then added to
each tube, which were each then vortexed for 15 seconds. After 2-3 minutes, the
tubes were microfuged at 13,000rpm for 5min. The upper, aqueous, phase was then
removed immediately from each tube and placed into a fresh RNase-free 1.5ml tube.
The RNA was then precipitated from the aqueous phase by the addition of
0.5ml isopropanol. After mixing, the tubes were placed at -70°C for a minimum of 1
hour, then centrifuged at 13,000rpm at 2-8°C for lOmin to precipitate the RNA. The
supernatant was then removed and the pellets washed with 0.4ml 75% ethanol and
centrifuged at 13,000rpm at 2-8°C for 5 minutes. The supernatant was removed and
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pellets left to air dry for 15min at room temperature before being resuspended in
0.1ml DEPC-treated water by leaving at room temperature for a further 15min.
After samples were taken for analysis of RNA integrity and concentration
(section 3.4.2), the RNA was reprecipitated by the addition of 2.5vol 100% ethanol
and 1/10 vol 3M sodium acetate, and stored in this form at -70°C.
3.4.2 Measurement of RNA integrity and concentration
2pi of each RNA sample were diluted in 1ml DEPC-treated water for
measurement using a spectrophotometer (Cecil CE2020). 0.5ml of this was used for
measurement ofRNA concentration at a wavelength of 260nm. The remaining 0.5ml
was used to measure RNA integrity by comparing absorbance at 260 and 280nm. A
ratio of 1.8 to 2.0 is obtained when the RNA is undegraded and protein-free.
The integrity of the RNA was also examined by running 1 pi of each sample
on an agarose minigel, which should reveal the presence of strong 18 and 28S
ribosomal RNA bands if the RNA is intact. A 1.2% agarose gel in IX TBE buffer
was made, containing 5pi of ethidium bromide per 100ml. Samples were made up to
lOpl by the addition of 9pl of DEPC-treated water, and 2pl ofRNA loading dye (see
appendix I) was added. Samples were run at 100V until the 18 and 28S ribosomal
RNA bands were clearly separated when viewed using a UV light-box.
3.4.3 PolyA+ RNA preparation from total RNA
Preparation of poly A+ RNA was carried out using a Mini-Oligo(dT) Spin
Column Kit (Flowgen). The mini-oligo(dT) cellulose spin column was inverted
several times to resuspend the resin, then positioned on top of an RNase-free 1.5ml
collection tube with a slotted cap. These were then placed inside a 15ml conical-
bottomed centifuge tube, and centrifuged at 200 x g for 10 seconds in a MSE Mistral
1000 to drain the storage buffer from the column. The buffer in the collection tube
was then discarded, and the column returned to the collection tube.
The total RNA sample was precipitated by centrifuging at 4°C for 30min,
then washed in 400pl 75% ethanol before being resuspended in 1ml DEPC-treated
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water, to achieve a concentration of lmg/ml. The sample was then heated to 65 °C for
5min before 0.25ml of the supplied loading buffer was added and the sample cooled
on ice.
lml of supplied 0.5M NaCl buffer was applied to the spin column, which was
then uncapped and replaced on the 1.5ml collection tube, and centrifuged at 200 x g
for 10 seconds. The buffer was discarded from the collection tube, then the RNA
sample applied to the column, which was recapped and inverted to mix the sample
with the oligo(dT) cellulose resin. The column was then incubated at room
temperature for 15min, with mixing every 2-3min. The column was replaced on the
collection tube and centrifuged at 200 x g for lOsec. The buffer was discarded from
the collection tube, then lml of 0.5M NaCl buffer was applied to the column, which
was centrifuged at 200 x g for lOsec. The buffer was discarded from the collection
tube, as before, then lml of supplied 0.1M NaCl buffer was applied to the column,
which was centrifuged at 200 x g for 10 sec. The buffer was discarded, and a second
lml of 1.0M NaCl buffer was applied, and the column centrifuged as before. The
column was then removed to a fresh 1.5ml slotted cap collection tube. 0.5ml of
supplied elution buffer, which had been prewarmed to 65°C, was applied to the tube,
which was immediately centrifuged as before. To elute the remainder of the polyA+
RNA, a further 0.5ml of prewarmed elution buffer was applied, and the column
immediately centrifuged again.
The eluted polyA+ RNA was then precipitated by the addition of 20pl of
lmg/ml mussel glycogen, lOOpl of 3M sodium acetate (pH 5.2) and 2.5ml (2.5
volumes) of cold 95% ethanol. The samples were mixed well, then placed at -70°C
for at least 2 hours to precipitate the RNA. The precipitate was collected by
centrifugation at 13,000rpm for 30min at 4°C. The pellet was washed twice with cold
70% ethanol, then once with cold 95% ethanol and left to dry before being
resuspended in 30pi ofDEPC-treated water.
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3.4.4 Agarose gel electrophoresis of RNA
An aliquot containing the required amount (10-30pg) of RNA ethanol
precipitate was centrifuged at 13,000rpm for 30min at 4°C. The resulting pellet was
then washed in 100pi of 75% ethanol and centrifuged at 13,000rpm for 5min at 4°C.
The supernatant was again removed, and the pellet left to dry on ice. When dry, the
pellet was resuspended in 30pi ofRNA sample buffer (see appendix I) and left on ice
to resuspend. 3pi of RNA molecular weight marker (0.24-9.5kb RNA ladder - Life
Technologies) was run with the samples. This was made up to 30pl by the addition of
RNA sample buffer, then treated the same as the other samples.
The RNA gel (see appendix I) was made by boiling together the agarose, lOx
MOPS buffer (see appendix I) and ddw to dissolve the agarose. The gel was then
cooled to 60°C in a water bath, after which the formaldehyde was added in a fume
hood, and the gel poured in the hood, where it was left to set. The gel tank, tray,
combs and gel ends were all treated with RNase Away, as before, to remove any
RNase contamination.
3pi of RNA loading dye (see appendix I) and lpl of lOmg/ml ethidium
bromide were then added, and the sample was denatured in a water bath at 65°C for
5min, before being chilled on ice and loaded onto the RNA gel. The gel was run in
the fume hood using lx MOPS buffer at 30mA overnight.
3.4.5 Northern transfer
After being photographed under UV light, the RNA was transferred from the
gel to a membrane by Northern transfer. This was carried out using a Blot Transfer
System (Life Technologies) as described in section 3.3.4, using RNA transfer buffer
(see appendix I), on to a Zeta-Probe® nylon blotting membrane (BioRad). After the
transfer, the membrane was soaked in 2x SSC, then left to dry between two sheets of
3MM paper. It was then viewed under UV light, and the positions of the RNA
marker bands and the 18 and 28S ribosomal RNA bands marked on the membrane
using a ball-point pen. The membrane was then placed between two sheets of 3MM
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paper and baked in an oven at 65°C for approximately 2 hours. It was then stored at
4°C in a plastic bag until use.
3.4.6 Radio-labelling of cDNA probe
Probes for hybridisation to Northern blots were prepared in the same manner
as those for the analysis of Southern blots, as described in section 3.3.5.
3.4.7 Hybridisation of labelled probe to filter
The filter to be hybridised and the gauze were rolled together and placed into
the hybridisation bottle, as described in section 3.3.6. Hybridisation ofNorthern blots
was then carried out using ExpressHyb™ hybridisation solution (Clontech). 10ml of
ExpressHyb™ solution, which had been prewarmed to 65 °C was added to the
hybridisation bottle, along with lOOp.1 of lOmg/ml sonicated salmon sperm DNA,
which had been denatured by boiling for 5min. The bottle was placed into the
hybridisation oven and rotated at 68°C for 30min. The radioactively-labelled probe
was denatured by boiling for 5min, as described for DNA filters, then mixed with the
solution from the hybridisation bottle, and the bottle returned to the hybridisation
oven to rotate for 1 hour at 68°C.
The radioactive hybridisation solution was removed, then the filter was
washed once using 2x SSC. The filter was then washed twice for 20min with 10ml of
wanned ExpressHyb™ solution, by returning to the oven and rotating at 68°C. After
this, the filter was removed using forceps and was immediately wrapped in Saran
wrap. The positions of the markers and the 18 and 28S rRNA bands were marked
using an ordinary lab marker, into which had been added a small amount of 33P-
adATP. This renders the marker positions visible on the autoradiograph. The labelled
filter was exposed to a piece of Fuji medical X-ray photographic film at -70°C for 24
hours.
After use, the blot could be stripped by incubating in 0.5% SDS in a 95°C
water bath with constant agitation for lOmin. After being left to cool at room
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temperature for lOmin, the filter was blotted dry and stored in a plastic bag at -20°C
until required.
3.4.8 DNasel treatment of total RNA
Total RNA to be used for reverse transcription into cDNA was first treated
with DNasel to remove any contaminating genomic DNA. Before treatment, the
RNA was diluted to a concentration of lmg/ml. 0.5ml of RNA was incubated with
lOOpl lOx DNasel buffer (see appendix I), 5pi Dnasel (10 units/pl; Roche) and
395pi DEPC-treated water at 37°C in an oven for 1 hour.
lOOpl of 10X termination mix (see appendix I) was then added, followed by
an equal volume (1.1ml) of phenol: chloroform: isoamyl alcohol (25:24:1; v:v:v)
(Sigma) and vortexed thoroughly. Each tube was then spun in a microfuge at
13,000rpm for lOmin to separate the phases. The top aqueous layer was then
transferred to a clean RNase-free tube and the lower phases were discarded. This
process was repeated with a further 1.1ml of phenol: chloroform: isoamyl alcohol.
1.1ml of chloroform: isoamyl alcohol (24:1; v:v) (Sigma) was then added to the
aqueous phase and mixed thoroughly. Each tube was spun in a microfuge at
13,000rpm for lOmin to separate the phases. The aqueous layer was removed and
transferred into a 2ml RNase-ffee microfuge tube. 1/5 volume of 7.5M NELOAc and
2.5 volumes of 96% ethanol were added, and the mixture vortexed thoroughly. The
tubes were then microfuged at 13,000rpm for 20min, and the supernatant carefully
removed. The pellets were gently washed with 200pl of 80% ethanol, then
microfuged at 13,000rpm for lOmin. The supernatant was carefully removed, then the
pellets left to air-dry for approximately lOmin before being resuspended in 500pl of
DEPC-treated water.
3.4.9 Reverse transcription of total RNA
First strand cDNA synthesis was carried out using the Superscript™
Preamplification System (Life Technologies). This was performed using the method
suggested by the manufacturers for first strand synthesis using oligo(dT) primers. 1-5
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pg of DNasel-treated total RNA was placed into each of two RNase-free 0.5ml
microfuge tubes, along with lpl of the oligo(dT)i2-i8 provided in the kit and sufficient
DEPC-treated water to make the volume up to 12pl. Samples were incubated at 70°C
in a heating block for lOmin, then placed on ice for at least lmin. To each reaction
tube was then added, in the following order: 2pl lOx PCR buffer, 2pi 25mM MgCfy
lpl lOmM dNTP mix, 2pl 0.1M DTT. The samples were then incubated at 42°C in a
heating block for 5 min, before lpl of Superscript™ II reverse transcriptase was
added to one of each pair of reaction tubes and the samples returned to the 42°C
heating block for a further 50min. The reactions were terminated by placing the tubes
in a 70°C heating block for 15min, then the samples were chilled on ice. lpl of
RNase H (1-4 units/pl) was added to each tube, and the samples were incubated at
37°C in a heating block for 20min. cDNA was stored at -20°C until required.
3.4.10 RT-PCR analysis of cDNA
PCR reactions were carried out in 0.5ml microfuge tubes, in a reaction
volume of lOpl. A Hybaid Omnigene thermal cycler was used, as before. As the PCR
was to be as sensitive as possible, to detect low levels of gene expression, a-33PdATP
was incorporated into the PCR products, to enable their detection by
autoradiography. For the PCR to be quantitative, the log phase of each reaction had
to be identified for a given range of template concentrations. This is the region where
the strength of signal produced on the autoradiograph is proportional to the amount
of starting template. The number of PCR cycles for which this was the case was
determined for each primer pair by setting up reactions with 0.5, 1 and 2pi of the
same template. The intensity of the bands produced on the autoradiograph was
measured using Molecular Analyst software on a BioRad Gel Doc 1000 machine.
When the band strength was seen to double in intensity with a doubling in template
volume, the log phase was assumed to have been located, and this number of cycles
was then used when amplifying all the samples. These could be assumed to be in the
log phase also, provided that the intensity of band fell within the range produced by
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the control samples. If this was not the case, the amount of template was adjusted to
produce a band intensity within the correct range.
The reaction mix consisted of 200pM of each dNTP, 1.5mM MgCb (unless
otherwise specified in appendix II), 0.5pmol of each primer, 1 unit of Taq DNA
polymerase, IX PCR buffer (for suppliers see section 3.3.7), 0.5,1 or 2pl of cDNA
and 0.5pl of 1:5 dilution of lOpCi/pl a-33PdATP (ICN). This was overlaid with 50pl
of paraffin oil to prevent evaporation. Reactions were carried out under the
conditions described in appendix II. After the reactions were complete, the products
were kept at 4°C until used.
PCR products were separated on a denaturing 6% polyacrylamide gel, as
described in section 3.3.8, as this produced the clearest band on the autoradiograph.
This was carried out using BRL S2 sequencing apparatus (Life Technologies). The
gel was poured as described, but a 30 well square-toothed comb was used instead of
a shark's tooth comb. The gel was prerun at 80W for 30 min, as before. In the
meantime, lOpl of sequencing gel loading dye (see appendix I) was added to each of
the PCR reaction tubes. The PCR products were placed at 99°C in a heating block for
3-4min before being placed on ice. The current through the gel was switched off, and
the wells flushed out using running buffer from the upper reservoir. 8pi of PCR
product was placed into each well, and the gel run at 80W for 3 hours. The gel was
dried and exposed to film as described in section 3.3.8.
3.4.11 Expression analysis using Clontech mouse atlas expression arrays
Clontech mouse atlas expression arrays were used to examine gene
expression in the mutant and wild-type ES cells and their RA-differentiated progeny.
Total RNA for probing the mouse atlas expression arrays was first treated with
DNase I, using the method described in section 3.4.8, then polyA+ RNA was purified
from the total RNA as described in section 3.4.3. lpl of this polyA+ RNA was then
converted into P-labelled cDNA according to the manufacturer's instructions.
In a shielded safety cabinet, 2pl of 5x reaction buffer, lpl of lOx dNTP mix,
3.5pl of (a-32P)dATP (3,000Ci/mmol, lOmCi/ml), 0.5pl of lOOmM DTT and lpl of
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MMLV reverse transcriptase (provided in the kit, except for P-adATP - ICN) were
combined in an RNase-free 0.5ml microfuge tube for each RNA sample to be
labelled, lpl of the polyA+ RNA samples (contained in 1-2pi) were each combined in
0.5ml microfuge tubes with 10X CDS primer mix (supplied in kit), and sufficient
DEPC-treated water to make the volume up to 3pi. This was incubated in a preheated
70°C heating block for 2min. The tubes were then incubated in a 50°C heating block
for a further 2min. The previously prepared master mix was then added to each
reaction tube in a shielded safety cabinet, and mixed. The reaction tubes were then
placed into a 50°C heating block for 20min, then lpl of lOx termination mix was
added to stop the reaction.
Chroma spin-200 DEPC-H2O columns (provided in kit) were used to purify
the labelled cDNA by removing unincorporated labelled nucleotides and small cDNA
fragments. The labelled cDNA sample was carefully applied to the centre of the flat
surface of the gel bed and left to fully absorb into the resin. 40pl of deionised water
was applied to the column and allowed to completely drain out. This was discarded in
a radioactive waste container. Four fractions were then collected by transferring the
column to a clean 1.5ml tube, applying lOOpl of deionised water to the column and
allowing it to completely drain out. The two fractions with the highest activity
(usually fractions two and three) combined to make up the probe.
15ml of Clontech ExpressHyb™ hybridisation solution (provided in kit) was
prewarmed to 68°C, then 150pl of lOmg/ml sheared salmon testes DNA (Sigma)
which had been denatured in a boiling water bath for 5 min was added. The Atlas
array was dampened with deionised water, rolled up with a gauze, then placed into a
hybridisation bottle. 10ml of the prewarmed ExpressHyb™ solution containing
denatured salmon testes DNA was added, and the bottle placed into a hybridisation
oven at 68°C and prehybridised on a low speed setting for 30min.
The labelled cDNA probe was mixed with 1/10th volume (about 22pl) of 10X
denaturing solution (1M NaOH, lOmM EDTA) in a shielded fume hood, then
incubated at 68°C for 20min. 5pi of Cot-1 DNA (provided in kit) and an equal
volume (about 225pl) of 2X neutralising solution (1M NaH2P04 (pH 7.0)) were then
added, then the probe was returned to the 68°C water bath for a further lOmin. This
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was then added to the remaining 5ml of prewarmed hybridisation mix in a shielded
fume hood and mixed by inversion. The prehybridisation solution was discarded and
replaced with the solution containing the probe. The hybridisation bottle was
replaced in the hybridisation oven and left to prehybridise overnight at 68°C.
Washing solutions 1 (2X SSC, 1% SDS) and 2 (0.1X SSC, 0.5% SDS) were
prewarmed to 68°C. The hybridisation solution was discarded and replaced with
200ml ofprewarmed washing solution 1. The filter was washed at 68°C for 20min at
a high speed setting. This was repeated 3 more times. Two additional 20min washes
were performed using washing solution 2 at 68°C. The Atlas array was then removed
from the bottle using forceps and immediately wrapped in Saran wrap, then mounted
on Whatman 3MM paper and either exposed to x-ray film in an autoradiography
cassette at -70°C or to a phosphorimager screen at room temperature.
To strip the Atlas array for re-use, the plastic wrap was removed from the
array, which was then immediately immersed in boiling 0.5% SDS. This was left to
boil for 5-10min, then removed from the heat and allowed to cool for lOmin. The
array was then removed from the solution and checked for radioactivity using a
Geiger counter. If radioactivity could still be detected, the stripping procedure was
repeated. Otherwise, the array was wrapped in plastic wrap and stored at -20°C until
the next use.
3.5 Protein analysis
3.5.1 Protein preparation from ES cell pellets
Protein was prepared from either fresh ES cell pellets, or from pellets stored at -
70°C. 2.5 volumes of sucrose buffer (see appendix I) were used to resuspend each
pellet. 1/10 vol. of 1% NP40 was then added to each pellet, before placing them on
ice for 5min.
To prepare only total protein from the cell pellet (performed when making
positive control protein from Ml5 cells), 1/10 vol. 5M NaCl was then added. Pellets
were left at 4°C for lOmin, and then immediately sonicated, using a MSE sonicator.
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This was carried out on ice, at 3A power for 20-30sec. Protein concentration was
determined (described below), and aliquots frozen at -70°C.
To prepare both nuclear and cytoplasmic protein (for experimental samples), after
5min on ice, cell nuclei were pelleted by a lOsec microfuge at 13,000rpm, at 4°C.
The supernatant, containing the cytoplasmic proteins, was removed and retained.
Protein concentration was determined (described below), and aliquots were frozen at
-70°C. The pelleted cell nuclei were then washed with 1.5ml PBS at 4°C, then
resuspended in 2.5 vol. sucrose buffer, and 1/10 vol. 5M NaCl was added. After
being left at 4°C for lOmin, sonication was performed, as described above.
Measurement of protein concentration was carried out using a Cecil CE2020
spectrophotometer. Measurements were performed at 595nm in a plastic disposable
cuvette. A standard curve was first prepared by measuring the OD of known
concentrations of BSA in 1ml BioRad Protein Assay Dye Concentrate, diluted 1:5
with ddw. ODs of the experimental samples were measured, usually at two different
dilutions (2pl and 4pl of sample, in 1ml BioRad reagent), and the concentrations of
the samples determined using the standard curve. Protein was stored in aliquots at -
70°C.
3.5.2 SDS-PAGE
SDS polyacrylamide gel electrophoresis was performed in a Hoefer® SE 600-
15-1.0 dual cooled vertical slab unit (Amersham Pharmacia). Gels were prepared as
described in the manufacturer's instructions. Two clean 18x16cm glass plates were
clamped together, using 1mm spacers. The plates were then inserted vertically into
the casting cradle, and fastened into place. A 10% or 8% resolving gel (see appendix
I) was prepared first, and poured to a depth of approximately 10 cm. This was
immediately overlaid with ddw, to a depth of approximately 0.5cm. After 30min, the
gel was set and the water could be poured off. The comb was then placed into the gap
between the two glass plates. The stacking gel (see appendix I) was then prepared
and poured to level with the top of the glass plates. This was also left to set for 30min
before the comb was carefully removed, and the plates unfastened from the casting
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cradle and fastened to the upper buffer reservoir. Sufficient TGS running buffer (see
appendix I) to cover the bottom of the gel sandwich was placed into the gel tank, and
the upper reservoir and gel were placed into position. TGS running buffer was placed
into the upper reservoir.
Samples were prepared for electrophoresis by making them all up to the same
volume with PBS. A volume of 2x loading buffer (see appendix I) equal to this total
sample volume was then added. Samples were heated to 95°C for 3min, just prior to
being loaded into the gel. While the samples were being heated, the wells were
flushed out using TGS buffer from the reservoir with a 5ml syringe and needle. A
Benchmark™ Prestained Protein Ladder (Life Technologies) size standard was also
prepared, by taking 20pl of marker and adding the appropriate volumes of PBS and
loading buffer. The samples and marker were then loaded into the gel, which was run
at 55V overnight.
3.5.3 Western transfer
Transfer of the protein from the gel to a Hybond™- C extra nitrocellulose
filter (Amersham Pharmacia) was carried out in a BioRad Trans-Blot™ Cell. The gel
and filter were placed between two sheets of 3MM paper and placed inside the
transfer insert. The insert was then placed into the transfer tank, in the correct
orientation towards the electrodes. The tank was filled with 2.5L ofWestern transfer
buffer (see appendix I), and run at 50V for 2 hours.
The filter was then stained for the presence of protein using an Instaview
Nitrocellulose Staining Kit (Merck), according to the manufacturer's instructions. To
97ml of ddw were added 2ml of 50x stain concentrate and 1ml of lOOx enhancer
concentrate. The filter was placed in a plastic box, and incubated with the staining
solution on a rocking platform for 2-5min. The staining solution was then discarded,
and replaced by 99ml ddw to which 1ml enhancer concentrate had been added. This
was left to rock for a further 5min. The stained filter was then photographed. 20ml of
lOx destain concentrate were added to 180ml ddw, and this was used to wash the
filter several times.
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3.5.4 Protein detection using antibodies
Before application of antibodies to the filter, blocking was carried out to
reduce background signal. This was done by incubating the filter in 5% Marvel
powdered milk in TBST (see appendix I) for one hour at room temperature. The
blocking solution was then replaced with fresh blocking solution containing the
primary antibody. The WT1 N-terminal antibody (N-terminal monoclonal mouse
anti-human WT1 M3561, clone 6F-H2, subclass IgGl, kappa - Dako), which shall be
referred to as WT1 H2, was used at a concentration of 1/500. The WT1 C-terminal
antibody (C-terminal polyclonal rabbit anti-human WT1 sc-192, C-19, IgG -
Autogen), which shall be referred to as WT1 CI9, was used at a concentration of
1/250. The filter was rocked on a 3D rocking platform in primary antibody solution
for 1 hour. The antibody solution was then removed and the filter washed in changes
of TBST for 4 x lOmin (WT1 H2) or 3 x lOmin (WT1 C19), with agitation. The
secondary antibody was then added in 5% Marvel/TBST. HRP-conjugated sheep
anti-mouse IgG (Scottish Antibody Production Unit (SAPU)) was used with WT1
H2, at a concentration of 1/250. HRP-conjugated donkey anti-rabbit IgG (SAPU) was
used with WT1 C19, at a concentration of 1/1000. The filter was rocked in secondary
antibody solution for one hour. The antibody solution was then removed, and the
filter washed in changes ofTBST for 4 x lOmin (WT1 H2) or 3 x lOmin (WT1 C19).
After the washing was completed, the filter was placed into a folder made
from two acetate sheets. The folder was then placed into an autoradiography cassette.
Detection was performed using the ECL detection system (Amersham Pharmacia).
Equal amounts ofECL reagents 1 and 2 were placed in a plastic 20ml universal tube.
0.5ml of each reagent was found to be sufficient for each filter. In the dark room, the
mixed ECL reagents were placed into the acetate folder, on to the filter. The folder
was closed to prevent contact between liquid and film. After approximately lmin, a
piece of ECL film was placed on top of the folder, under safe-light conditions, and
the autoradiography cassette was closed. The first piece of film was exposed to the
filter for 30 seconds. This was followed by another piece of film for lmin. These two
pieces of film were developed in the hyperprocessor, and the level of signal obtained
examined. According to this level, further pieces of film were exposed to the filter for
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longer or shorter time periods, as necessary, until the required level of signal was
obtained.
3.5.5 Immunofluorescence analysis
ES cells for immunofluorescence analysis were grown on 22x22mm glass
coverslips, each in a single well of a six-well plate. After aspiration of the cell culture
medium, the cells were washed twice in ice-cold PBS, before being fixed with 5ml of
1:1 (v:v) methanobacetone for lOmin at room temperature. The fix was then removed
and 5ml of immunofluorescence blocking solution (see appendix I) was added, and
the cells left at room temperature to block overnight.
The blocking solution was then removed, and the surface of the petri dish
around the coverslip dried to prevent the antibody solution from running off. 100pi of
primary antibody (1:250 in blocking solution) was then carefully placed onto the
coverslip and left for an hour at room temperature. The cells were then washed three
times in PBS/0.05% Tween 20 at room temperature. The inside of the dish around the
coverslip was again dried, then lOOpl of FITC-conjugated secondary antibody (1:100
in blocking solution) was carefully placed on the coverslip. The coverslips were then
left for 30 minutes in the dark at room temperature, before being washed three times
in PBS/0.05% Tween 20 at room temperature.
The coverslips were mounted on glass slides using Vectashield (Vector
Laboratories) mounting medium, containing 1.5pg/ml DAPI. After sealing the edges
of the coverslips using nail varnish (or vulcanising solution if the slides were to be
examined using a confocal microscope), the slides were stored in the dark at 4°C.
3.6 In vivo methods
3.6.1 Production of chimaeras by blastocyst injection
Blastocyst injections were performed by Jennifer Doig, Tracy Higgins and
Charles Patek. Targeted ES cells were injected into day 3.5 blastocysts, F2(C57Bl/6 x
CBA). Only a small number of cells (approximately 2-10) were injected into each
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blastocyst. The blastocysts were then implanted into the uterus of a day 2.5
pseudopregnant recipient Fi(C57Bl/6 x CBA).
3.6.2 Glucose phosphate isomerase analysis
This analysis was kindly performed on my behalf by Deborah Bruce. As the
ES cells used for injection express GPI 1A and the blastocysts express GPI IB, the
level of chimaerism in any possible chimaeras born could be measured by
determining the proportion of each GPI isomer in particular tissues. Method adapted
from West and Green, 1983; West et al., 1986. The cellulose acetate plates (Titan III,
Helena Biosciences) for running the protein were presoaked in Supre heme buffer
(Helena Biosciences) for at least 30 min. Approximately 4mm2 of each of the tissue
samples to be tested, along with standards A and B (mouse foetal liver, A from
strains 129/Ola or BALB/c, B from CBA or C57B1), were homogenised with 2
volumes of sample buffer (see appendix I) in microfuge tubes. Samples were then
microfuged at 13,000rpm for 4min and placed on ice until required. The
electrophoresis tank was prepared by placing 50ml of heme buffer into the reservoir
at each end and placing cooling sponges (kept at -20°C) in the centre. 8pi of the
supernatant from each sample was placed into a well on the applicator tray, along
with supernatant from standards A and B. The presoaked cellulose acetate plates
were blotted dry then placed gel side up on the loading tile. Samples were transferred
on to the plate using the applicator. The plates were then placed into the
electophoresis tank gel side down and 350V was applied across then for
approximately 2 hours.
In the meantime, the agar was prepared by melting on a heating block and
keeping at 65°C in a water bath. 7.2ml of agar was transferred into a 20ml glass jar
and returned to the water bath. Just before the plates were removed from the
electrophoresis tank, 1.2ml 0.5M Tris, 3ml Assay stock (see appendix I), 45pi
Glucose-6-phosphate dehydrogenase (G-6-PD) enzyme (lmg/ml)(Sigma), 1.5ml
0.02M 3-[4,5-Dimethylthiazol-2-oyl]-2,5-diphenyltetrazolium bromide (MTT)
(Sigma) and 1,5ml 8mM Phenazine methosulphate (PMS) (Sigma) were mixed in a
20ml universal tube. This was then added to the 7.2ml of warmed agar, mixed and
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quickly poured over the gel side of the cellulose acetate plate. The plate was placed in
the dark until bands developed revealing the positions of the GPI isomers, then fixed
overnight in fixing solution (see appendix I).
3.6.3 Teratoma production
These procedures were carried out by Dr. Colin Miles of the MRC Human
Genetics Unit, Edinburgh. The ES cells for injection were removed from their flask
as described in section 3.1.2, then washed once with PBS. The cell concentration was
measured using an Improved Neubauer haemacytometer. The cells were then
centrifuged at lOOOrpm in a hanging bucket centrifuge for 5 minutes, the supernatant
was removed, then the cells were resuspended in PBS so that the number of cells
• • ft 7
required for the injection was contained in 0.1ml. 1 x 10-1 x 10 ES cells were
injected subcutaneously into the flank of a 129 Ola mouse. Comparable numbers of
cells were injected for each genotype on a given day. ES cells of different genotypes
could be injected into the same mouse, one genotype into the left flank, one into the
right.
Teratomas were left to develop for 25-60 days, with their sizes monitored so
that teratomas were not allowed to reach a size at which they were causing the animal
distress. Mice were killed and the teratoma mass dissected out and fixed overnight in
buffered formalin. Teratomas were then weighed using a top pan balance, and their
weights recorded before being placed in 70% ethanol and sent for wax embedding.
3pm sections were cut from the wax blocks using a microtome, which were mounted
on glass microscope slides and stained using haematoxylin and eosin. Histology was
examined using bright field microscopy.
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4. Sequential targeting and analysis of sequentially targeted cells
4.1 Sequential targeting
The main aim of the project involved the production and analysis of
sequentially targeted ES cells with similar mutations in both alleles of the Wtl gene.
These mutations would resemble a subset of those found in Denys-Drash syndrome
(DDS) (see section 1.6), and would lead to the production of truncated WT1 proteins,
lacking the final two of the fourWT1 zinc fingers.
The work began using DDS heterozygous CGR8 ES cells, which had
previously had one allele of Wtl disrupted using the isogenic targeting vector WTV1
(see figure 4.1) (Patek et al., 1999). A second targeting vector, WTV2, similar to the
first, but containing a hygromycin rather than G418 selectable marker, had already
been prepared for the purpose of targeting the second allele.
4.1.1 Confirmation of genotype of DDS heterozygous ES cells by Southern
analysis.
Before introducing the second targeting event to DDS heterozygous
ES cells, the genotypes of several heterozygous clones were confirmed using the
Wilms' internal probe (W1 B4.3) (figure 4.1). Homologous recombination of the
WTV1 targeting vector used to create the initial targeting event leads to the
introduction of a novel Hindlll restriction site, and the reduction of this restriction
fragment from 19kb to 13kb (see figure 4.1). All putative heterozygous clones
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Figure 4.1 Sequential targeting of Wt1 using vectors WTV1 and WTV2
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2. Targeting vector WTV1.
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analysed produced the anticipated pair of bands at 19 and 13kb after restriction
digestion with Hindlll and agarose gel electrophoresis (figure 4.2, table 4.1).
Table 4.1 Band sizes expected after digestion with HindIII
Expected band size (kb)
Genotype Probe Probe Neo WTV2 hygro
W1 B4.3 HS 8.5 probe probe
+/+ 19 19 - -
+/- 19+13 19+13 5.7 -




-/- compound heterozygous cells
4.1.2 Determination of the optimal concentration of hygromycin B to use to
select against non-targeted cells.
Before the selection against untargeted cells using hygromycin could be
performed, it was necessary to determine the appropriate concentration of
hygromycin to use. The aim was to find a concentration of hygromycin B that would
kill cells not possessing the hygromycin resistance sequences present in WTV2, but
not be high enough to select for genetic changes, as utilised in high G418 selection
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10(8) 15(7) +/+ WT -/-
Figure 4.2 Confirmation of genotype of heterozygous clones.
Before introduction of the second targeting event, the genotypes of several clones
were determined to ensure that the electroporation was being performed on clones which
were heterozygous at this locus. The probe used was the Wilms' internal probe (W1B4.3)
(see figure 4.1), which detects an alteration in a Hindlll restriction fragment from 19 to
13kb. The two heterozygous clones indicated by arrows were the ones later selected for
electroporation with vector WTV2.
10(8) = clone 10 at passage 8
15(7) = clone 15 at passage 7
+/+ = DNA from wild-type mouse (129 Ola)
WT = heterozygous DNA from Wilms' tumour found in DDS chimaeric mouse (Patek et
al, 1999)
-/- = DNA from ES cell made homozygous by high G418 selection (DK3A - Patek et al,
1999)
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(Mortensen et al., 1992). Heterozygous ES cells were grown until approximately
50% confluent and then various concentrations of hygromycin were added.
Hygromycin was added to the cells every two days, as the medium was changed. A
concentration was sought at which the cells would die gradually over a period of
approximately a week, rather than immediately. Cell survival of the two different
heterozygous clones used is shown in table 4.2. Survival of cells was measured on a
scale from ++, which indicates that the majority of the cells survived, to -, which
represents no surviving cells.
Table 4.2 Determination of concentration of hygromycin to use in selection
After 5 days of hvaromvein After 12 davs of hvaromvein
Cone (ua/ml) clone 8(8) clone 15(9) clone 8(8) clone 15(9)
50 ++ ++ + +
100 + + - -
150 - + - -
200 - - - -
250 - - - -
It was therefore decided to use the hygromycin B at a concentration of 100pg/ml.
4.1.3 Confirmation of chromosome number in heterozygous clones by
production of metaphase spreads.
Heterozygous clones which were candidates for sequential targeting had their
modal chromosome number per cell checked, to ensure that only clones with the
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correct chromosome complement (n = 40) were used to produce compound
heterozygous cells.
The two clones selected for electroporation with the second targeting vector
(WTV2) were those with the highest proportion ofmetaphase spreads seen to contain
40 chromosomes. These were clone 15 (passage 7) and clone 10 (passage 8), which
contained 75% and 80% (15 and 16/20) metaphases with the correct chromosome
count, respectively.
4.1.4 Confirmation of identity of WTV2 plasmid using diagnostic restriction
enzyme digestion.
Before introducing the WTV2 targeting vector (figures 4.1 & 4.3) into the
chosen heterozygous clones, the identity of the plasmid vector was confirmed by
diagnostic restriction enzyme digestion.
Four different restriction enzymes were used to cut the plasmid. The expected
sizes of the bands produced with each enzyme were:
a. Notl - 16.9kb
b. BamUl - 15.3kb, 1.6kb
c. HindiII- ll.lkb, 5.8kb
d. EcoRl - 9.0kb, 2.1kb, 2x 1.8kb, 1.4kb, 0.8kb
The plasmid was digested with each of the four enzymes, and bands of the
expected sizes were produced in each case (figure 4.4). Thus the plasmid was






Figure 4.3 Targeting vectorWTV2
VectorWTV2 was created for the purpose of targeting the second allele of
Wtl. The vector contains 9.9kb of sequence homologous to the genomic region
containing exons 7, 8, 9 and 10 of Wtl. Exon 9 is disrupted by the insertion of the
hygromycin B phosphotransferase gene, driven by the PGK promoter sequence.
The HSV thymidine kinase (TK) gene is also present, enabling negative selection against
clones in which non-homologous recombination has occurred.
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a b
X HindiW marker Noti EcoRI w/ncfll1 SamHI
Figure 4.4 Diagnostic restriction enzyme digests to confirm identity of WTV2
plasmid vector.
Approximately 2pg ofWTV2 vector was digested with a selection of restriction
enzymes which are known to cut the plasmid at specific sites, producing bands of known
sizes. All the enzymes used gave bands of the expected sizes, thus confirming the
identity of the plasmid and enabling the electroporation to proceed.
Notl lane a contains twice as much plasmid as lane b. The apparently higher
molecular weight band is due to residual undigested supercoiled plasmid DNA.
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4.2 Analysis of sequentially targeted cells
4.2.1 Southern analysis of clones surviving positive-negative selection
The WTV2 targeting vector was introduced into heterozygous clones 15
(passage 7) and 10 (passage 8) by electroporation. Cells were then grown in the
presence of G418 and hygromycin, as correctly targeted colonies should contain
regions of both WTV1, which confers G418 resistance, and ofWTV2, which confers
hygromycin resistance. Selection with both antibiotics prevents survival of cells in
which the first targeted allele has been replaced by the second targeting event. After
four days, negative selection was also performed by the addition of ganciclovir,
which kills colonies in which non-homologous insertion has occurred, via the
presence of the thymidine kinase gene (see section 1.1).
Clones surviving the positive-negative selection regimen were picked and
cultured, and then DNA was extracted for the purpose of Southern analysis, to
confirm the genotype. 167 clones were picked from electroporation A (clone 15,
passage 7), and 116 clones were picked from electroporation B (clone 10, passage 8).
The first probe used was the Wilms' internal probe (W1 B4.3), which gave only a
band of the reduced size, 13kb (see table 4.1), in sequentially targeted cells (figure
4.5). From electroporation A, 25 of 81 clones analysed (28%) gave the desired result,
and from electroporation B, 19 from 54 clones (35%) were successful. These clones
were then screened using the Wilms' external probe, HS8.5, to confirm that
homologous recombination had taken place (figure 4.6). This probe produces the
same sizes of mutant and wild-type band as the internal probe. Further screenings




Figure 4.5 Use of Wilms' internal probe (W1B4.3) to identify possible
sequentially targeted clones after electroporation with WTV2.
DNA from clones surviving selection with G418, hygromycin B and gancyclovir
was digested with Hindlll. Successfully sequentially targeted clones should reveal only
the 13kb band.
Lane 6 shows a clone which was then tested using further probes. The
heterozygous clones in lanes 1-5 survived selection with G418 and hygromycin due to
random insertions ofWTV2 (lower bands).
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+/+ +/- -/-
Figure 4.6 Use ofWilms' external probe (HS8.5) to confirm genotypes of
sequentially targeted clones.
After use of the Wilms' internal probe to select possible sequentially targeted
clones, the Wilms' external probe (see figure 4.1) was used to confirm the genotype. This
probe shows the same reduction of a Hindlll fragment from 19kb to 13kb.
(neo) and the hygromycin resistance gene from WTV2 (WTV2 hygro), to confirm
that these sequences were both present in the sequentially targeted clones (figures
4.7 & 4.8, table 4.1 for expected band sizes). All clones that gave the correct band
size with the internal probe were shown to have the correct genotype with the other
three probes. The high level of success obtained is probably due to the isogenic
nature of the targeting vector.
4.2.2 Confirmation of chromosome number in sequentially targeted clones
by production of metaphase spreads.
Before any study of the sequentially targeted clones, either in vivo or in vitro,
could be carried out, the chromosome numbers of the clones were checked.
Metaphase spreads were again prepared from the clones, and the average number of
metaphases containing 40 chromosomes was determined.
All the sequentially targeted clones were seen to have 40 chromosomes in at





Figure 4.7 Presence of initial targeting event in sequentially targeted clones
shown using probe specific to neomycin resistance sequence.
A neomycin resistance probe (neo) was used to confirm the fact that the
sequences contributed by the first targeting event were still present in the sequentially
targeted clones.




Figure 4.8 Presence of second targeting event in sequentially targeted clones
shown using probe specific to hygromycin resistance sequences from vector
WTV2.
A probe made from the WTV2 plasmid (WTV2 hygro) was used to confirm the
presence of vector sequences in putative sequentially targeted clones. The figure also
reveals the absence ofthese sequences in heterozygous and wild-type cells.
After digestion with Hindlll, a 5.8kb band was detected in sequentially-targeted
clones only.
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Table 4.3 Homozygous clones with the proportions of cells seen to contain 40
chromosomes
















4.2.3 Compound heterozygous nature of sequentially targeted clones
revealed by sequencing of vector WTV2.
The section of targeting vector WTV2 containing the Rsrll restriction site
into which the hygromycin resistance gene was inserted within exon 9 of the Wtl
gene was sequenced (figures 4.3, 4.9). This was done by PCR amplification of this
region, using a forward primer in the Wtl exon 9 sequence and a reverse primer in
the 5' end of the PGK promoter driving the hygromycin resistance gene (see
appendix II for primer sequences). This was to determine the nature of the Wtl
modification conferred by the targeting event, and compare it with that produced by

















Figure 4.9 Sequencing of targeting vector WTV2 to determine the nature of the
modification produced by the second targeting event.
a. Diagram (not to scale) of section ofWTV2 plasmid to indicate positions of forward
and reverse PCR primers. Numbers indicate exons of Wtl. F- forward primer,
WTV2F/DS26393 (Patek et al, 1999). R- reverse primer, WTV2R.
b. Primers (WTV2F and WTV2R) were designed to produce a PCR product spanning
the region where the hygromycin sequences, plus their PGK promoter, were inserted
into exon 9 of Wtl (see appendix II). This product was then sequenced, revealing the
production of a nonsense codon at amino acid position 403 (see figure 4.10).
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The sequences of wild-type Wtl, the original DDS allele WtltaT396 and the
second allele produced by WTV2 are compared in figure 4.10. When the sequence of
this region in vector WTV2 was examined, it was seen to result in the production of
a stop codon only 7 amino acids downstream from the position of the stop codon in
Wt]tmT396 por tpjs reasoip the second allele ofWtl was named WtlbnUm.
The original modification leads to the truncation of the WT1 protein in ZF3,
leading to the functional loss of both ZF 3 and 4 and loss of the KTS region. This
means that it can functionally be classed as a Denys-Drash syndrome mutation (see
section 1.6). Insertion of WTV1 led to an amino acid substitution (S395R),
immediately followed by a translational stop codon at position 396 (Patek et al.,
1999). The second modification, produced by targeting with vector WTV2, leads to 8
amino acid substitutions, beginning at position 395, followed by a stop codon at
position 403. Although this obviously produces a longer protein than the first
targeted allele, the substitutions of the functional amino acids making up this part of
ZF 3 with the random sequence produced by the PGK promoter region will cause
disruption of the zinc finger at the same place as the protein produced by WTV1
insertion. The amino acids immediately following the point of termination (or amino
acid substitution) are some of those which are directly involved in zinc complexing
(amino acids 401 and 405) (Borel et al., 1996). Their loss or replacement will
completely prevent correct zinc finger formation. The mutations produced by
insertion of vectors WTV1 and WTV2 lead to the removal of amino acid 396 in one
case (WTV1) and its substitution in the other. This amino acid is involved in DNA
sequence recognition (Pavletich and Pabo, 1991) and its loss is sufficient to disrupt
WT1, as several DDS patients have been reported with point mutations leading to
Wild-type Wtl
394 RSDHL KTHTR
1657 CGG TCC GAC CAT CTG AAG AAC CAC ACC AGG
First mutant allele - Wt1tm7396
394 R R
1657 CGG CGA TAG
Second mutant allele - WtltmT403
394 RSSSMNST G*
1657 CGG TCA TCA TCG ATG AAT TCT ACC GGG TAG
* denotes position of stop codon
Figure 4.10 Comparison of the wild-type Wt1 allele with the mutations
produced by the first and second targeting events.
The first mutant allele was generated as described in Patek et al, (1999). The
second was produced by the introduction of vector WTV2 to the previously targeted
cells. Insertion of the PGK-hygro cassette into exon 9 of Wtl is seen here to produce
a stop codon at amino acid position 403, and is therefore predicted to lead to a
protein truncated 7 amino acids downstream from the truncation produced by the
first targeting event.
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amino acid substitutions at this site (Pelletier et al., 1991b; Baird et al., 1992; Little
et al., 1993; Nordenskjold et al., 1994). Neither of these two proteins is therefore
predicted to be able to bind to the usual WT1 DNA consensus sequences
(Drummond et al., 1994; Hamilton et al., 1995).
4.2.4 Absence of Wt1 expression in undifferentiated ES cells revealed by
Northern and Western analysis.
After production of sequentially targeted DDS cells, and their confirmation
as such by Southern analysis, the next step was to characterise the cells in terms of
Wtl expression, by both Northern and Western analysis. Previous analysis of the
DDS heterozygous clones and some homozygous clones produced by high G418
treatment (Mortenson et al., 1992) of the heterozygotes had revealed that Wtl
expression could be detected in undifferentiated ES cells (Patek et al., 1999).
However, study of wild-type, heterozygous and compound heterozygous ES cells in
the present study, using both Northern and Western analysis, failed to detect any Wtl
signal in undifferentiated cells (figure 4.11). As the Western analysis was performed
using the same protocol and the same antibody as had been used in the previous
work, the failure to detect WT1 protein here is unlikely to be due to experimental
differences in sensitivity. It is more likely that the ES cell cultures in which Wtl
expression had previously been detected contained a higher proportion of
differentiated cells than those studied here, as it has been demonstrated that ES cells
induced to differentiate by the addition of all-trans retinoic acid exhibit high levels






Figure 4.11 Western analysis of nuclear extracts from undifferentiated ES cells.
Nuclear protein was extracted from undifferentiated wild-type, DDS heterozygous
and DDS homozygous CGR8 ES cells. 75 jig of this was separated using SDS-PAGE on a
10% polyacrylamide gel, along with lOpg of positive control total protein from the Ml 5
mouse mesonephric cell line (Larsson et al, 1995). Western analysis was performed.
a. The filter was stained using the Instaview system (BDH) to reveal the relative
amounts ofprotein transferred.
b. The N-terminal antibody 6F-H2 (Dako) was used to detect the presence of WT1
protein.
107
4.3 Use of retinoic acid to induce Wt1 expression in ES cells
As undifferentiated ES cells were found to not express detectable Wtl RNA
or protein, the presence of mutant RNA transcripts and truncated proteins in the
targeted cells could not be confirmed. It was particularly important that this was
done, as previous work had revealed a discrepancy between levels of mutant and
wild-type RNA and protein in DDS heterozygous cells, with the mutant and wild-
type transcripts being present at approximately equal levels, yet a 20:1 excess of
wild-type over mutant protein detected (Patek et al., 1999). More relevant to the
DDS compound heterozygous cells, cells that had been made homozygous for the
original mutation using high G418 selection revealed a total absence ofWT1 protein
(C. Miles, personal communication), despite the presence of Wtl mRNA (Patek et
al., 1999). Treatment with all-trans retinoic acid has been shown to increase Wtl
expression in embryonal carcinoma (EC) and ES cells (Scharnhorst et al., 1997). It
was decided to induce Wtl expression in this manner to enable the detection of
mutant and wild-type Wtl RNA and protein.
4.3.1 Determination of optimum level of retinoic acid needed to induce Wt1
expression in ES cells.
Before treating the ES cells with retinoic acid to obtain Wtl expression, the
concentration of retinoic acid that gave the highest level of Wtl transcripts with a
suitably low level of toxicity needed to be determined. Wild-type ES cells were
seeded out into 75cm flasks, and retinoic acid applied with the cell culture medium
for four days. Retinoic acid was added in three different concentrations, 1, 5 and
IOjlxM prepared from a stock solution in DMSO. Additional flasks were also set up in
parallel, with normal tissue culture medium containing LIF, and normal tissue
culture medium without LIF, both with the appropriate concentration of DMSO to
control for any associated effects.
Total RNA was extracted from the cells after differentiation for four days.
PolyA+ RNA was then purified and separated on an agarose gel. After Northern
transfer, the filter was hybridised first with a Wtl cDNA probe, then stripped and
reprobed with a probe specific to /? act in RNA, to determine relative levels of
loading in each lane (figure 4.12). No signal was seen with the Wtl probe in the lane
containing RNA from undifferentiated ES cells, and only a very weak signal was
seen in the lane from the cells from which LIF had been withdrawn. In the lanes
containing RNA from cells to which retinoic acid had been added, the weakest signal
relative to the p actin signal was seen in the IjuM lane. There was very little
difference seen between the 5 and 1 OpM lanes.
It was thus demonstrated that all-trans retinoic acid could be used to induce
Wtl expression, enabling its detection in mutant and wild-type ES cells. From this
result, it was decided to use 5pM retinoic acid to induce differentiation of ES cells,
as increasing this level to lOjaM had no obvious effect on Wtl upregulation, and a
lower retinoic acid concentration was desirable, to keep any associated toxicity to a
minimum.
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Figure 4.12 Determination of concentration of retinoic acid to use for cell
differentiation.
Wild- type CGR8 ES cells were grown for 5 days under the following conditions:
Lane 1: LIF + 0.05% DMSO
Lane 2: lpM retinoic acid + 0.05% DMSO
Lane 3: 5pM retinoic acid + 0.05% DMSO
Lane 4: lOpM retinoic acid + 0.05% DMSO
Lane 5: 0.05% DMSO
Poly A+ RNA was extracted from each and separated by electrophoresis on a
formaldehyde gel. After transfer to a nylon membrane, the RNA was first hybridised to a
cDNA probe specific to Wtl. The membrane was then stripped and reprobed with a probe
specific to,6actin to control for unequal lane loading.
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4.3.2 Northern analysis of RNA from RA-treated ES cell progeny
After the level of retinoic acid needed for the differentiation of ES cells was
established, wild-type, DDS heterozygous and DDS compound heterozygous CGR8
ES cells were induced to differentiate in this way.
Cells of each genotype were seeded out into large (162 cm2) flasks, then 5pM
retinoic acid was added for four days. Control flasks with normal tissue culture
medium, containing LIF, were set up in parallel. Total RNA for RNA analysis was
then extracted from some of the cells and separated on an agarose gel. After
Northern transfer, the resulting filter was hybridised with probes specific to Wtl and
P actin.
Unfortunately, although many attempts were made to distinguish between
mutant and wild-type Wtl RNA by Northern analysis, none was successful. This was
despite using RNA which was clearly of good quality and which gave a clear signal
with a /? actin probe. Use of poly A+ RNA instead of total RNA also failed to
produce a signal.
4.3.3 Mutant and wild-type WT1 protein detected by Western analysis after
treatment of ES cells with retinoic acid
After the conditions required for the detection of Wtl expression in ES cells
had been determined, cells were differentiated with 5p.M RA for the production of
protein for Western analysis.
Wild-type, DDS heterozygous and DDS compound heterozygous cells were
each seeded out into 6 medium (75cm ) flasks. These were then grown in the
presence of 5pM all-trans retinoic acid for four days before being harvested. Nuclear
protein extracts were produced from the differentiated cells. 75pg of this protein was
separated using a 10% SDS-PAGE gel, then transferred on to a nitrocellulose
membrane, and the presence ofWT1 protein detected using the WT1 N-terminal 6F-
H2 antibody (Dako).
Before use of the WT1 antibody to detect protein, the filter was stained using
an Instaview Nitrocellulose kit (BDH). This reveals how much protein is actually
present on the membrane, and can be used to see how equally the different lanes are
loaded (figure 4.13a).
The 6F-H2 N-terminal WT1 antibody was used to detect both mutant and
wild-type WT1 protein (figure 4.13b). Wild-type WT1 protein can clearly be seen in
both the wild-type and heterozygous lanes. Mutant protein can be seen in both the
heterozygous and compound heterozygous lanes.
Four bands (65, 63, 54, 52kDa) are visible when wild-type WT1 protein is
separated on an SDS-PAGE gel. These consist of two doublets, one from each of the
two translation initiation sites (see section 1.5.1). The two bands making up each
doublet consist of the + (65/63kDa) and - 17aa (54/52kDa) isoforms from each
initiation site (the presence or absence of the KTS region can not be resolved using
these gels). In the DDS heterozygous cells, both the higher molecular weight mutant
bands and lower molecular weight wild-type bands lie in the same region on the
filter, so it is not possible to distinguish one pair from the other. In wild-type cells
and other WT1-expressing cells such as the Ml 5 cell line, the higher molecular
weight doublet (65/63kDa) is less strongly expressed than the other pair (54/52kDa).
With this in mind, the relative intensities of the lower molecular weight mutant






Figure 4.13 Western analysis of nuclear extracts from differentiated ES cells
Wild-type, DDS heterozygous and DDS compound heterozygous CGR8 ES cells
were differentiated for 4 days with 5pM all-trans retinoic acid. Nuclear extracts were
prepared from the differentiated cells and separated on a 10% SDS-PAGE gel.
a. After Western blotting, the nitrocellulose filter was stained using Instaview (BDH) to
determine how equally loaded the lanes were.
b. WT1 protein was then detected using the 6F-H2 antibody.
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compared in heterozygous cells. This reveals a huge excess of wild-type over mutant
protein.
Comparing the relative levels of protein loading using the stained filter
(figure 4.13a), it can be seen that protein from the three genotypes is present on the
filter at approximately equal levels. This means that the observed scarcity of WT1
protein in the DDS compound heterozygous lane indicates a genuine reduction in the
amount ofmutant protein in the cells. It can be seen from figure 4.13 that the level of
lower molecular weight WT1 protein (44/42kDa) in the compound heterozygous
cells approximates to that in the heterozygous cells. As this represents only a tiny
fraction of the total amount of WT1 protein in the heterozygous lane, but the
majority of that in the compound heterozygous lane (in which it is being produced
from two alleles, rather than one), it can be concluded that, although DDS compound
heterozygous cells do contain WT1 protein, it is found at a much lower level than the
WT1 protein in the wild-type and DDS heterozygous cells.
A significantly lower level of mutant than wild-type protein had previously
been shown to be present in DDS heterozygous cells (Patek et al., 1999). This
occurred despite equivalent levels of mutant and wild-type RNA. When
heterozygous ES cells were made homozygous using high G418 selection, no WT1
protein was detected, despite the presence ofmutant mRNA being demonstrated by
Northern analysis (C.E. Patek, personal communication). The scarcity of mutant
protein in the nuclear extracts is shown here by Western analysis not to be due to
abnormal localisation to the cytoplasmic fraction (figure 4.14).
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Figure 4.14 Western analysis of cytoplasmic extracts from differentiated ES
cells.
To demonstrate that the lack of WT1 mutant nuclear protein in DDS
heterozygous and compound heterozygous ES cells is not due to its sequestration in the
cytoplasm, Western analysis with the 6F-H2 WT1 antibody was performed on
cytoplasmic extracts from these cells. CGR8 ES cells were differentiated as before, then
separated on a 10% SDS-PAGE gel.
a. After blotting, the filter was stained with Instaview to determine levels of loading.
b. Analysis with the 6F-H2 antibody. Nuclear protein from RA-differentiated wild-type
ES cells was included as a positive control.
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If the situation in the compound heterozygous cells resembles that in the high
G418 homozygous cells, with mutant mRNA found at appropriate levels and yet a
lower than expected amount of mutant protein detected, some kind of post-
translational mechanism is at work, possibly affecting mutant protein stability. The
relatively high levels of mutant protein found in heterozygous cells, as compared
with homozygous cells, may indicate that the presence of WT1 wild-type protein in
the same cell stabilises the DDS mutant form in some way.
4.3.4 Immunofluorescence analysis of ES cells of different DDS genotypes
after differentiation with retinoic acid
Having established that treatment with all-trans retinoic acid causes induction
of Wtl expression in ES cells, it was decided to investigate further the actual effect
of the RA on the cells. The mode of action ofRA on Wtl expression in ES cells is, as
yet, unknown, but is believed not to be a direct action on Wtl transcription via RA-
receptors (Scharnhorst et al., 1997). Immunofluorescence analysis was used to
enable the Wtl expression status of individual cells to be determined. It could then
be seen whether Wtl expression in retinoic acid-treated cells is universal, or only a
property of a subset of the cells, those which have differentiated along a particular
developmental pathway. The morphology of specific cells and whether or not they
were expressing WT1 could be observed and related.
In an initial experiment, performed to determine whether
immunofluorescence analysis could detect WT1 protein in differentiated ES cells,
wild-type ES cells only were grown on glass cover-slips both in the presence and in
the absence of retinoic acid. After four days under these conditions, the cells were
washed, fixed and blocked, then the C-terminal C-19 WT1 primary antibody applied.
This antibody was used because it was known to give the strongest signal in
immunofluorescence analysis. The secondary antibody was FITC-conjugated,
enabling the location of the WT1 protein to be detected using a fluorescence
microscope.
When undifferentiated ES cells were examined, the level of FITC observed
approximated background level, supporting the previous observation that
undifferentiated ES cells do not express WT1 (figure 4.15d). When differentiated
wild-type cells were examined, virtually all cells were seen to contain WT1 protein
at high levels in their nuclei (figure 4.15b).
As a further comparison of relative levels of WT1 in cells of different DDS
genotypes, cells of all three genotypes were then differentiated with retinoic acid on
coverslips for 4 days. The cells were then washed, fixed and blocked, then the N-
terminal WT1 antibody 6F-H2 was applied. This detects both mutant and wild-type
forms of WT1. A FITC-conjugated secondary antibody was used, causing the
location of WT1 protein to be marked by green fluorescence. The mountant used
when the coverslips were mounted on to glass slides contained DAPI, enabling cell
nuclei to be identified.
Examination of RA-differentiated wild-type and DDS heterozygous cells
revealed that Wtl expression occurs in virtually all cells (figure 4.16a-d). Expression
was far less in compound heterozygous cells, with the vast majority of cells again
expressing Wtl, but at far lower levels (figure 4.16e & f). Signal intensities are
comparable, as images were captured using the same exposure times and settings.
This agrees with the data obtained by Western analysis, which showed far lower
Figure 4.15 Immunofluorescence analysis of WT1 expression in differentiated
and undifferentiated wild-type CGR8 ES cells.
a. RA-differentiated cells, DAPI staining
b. RA-differentiated cells, C19 WT1 primary antibody, FITC-conjugated secondary
antibody
c. Undifferentiated ES cells, DAPI staining





Figure 4.16 Examination of WT1 protein in RA-differentiated ES cells of different
DDS genotypes using immunofluorescence analysis
ES cells were differentiated on glass cover slips for 4 days with 5pM RA.
Immunofluorescence analysis was then performed using the 6F-H2 WT1 primary
antibody and a FITC-conjugated secondary antibody. Magnification x400.
a. Wild-type cells, 6F-H2 b. Wild-type cells, DAPI
c. Fleterozygous cells, 6F-FI2 d. Heterozygous cells, DAPI
e. Compound heterozygous cells, 6F-H2 f. Compound heterozygous cells, DAPI
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WT1 protein levels in the sequentially targeted cells than would be expected from
the amount of protein loaded. The immunofluorescence evidence reveals that this
low level is due to universal lowered expression, rather than a small proportion of
cells expressing Wtl at levels comparable to the other two genotypes.
The presence of WT1 signal in nearly all differentiated cells may indicate
that retinoic acid acts directly on Wtl transcription, or at least upstream of something
acting on Wtl transcription, rather than causing the cells to differentiate into
different types, some ofwhich normally express Wtl. To examine this more closely,
experiments were designed to examine Wtl expression immediately after addition of
retinoic acid, as well as in retinoic acid-differentiated cells after retinoic acid had
been withdrawn.
4.3.5 Immunofluorescence analysis of cells after addition of retinoic acid
reveals when WT1 protein appears.
An idea of the mechanism by which RA causes Wtl induction in
differentiating ES cells could be obtained by determining the length of time taken
after RA addition for WT1 protein to be detected. A rapid reaction of Wtl to RA
would suggest a direct action of RA on Wtl transcription, whereas a delay would
imply that the observed Wtl expression results from the differentiation status of the
cells.
To determine how soon after the addition of retinoic acid to undifferentiated
ES cells WT1 expression begins, wild-type CGR8 ES cells were differentiated on
glass cover slips with retinoic acid for lengths of time ranging from 12 hours to 4
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days. Immunofluorescence analysis was then performed using the WT1 C19
antibody to detect the appearance ofWT1 protein.
WT1 protein was first seen in a few cells after 36 hours of exposure to
retinoic acid (figure 4.17). By 48 hours of exposure, the vast majority of the cells
were seen to express WT1. It was not possible to determine whether individual cells
seen to be expressing WT1 had a more differentiated morphology than their non-
expressing neighbours using phase contrast microscopy, but by the time WT1
expression was universal, it was clear that the cells had generally lost their initial ES
cell-like appearance (figure 4.18). However, the length of time taken before WT1
expression appeared suggests that the activation of Wtl is not a direct result of
retinoic acid addition, but caused by differentiation of the cells.
4.3.6 Immunofluorescence analysis of retinoic acid-differentiated cells after
retinoic acid withdrawal.
Addition of all-trans retinoic acid to ES cells causes induction of WT1
expression, which first appears in some cells after 36 hours of exposure, then quickly
spreads to all cells by 48 hours. The seeming unrelatedness of this expression to cell
morphology (i.e. cells of very different appearance express Wtl) suggests that
retinoic acid-induced differentiation into particular cell types that normally express
Wtl is not the mechanism in action here. However, the slow response of Wtl
expression to RA indicates that RA probably does not directly affect Wtl
transcription. In an attempt to clarify this, the effects of differentiation with retinoic
acid followed by its removal were examined. This would indicate whether the
continued presence of retinoic acid in the cell culture medium is necessary for Wtl
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Figure 4.17 Induction of WT1 expression by the addition of retinoic acid to
wild-type ES cells
Using C19 WT1 antibody. Magnification x400. Time after retinoic acid addition:
a. 12 hours b. 24 hours c. 36 hours
d. 48 hours e. 72 hours f. 96 hours
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Figure 4.18 Cell morphology after addition of retinoic acid to wild-type ES cells
Time after retinoic acid addition:
a. 12 hours b. 24 hours c. 36 hours
d. 48 hours e. 72 hours f. 96 hours
Magnification x400.
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expression, thus showing that the effect is a direct one, or if Wtl expression
continues, pointing to the differentiated nature of the cells as the cause.
Wild-type ES cells were differentiated with retinoic acid for 4 days. The
medium was then replaced with normal tissue culture medium, containing LIF, for
lengths of time ranging from zero to 10 days. Immunofluorescence analysis was then
performed using the C19 WT1 antibody. WT1 protein was found in the vast majority
of cells up to 10 days after the withdrawal of retinoic acid (figure 4.19). This
indicates that after the cells have been differentiated for 4 days with retinoic acid, the
continued presence of retinoic acid is no longer necessary for the cells to maintain
Wtl expression.
This suggests that the action of retinoic acid on Wtl expression does not
occur directly on Wtl transcription, unless some type of positive feedback loop is
triggered which continues to function once the RA is removed. A more likely mode
of action is indirectly through differentiation of the ES cells. This suggests that the
presence of RA in the cell culture medium causes the cells to differentiate into cell
types of different morphologies, which nonetheless all express Wtl. Whether or not
the cells continue to differentiate after the removal of the RA, the Wtl expression
remains constant for at least 10 days after this point. This observation is unexpected,
considering that very few cell types express Wtl during development.
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I. III.
Figure 4.19a Effects of withdrawing retinoic acid from differentiated ES cells for 0
and 2 days
I. 0 days, C19 WT1 antibody III. 2 days, C19 WT1 antibody
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Figure 4.19b Effects of withdrawing retinoic acid from differentiated ES cells for
4 and 6 days
Magnification x400.
I. 4 days, C19 WT1 antibody III. 6 days, C19 WT1 antibody
H. 4 days, DAPI IV. 6 days, DAPI
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I. III.
Figure 4.19c Effects of withdrawing retinoic acid from differentiated ES cells for
8 and 10 days
Magnification x400.
I. 8 days, C19 WT1 antibody III. 10 days, C19 WT1 antibody
H. 8 days, DAPI IV. 10 days, DAPI
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4.4 Effects of DDS mutations on subnuclear localisation and ratios of
Wt1 splice isoforms
4.4.1 Examination of the subnuclear localisation of WT1 protein by
immunofluorescence analysis in differentiated CGR8 ES cells
Denys-Drash syndrome-like mutant proteins have been shown to colocalise
with +KTS isoforms and splicing factors (Larsson et al., 1995). As these mutant
proteins have been suggested to act by binding to wild-type WT1 protein present in
the same cell and disrupting its normal function, it was hypothesised that this
binding leads to the colocalisation with splicing factors of all WT1 protein in a DDS
cell. Indeed, Englert et al. (1995) found that coexpression ofwild-type and truncated
WT1 protein in a cell resulted in an alteration of wild-type protein distribution to a
'speckled' pattern. This would prevent the wild-type WT1 present from performing
its normal functions as a transcription factor, but splicing functions might be left
intact.
To investigate whether this effect of truncated WT1 protein on wild-type
protein occurs in DDS heterozygous cells, wild-type and DDS heterozygous CGR8
ES cells were grown on glass cover slips in six-well plates for four days in the
presence of retinoic acid. After fixation and blocking, the C-19 C-terminal WT1
antibody was used to detect the subnuclear locations of the wild-type protein only,
and the 6F-H2 N-terminal antibody to detect both mutant and wild-type WT1
proteins (figures 4.20 & 4.21).
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Figure 4.20 Immunofluorescence analysis of RA-differentiated CGR8 wild-
type and DDS heterozygous ES cells using the 6F-H2 WT1 antibody.
Cells were grown and differentiated on glass cover slips, then immunofluorescence
analysis was carried out using the 6F-H2 WT1 antibody with a FITC-conjugated
secondary antibody. This antibody binds to the N-terminal region ofWT1, so will
detect both mutant and wild-type WT1 protein in the DDS heterozygous cells.
Examination of the subnuclear localisation of the protein was carried out using a
confocal microscope.
a. Wild-type cells.




Figure 4.21 Immunofluorescence analysis of RA-differentiated CGR8 wild-type
and DDS heterozygous ES cells using the C19 WT1 antibody.
Cells were grown and differentiated as in figure 3.20, then immunofluorescence analysis
was carried out using the C19 WT1 antibody with a Texas Red-conjugated secondary
antibody. This will only detect wild-type WT1 protein in the DDS heterozygous cells, as
the antibody will not bind to the truncated form of the protein. The subnuclear
localisation of the protein was examined using confocal microscopy. Magnification x400.
a. Wild-type cells
b. DDS heterozygous cells
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Examination of the slides using confocal microscopy did not reveal any
apparent difference in the subnuclear localisation of the wild-type WT1 protein in
the DDS heterozygote. A more speckled appearance was not apparent with either
the C-terminal or N-terminal antibody in heterozygous as compared with wild-type
cells. Thus, in these cells, endogenous DDS mutant proteins do not appear to affect
WT1 function by altering the subnuclear localisation of the endogenous wild-type
protein present.
4.4.2 Comparison of ratios of Wt1 isoforms possessing and lacking first
alternatively-spliced region
Studies of the expressed ratios of the different Wtl isoforms possessing and
lacking the first alternatively spliced region (exon 5) have found species-specific,
tissue-specific and developmental stage-specific differences in these ratios (Haber et
al., 1991; Renshaw et al., 1997). These studies did not examine ES cells, however,
so it was considered interesting to examine these ratios and compare them with those
previously reported for mouse tissues (Renshaw et al., 1997). It was already known
that differentiated ES cell progeny express WT1 isoforms both with and without
alternatively-spliced exon 5, as the 17 amino acid difference in size between these
two isoform groups can be detected on a Western blot (figure 4.14b). The
proportions of the two isoform groups had not been determined, however, and as the
ratios of mutant to wild-type forms changes from RNA to protein in the DDS
heterozygote (Patek et al., 1999), and the DDS compound heterozygote expresses
very little mutant protein, it was decided to examine the isoform ratios at the RNA
level by RT-PCR.
The PCR primer pair K447 and K448 was used in this analysis (Moore et al.,
1999)(appendix II). This amplifies a stretch of the Wtl cDNA surrounding the exon
5 region, and gives a band of 243bp with isoforms containing exon 5 and 192bp
from isoforms without. The PCR reactions were performed with the addition of 33P
a-dATP, products were run on a 6% polyacrylamide sequencing gel (see appendix
I), then dried and exposed to X-ray photographic film. Relative band intensities
were compared using a Gel Doc 1000 gel viewer and Molecular Analyst software
(BioRad).
Surprisingly, it was discovered by this method that undifferentiated ES cells
did in fact express Wtl, but at very low levels relative to retinoic acid-differentiated
cells (figure 4.22). This can be accounted for by the higher sensitivity of the RT-
PCR technique compared with Western analysis. An exception to this is the cDNA
from undifferentiated wild-type E14 ES cells. In this, and subsequent PCRs
performed on the same sample, it produced a strong signal, suggesting that either the
cDNA concentration was much higher than the other samples, or that the culture
contained a proportion of spontaneously differentiated cells, and was therefore
expressing higher than expected levels ofWtl.
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Table 4.4 Ratios of Wt1 isoforms with and without first alternatively-spliced
region shown by RT-PCR analysis of embryoid bodies and RA-differentiated
ES cell progeny
Genotype Isoform ratios - exon 5: + exon 5
CGR8 cells E14 cells CGR8 EBs E14 EBs
+/+ 0.65 0.36 0.50 0.43
+/- 0.57 0.68 0.56 0.63
-/- 0.65 0.42 0.56 0.61
It was found that all genotypes of RA-differentiated CGR8 cells, plus wild-
type, DDS heterozygous and DDS high G418 homozygous El4 cells and embryoid
bodies (EBs) produced from those cells (see section 5.2.4) expressed both isoforms.
The larger isoforms were more highly expressed, with ratios of the smaller to larger
isoforms having a mean value of 0.55 (ranging from 0.36-0.68:1). This is extremely
consistent with the median values of 0.28-0.64:1 published by Renshaw et al. (1997)
for various mouse tissues. No difference in this ratio was seen that could be
described as attributable to Wtl genotype.
4.4.3 Comparison of ratios of Wt1 isoforms possessing and lacking the KTS
alternatively-spliced region
The relative ratios of + and - KTS isoforms ofWT1 in embryonic stem cells
has not previously been examined. These two groups of isoforms, being only three
amino acids different in size, are not readily separable as proteins on an acrylamide
gel, so it was previously undetermined whether or not both isoforms were expressed
at all in differentiated ES cells. Previous studies had found both these groups of
isoforms expressed in all tissues examined, including Wilms' tumours, and human
foetal kidney and mouse adult ovary, testis and uterus (Haber et al., 1991; Renshaw
et al., 1997). Haber et al. (1991) found that isoforms containing the KTS insert were
always seen to be in the majority, in an average ratio of 3.3:1 with the isoforms
lacking KTS. This ratio is somewhat higher than those found in subsequent studies
(Simms et al., 1995; Renshaw et al., 1997).
Again, this analysis was carried out by RT-PCR, as described above, with
33P-labelled products being separated on a 6% polyacrylamide denaturing gel. The
primers used were J520 and J521, as described in Moore et al. (1999), which bind
within exon 9. For sequences and PCR conditions, see appendix II.
As the KTS region falls after the /Aril site into which the selectable marker
sequences are inserted in the WTV1 and WTV2 targeting vectors, it was expected
that no bands would be produced from the compound heterozygous cDNA (figure
4.23). The inserted region in each vector is approximately 2kb, and contains a
polyadenylation signal, so transcriptional read-through would not be expected.
Heterozygous clones would also only be expected to produce signal from one Wtl
allele. This was not the case, however, and cDNA from cells of all genotypes
(including E14 heterozygous and high G418 homozygous cells) was found to
produce the expected doublet of 115 and 106bp bands (figure 4.24). To confirm that
this result was due to transcriptional read-through, and not to use of the incorrect
genotype of cells, a second pair of primers was designed in this region. This primer
pair, DDS1 and DDS2, spanned the /Aril site, so a signal would not be obtained




Figure4.23ExonninofWt1,showingpositionsrim rdRT-PCR analysisof+/-KTSis forms Thefigureshowstpositionf/f rlls enexo9fWt ,i twhicht PGK-hygrocassetteofvectorWTV2ins rted(nottscale).Tposi i nsfprimer pairJ520and1(Mooreetl.,1999)rindica d,spr meriDDS1n DDS2,whichspantheifarllite,ndt ereforeg vnroductromta getedall l s.
D U D U D U
U - undifferentiated ES cells
D - RA-differentiated ES cells
b.
Differentiation time (days)
Figure 4.24 RT-PCR analysis of CGR8 RA-differentiated ES cells and embryoid
bodies using primers around the +/- KTS alternative splice site
Autoradiographs from PCRs performed with primers J520 and J521 (Moore et
al, 1999).
a. CGR8 undifferentiated and RA-differentiated ES cells
b. CGR8 embiyoid bodies
+/+ wild-type
+/- DDS heterozygote
-/- DDS compound heterozygote
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appendix II for primer sequences and PCR conditions). With this pair of primers, the
expected result was obtained: a pair of bands of expected sizes 164 and 173bp were
produced from wild-type and heterozygous, but not compound heterozygous or
homozygous cDNA (fig 4.25). This was only examined by separation on an
ethidium bromide stained gel, as it was merely the presence or absence of the bands
which was sought.
The bands produced by the +/- KTS primers (J520 and J521) from the
compound heterozygous and homozygous DDS cDNA (and presumably from the
cDNA from one allele of the heterozygous cells) appeared to originate from a
transcript under the control of the Wtl promoter, as the bands were far stronger in
the differentiated than undifferentiated cDNA. Unfortunately, as the precise nature
of the RNA transcript which is being amplified here is unknown, the relative
proportions of the + and - KTS transcripts derived from the wild-type allele in the
heterozygous cells cannot be reliably determined using primers J520 and J521. This
could have been done using primers DDS1 and DDS2, but time did not permit.
Therefore only the +/- KTS ratio in the wild-type cells can be examined. These
results, for RA-differentiated ES cells and embryoid bodies (see section 5.2.4) are
presented in table 4.5.
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Figure 4.25 RT-PCR to confirm genotype of sequentially targeted cells
As unexpected positive signals were produced by cDNA from DDS
compound heterozygous and homozygous cells, a PCR was designed which crossed
the site at which the selectable marker sequences were inserted in WTV1 and WTV2.
This should not amplify sequences from targeted alleles, as the insertion places 2kb
of sequence between the two primers. Results are shown for differentiated and
undifferentiated cells from both the E14 and CGR8 cell lines, revealing that no bands
were seen in either the compound heterozygous or homozygous cDNA.
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Table 4.5 Ratios of KTS isoforms in wild-type embryoid bodies and RA-
differentiated ES cells




n/d - not determined
Renshaw et al. (1997) found no consistent ratio differences between species,
tissue or developmental stage for these isoforms, with median values for the mouse
ranging from 1.04-1.41. The ratios in table 4.5 are also fairly similar to one another,
although these are lower than those found by Renshaw et al., with a higher
proportion of transcripts without the KTS insert found.
4.5 Discussion of chapter 4
The results described above indicate that the cells used for sequential
targeting began the experiment with the correct genotype and a high proportion of
cells containing the correct number of chromosomes. The identity of the plasmid,
WTV2, used to produce the second targeting event was also confirmed before
electroporation was performed. The correct amount of hygromycin B to use for
selection of targeted cells after electroporation with WTV2 was determined.
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Due to the isogenic nature of the targeting vector, a high level of success was
achieved in the two electroporations performed. Approximately 30% of surviving
clones were found to have the targeted genotype with both the Wilms' internal and
external probes. The continuing presence of the neomycin and hygromycin resistance
sequences from WTV1 and WTV2 was demonstrated using probes specific to these
sequences. A high proportion of cells in these sequentially targeted clones was found
to contain the correct number of chromosomes.
Sequencing of the second targeting vector revealed the nature of the second
mutation. The insertion of hygromycin resistance sequences at this point in exon 9 of
Wtl was found to produce a similar, although not identical, truncation to the first.
This also has the desired effect of producing a mutant form ofWT1 that functionally
lacks the last two zinc fingers.
Contrary to results obtained during analysis of the first targeting event (Patek
et a!., 1999), ES cells of none of the genotypes studied, including wild-type, were
found to express detectable Wtl by Northern or Western analysis. No difference in
the sensitivity of the techniques used in the two cases could explain this, as the same
experimental protocols were used each time. The only possible explanation is that
the wild-type and DDS heterozygous cells analysed in the first case contained a
proportion of differentiated cells, or had been grown in other conditions which
promoted Wtl expression. As treatment of ES cells with retinoic acid was known to
upregulate Wtl expression (Scharnhorst et al., 1997), it was decided to differentiate
the cells in this manner in order to obtain the desired Wtl signal.
The optimum level of all-trans retinoic acid required to induce Wtl
expression for further experiments was determined by differentiating cells for 5 days
with different RA concentrations. A concentration of 5pM was chosen, which led to
WT1 protein being detectable by Western analysis. It had previously been
demonstrated using high G418 DDS homozygous cells that cells with two alleles
producing proteins with truncations in ZF3 of WT1 contain no WT1 protein (C.
Miles, personal communication) despite presence of mutant Wtl mRNA (Patek et
al., 1999). It unfortunately was not possible to confirm that this was also true of the
compound heterozygous cells, as Northern analysis of these cells was unsuccessful.
A suggested mechanism for this could be decreased mutant protein stability, as the
putative WT1 nuclear localisation signal is not affected by the truncation (Bruening
et al., 1996), nor is WT1 protein found in the cytoplasmic fraction of these cells. The
lower than expected level of the mutant forms ofWT1 in the DDS heterozygote are
still higher than WT1 protein levels in the compound heterozygote. This could be
due to the presence of wild-type WT1 in the same cell stabilising the mutant in some
way (Patek et al., 1999), possibly through the formation of complexes, as WT1 is
known to be able to self-associate via the N-terminal domain, which is still intact in
DDS mutant protein (Holmes et al., 1997).
When examining both wild-type and DDS heterozygous cells by
immunofluorescence analysis, it was found that the vast majority of cells expressed
WT1 after 4 days of treatment with 5pM retinoic acid. In other words, the WT1
signal produced after retinoic acid differentiation is not just due to certain cells
differentiating along particular pathways and expressing WT1 in abundance, but a
general effect on all cells. The expression levels of WT1 protein in wild-type and
DDS heterozygous differentiated cells do not seem to differ significantly, bearing in
mind that expression from the wild-type allele is normal and expression from the
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mutant allele highly reduced. This is in contrast to a result published by Yang et al.
(1999), who examined WT1 protein expression in the podocytes ofDDS patients and
found a much more significant decrease in this expression as compared with normal
kidneys. This may be a suggestion that the situation in differentiated ES cells
containing a DDS mutation may not be a true reflection of the in vivo situation.
However, the study by Yang et al. (1999) was performed on biopsy specimens from
patients already diagnosed with DDS, and the lengths of time between the first
symptoms of nephropathy and end-stage renal failure in this study are short (median
= 0.6 years). This could mean that the disappearance ofWT1 protein does not occur
until a fairly late stage in the progression of DDS and that the results from the ES
cells are representative of an earlier stage of the in vivo situation.
The induction of Wtl expression was first seen after 36 hours of exposure to
retinoic acid and was universal after 48 hours. This was accompanied by an
alteration in cell morphology away from an ES cell-like appearance. This, and the
length of time taken for WT1 protein to appear, suggests that induction of Wtl by
retinoic acid is due to the resulting differentiated state of the cells, rather than a
direct transcriptional effect of retinoic acid on the Wtl gene. This is supported by the
finding that after differentiation with retinoic acid for 4 days, followed by its
removal, ES cells continue to express Wtl for at least 10 days. If the retinoic acid
were acting directly on Wtl transcription, WT1 protein would be expected to
disappear upon its removal. Other groups examining effects of RA on WT1
expression in different cell types have found evidence which also suggests that RA
does not act directly on Wtl. Scharnhorst et al. (1997) found a delay in RA-induced
Wtl expression in ES and P19 embryonal carcinoma cells similar to that found here.
HL60 cells show a down-regulation of Wtl when induced to differentiate using RA,
and K562 cells do not differentiate in response to RA, and no change is seen in Wtl
expression upon its addition (Sekiya et al., 1994). This would indicate that RA does
not only not act directly on Wtl expression, but does not always even induce it
indirectly when added to cells. It strongly suggests that the observed Wtl expression
is merely the result of the nature of the cellular differentiation induced, which will of
course vary depending on the nature of the starting cells.
The cell type or types produced from ES cells by the addition of RA in this
experiment have not been determined. It does seem strange that, despite the
variations in morphology seen in the differentiated cultures, the vast majority of
these cells give a signal with WT1 antibody. Wtl expression during development is
far from ubiquitous, with expression confined to specific developing organs, such as
the kidney, at particular developmental stages (Armstrong et al., 1992). Most of the
tissues in which Wtl is found to be expressed are mesodermally derived, with the
exception of some ectodermally derived regions of the central nervous system
(Armstrong et al., 1992). Not all mesodermally and ectodermally derived tissues
express Wtl, however, so the control of Wtl expression involves far more specific
mechanisms than simply the production of a particular cell type. This makes it
extremely unlikely that all the cell types produced during differentiation of ES cells
with retinoic acid are those which normally express Wtl. It would be possible to
study in more detail the cell types produced by RA-differentiation of ES cells to
establish the nature(s) of the cells that are shown here to express Wtl. This could be
done through immunological techniques to look for the presence of markers of
particular cell lineages, or through gene expression analysis (see section 6.1).
Denys-Drash syndrome type proteins have been shown to colocalise with
cellular splicing factors in a similar manner to +KTS wild-type WT1 isoforms
(Larsson et al., 1995). DDS mutant proteins are also suggested to alter the function
of the wild-type protein in a heterozygous cell through protein-protein interaction
(Reddy et al., 1995) and affect the subnuclear localisation of wild-type WT1 protein
(Englert et al., 1995). This suggests that binding between mutant and wild-type
protein in a DDS cell could lead to the abnormal localisation of wild-type -KTS
isoforms to the splicing compartment, preventing transcriptional activity. Wild-type
and DDS heterozygous cells were examined using immunofluorescence to determine
whether any abnormal localisation of the wild-type WT1 protein could be detected in
the heterozygous cells. Two WT1 antibodies were used: the C-terminal antibody C-
19 and the N-terminal antibody 6F-H2. The former will only detect the wild-type
protein, as the epitope it recognises is found in the region of the protein encoded by
exon 10, and is therefore missing from the truncated protein. 6F-H2 will recognise
both mutant and wild-type WT1. No difference in expression pattern was seen with
either antibody between the mutant and wild-type cells, suggesting that the presence
of DDS mutant protein does not significantly affect the localisation of wild-type
WT1 protein also present. The study by Englert et al. (1995), in which mutant WT1
was shown to alter the subnuclear localisation of wild-type WT1, used transient
transfection of these proteins into a cell and only used one isoform at a time. This
use of exogenous WT1 protein at non-physiological levels means that the experiment
does not accurately reflect the in vivo situation. My use of endogenous WT1 protein,
expressing all the different isoforms, may mean that subtle differences in the
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localisation of some of the isoforms may have been hidden, whereas these were
magnified in the study ofEnglert et al.
It is not known whether the colocalisation of some WT1 isoforms with the
cellular splicing machinery is due to a function ofWT1 protein in splicing or just a
sequestration of non DNA-binding isoforms in clusters. It has been suggested that
WT1 could be involved in splicing (Larsson et al., 1995; Ladomery et al., 1999). In
this case, the presence of DDS mutant protein in a cell could affect Wtl RNA
splicing and result in an altered ratio ofWT1 isoforms. An alteration in these ratios
is implicated in diseases such as Frasier syndrome (Barbaux et al., 1997; Klamt et
al., 1998). The ratios of the various WT1 isoforms have been found to vary in a
species-specific, tissue-specific and developmental stage-specific manner (Renshaw
et al., 1997), but the differentiated progeny ofES cells, as studied here, had not been
investigated. RT-PCR analysis was used to examine the relative proportions of the
RNA species giving rise to the different WT1 isoforms for two purposes: (1.) To
determine whether the isoform ratios in wild-type differentiated ES cells were
similar to those previously reported in other cell types and (2.) To see whether these
isoform ratios differed according to genotype in DDS mutant cells.
The ratios of the different Wtl splice isoforms differing by the presence or
absence of the exon 5 insert were determined by RT-PCR analysis. These were very
similar to those published by Renshaw et al. (1997) for a range of mouse tissues.
This previous study found a variation between different tissue types, with higher
levels of exon 5-containing transcripts found in kidney and testis, but the RA-
differentiated ES cell cultures examined here do show morphological heterogeneity,
so isoform ratios covering the full range found in mouse tissues is not unexpected.
No difference was found between the +/- exon 5 ratios that was attributable
to Wtl genotype. This would suggest that either WT1 has no effect on its own
splicing, or that the region of the WT1 protein required for this effect is not affected
by the DDS truncations examined here.
The results obtained for the ratios of Wtl mRNA transcripts possessing and
the lacking the KTS alternatively spliced region in wild-type ES cell differentiated
progeny, on the other hand, differed from previously published findings. These
results were consistent between the cell lines examined, ranging from 0.71-0.91:1,
but are very different from the 3.3:1 ratios obtained by Haber et al. (1991). Simms et
al. (1995) and Renshaw et al. (1997) found +/- KTS ratios closer to 1:1, but these
also had the isoforms containing the KTS insert in the majority, whereas the present
study found a higher level of isoforms lacking this region. Although Renshaw et al.
(1997) found no developmental stage-specific differences in these isoform ratios,
the only foetal tissue studied was human kidney, which does not rule out the
possibility that mouse foetal tissues express different ratios, more consistent than
those found for ES cells in the present study.
The above results indicate that cells of the desired genotype were produced by
the targeted strategy utilised. These cells contain less WT1 protein than expected,
although how this relates to mRNA levels could not be determined. If these
compound heterozygous cells do contain a higher level of Wtl mRNA than would
account for the levels of protein observed, as was previously found in high G418
homozygous cells, some kind of post-translational mechanism is believed to be in
action, possibly through protein stability. ES cells were found to be induced to
express Wtl upon differentiation with all-trans retinoic acid, and the results obtained
using immunofluorescence analysis suggest that this is more likely to operate
through the differentiation of the cells, rather than a direct transcriptional activation
of Wtl by retinoic acid. Other immunofluorescence work revealed that presence of
DDS mutant WT1 protein in a cell does not appear to alter the subnuclear
localisation of wild-type WT1 protein also present. The presence of DDS mutant
protein does not alter the relative proportions of Wtl mRNA species possessing and
lacking the exon 5 alternatively spliced region, which were found to be very similar
to the proportions of these isoforms previously published for other cell types. The
proportions of +/- KTS isoforms could only be determined for wild-type cells and
embryoid bodies, and were found to agree with some previously published results
and differ from others.
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5. Comparison of wild-type and Wt1 mutant ES cells bv differentiation
into embrvoid bodies.
When grown in the absence of LIF and allowed to form three-dimensional
structures, ES cells will differentiate into embryoid bodies (EBs). These contain cells
from all three embryonic germ layers (ectoderm, mesoderm and endoderm)
(Doetschman et al., 1985). EBs have proved to be a useful tool for the examination
of early developmental processes. They have been allowed to differentiate over a
period of time and used to study the temporal expression patterns of various genes,
for example, muscle isoactin (Ng et al., 1997). The effects of overexpression of
particular genes in EBs has been examined, including the effects of m-twist
expression on myogenic differentiation, and hepatocyte nuclear factor 3 on
endodermal differentiation (Rohwedel et al., 1995; Levinson-Dushnik and
Benvenisty, 1997). ES cells null for the desmin gene have been shown through EB
production to be unable to differentiate into smooth or skeletal muscle (Weitzer et
al., 1995).
Systems have been established for the promotion of the development of
particular lineages within EBs. These involve the culture of the EBs in medium
containing specifically tailored combinations of growth factors. For example, one
can choose to produce outgrowths from embryoid bodies consisting predominantly
of neuronal, myogenic or haematopoietic lineages (Bain et al., 1994; Drab et al.,
1997; Wiles and Keller, 1991). Four day old EBs will produce many cells with
neuronal properties when differentiated for a further four days with all-trans retinoic
acid then allowed to attach to a surface and form outgrowths (Bain et al., 1994).
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Embryoid bodies made using hanging drop culture, grown in suspension for 5 days,
then allowed to attach in the presence of all-trans retinoic acid and dibutyryl-cAMP
(db-cAMP) can produce up to 60% smooth muscle cells under optimum conditions
(Drab et al., 1997). Wiles and Keller (1991) produced EBs by culturing ES cells in
methyl cellulose, then transferred the EBs to tissue culture plates and allowed them
to attach. The medium was then supplemented with IL-3 to promote mast cell growth
and IL-3 and M-CSF for macrophage development.
As Wtl is expressed early in development (mouse early E9 - Armstrong et
al., 1992), it was thought that embryoid body experiments might be a useful method
for assessing the developmental capabilities of Wtl mutant ES cells. This initially
just consisted of a straightforward EB differentiation in the absence of LIF, and then
proceeded to include an examination of haematopoietic differentiation in wild-type
and Wtl mutant embryoid bodies.
5.1 Use of RT-PCR analysis to examine Wt1 expression in embryoid
body time courses
RT-PCR analysis was used to demonstrate that Wtl expression was occurring
within embryoid bodies, so that any differences in phenotype found could be
attributed to the Wtl mutation. It was established that undifferentiated ES cells do
not express Wtl at levels detectable by Northern or Western analysis (see section
4.2.4), but that ES cells differentiated with 5pM retinoic acid for four days express
high levels of Wtl (section 4.3.1).
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Analysis was performed on the same cDNA samples as used in section 5.3.4,
using the K447 and K448 Wtl primers (see section 4.4.2). These results are
presented in table 5.1, and level of expression, is assigned a value on a scale ranging
from - (no detectable expression) to +++ (high levels of expression).
Table 5.1: Wt1 expression in embryoid body time courses measured using
RT-PCR
Diffn. Genotype
time CGR8 embryoid bodies E14 embryoid bodies
(days) +/+ +/- -/- +/+ +/- -/-
4 + +++ + - ++ +++
8 + + + + ++ not done
12 + + + + + ++
+/+ wild-type
+/- heterozygote
-/- homozygote/ compound heterozygote
It can be seen from the table that Wtl expression was detected at all but one time
point examined, for both CGR8 and E14 embryoid bodies. There appears to be no
obvious relationship between levels of expression and time, but the fact that Wtl
expression is detected at all in these time courses means that any phenotypic
differences mentioned later in this chapter which vary consistently with Wtl
genotype may well be due to the Wtl mutation.
5.2In vitro differentiation of wild-type, DDS heterozygous and DDS
compound heterozygous CGR8 ES cells into embryoid bodies
As Wtl may play an important role in the differentiation of several different
cell types, it was decided to produce embryoid bodies from wild-type, DDS
heterozygous and DDS compound heterozygous ES cells. The aim was to see
whether the Wtl mutant cells were incapable of producing any particular lineages, or
whether an excess of a particular cell type could be detected, for example muscle
cells, as myogenic differentiation is believed to be promoted in the absence ofWT1
(Miyagawa etal., 1998).
ES cells were differentiated by the cell aggregation method (Martin and
Evans, 1975; Smith and Hooper, 1987), in which cells are grown to high density in a
dish, then gently broken up into clumps and allowed to differentiate into embryoid
bodies in suspension in the absence of LIF. Embryoid bodies were either kept in
suspension until being harvested for analysis, or removed to tissue culture dishes just
after cavitation and allowed to attach to the surface of the dish and form outgrowths.
Suspension embryoid bodies were harvested at various time-points,
embedded, then sectioned and stained with haematoxylin and eosin. These sections
were then examined by bright field microscopy to see whether any differences in
histology were apparent. Embryoid bodies that had been allowed to attach to the
surface of a dish were examined by phase contrast microscopy while growing.
Suspension embryoid bodies were found to exhibit endoderm formation and
cavitation (figure 5.1), and outgrowths from attached embryoid bodies showed a
range of cell types, including beating cardiomyocytes (figure 5.2). No difference was
Figure 5.1 Section of suspension embryoid bodies
Section ofH&E stained CGR8 DDS compound heterozygous embryoid bodies
after 14 days differentiation in suspension. Parietal and visceral endoderm and
cavitation can be observed.
Magnification x200.
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seen between the three genotypes of embryoid body in terms of time taken for
cavitation to occur or presence of beating cardiomyocytes. No cell types were
obviously missing or more prevalent in mutant or wild-type embryoid bodies. This
suggests that absence of wild-type WT1 protein has no gross effect on the lineages
produced during embryoid body development. No blood islands were observed
during these experiments, which therefore yielded no information on any role of
WT1 in haematopoiesis. It would, of course, be possible to use marker genes for
specific lineages to examine embryoid body development in more detail, but no
starting point for this analysis was suggested by this experiment. As no apparent
differences were seen, it was decided to use a more subtle approach to specifically
examine in vitro the role ofWT1 in haematopoiesis.
5.3 Investigating the role of WT1 in early haematopoiesis using the CFU-
A assay and RT-PCR
The role ofWT1 in haematopoiesis remains unclear. As described in section
1.7, it is known that WT1 expression occurs in the population of bone marrow cells
believed to contain the HSC and is then down-regulated (Baird and Simmons, 1997).
This down-regulation is accompanied by cellular differentiation, suggesting that it
could be some kind of switch, required to allow differentiation to proceed. Indeed,
the expression of antisense WT1 oligonucleotides in proliferating leukaemic cells
induces them to differentiate (Yamagami et al., 1996), and expression of WT1 in
monoblastic cell line U937 prevents differentiation, even in the presence of inducing
agents (Svedberg et al., 1998). This being the case, the importance of WT1 in the
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haematopoietic differentiation process must be considered. Is WT1 expression in this
period of early haematopoietic development crucial for later development to occur?
The definitive test for haematopoietic potential is through long-term
repopulation of a lethally-irradiated recipient mouse (Moore and Metcalf, 1970), but
in vitro assays are also available which can give an idea of the ability of cells to
generate haematopoietic lineages (Johnson et al., 1980; Humphries et al., 1979;
Pragnell et al., 1988). These generally involve the use of semi-solid media, such as
methylcellulose or agar, containing specific haematopoietic growth factors, or
conditioned medium known to contain such growth factors. Cells such as bone
marrow or ES cells, or embryoid bodies, are grown in this environment and the
morphologies of any colonies formed are examined by phase contrast microscopy
(Pragnell et al., 1988; Hole et al., 1996). The growth factors used in the assay
determine from which subset of haematopoietic progenitors colonies will form. Such
assays include those for high proliferative potential colony-forming ceils (HPP-CFC),
granulocyte-macrophage colony-forming units (CFU-GM) and colony forming unit A
(CFU-A). Relationship of these to one another and to the CFU-S detected by the in
vivo spleen colony-forming assay has been determined, and a presumptive hierarchy
established (figure 5.3)(Kriegler et al., 1994).
5.3.1 Comparison of wild-type and Wt1 mutant ES cells from the CGR8 and
E14 lines using an in vitro assay for haematopoietic differentiation
As a role for WT1 has been suggested in leukaemia (see section 1.7), it was
decided to compare the relative performances of the three DDS genotypes of ES
















haematopoietic progenitors. The CFU-A assay was chosen to compare the abilities of
different DDS genotypes to differentiate into haematopoietic cells because it
examines a very early stage of haematopoietic development, before the
lymphoid/myeloid split (see figure 5.3), and as WT1 mutations have been identified
in leukaemias originating from both these lineages, the role of WT1 in normal
haematopoiesis is likely to occur at an early stage (King-Underwood and Pritchard-
Jones, 1998). Another reason for the use of this assay is that the behaviour of wild-
type ES cells in the CFU-A assay has previously been well characterised (Hole et al.,
1996). It has been demonstrated that wild-type embryoid bodies will produce
recognisable haematopoietic cells even in the absence of externally applied growth
factors (Wiles and Keller, 1991). The CFU-A assay uses haematopoietic growth
factors to encourage the growth of haematopoietic colonies from embryoid bodies
(Hole et al., 1996). The growth of a colony indicates the presence of at least one
haematopoietic progenitor within the embryoid body from which it grew. Positive
colonies are at least 1mm in diameter, and consist of mixed myeloid lineages,
predominantly macrophages (figure 5.4)(Hole et al., 1996).
Embryoid bodies were made using the hanging drop method (see section
3.1.11) from wild-type, DDS heterozygous and DDS compound heterozygous CGR8
ES cells. This method produces embryoid bodies of a uniform size, allowing
comparisons between different genotypes. These were then allowed to differentiate
in the absence of LIF for periods ranging from 2 to 18 days. The embryoid bodies
were then plated into the assay and grown in a 5% CO2/ 10% 02 incubator in the
presence of conditioned medium containing GM-CSF, CSF-1 and SCF for 7 to 14
days, at
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Figure 5.4 CFU-A positive and negative colonies.
The CFU-A assay was set up as described in the text. After 10 days, the assay was
scored, and colonies were photographed using a light microscope.
a. CFU-A positive colony (x40). A 'halo', consisting of cells ofmixed myeloid
lineages, has grown outwards from the original embryo id body, still seen in the
centre.
b. CFU-A negative colony (xlOO). This colony contained no haematopoietic precursors
of a suitable maturity to respond to the growth factors present in the assay. No change
has occurred to the embryoid body.
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which point the dishes were scored to determine the percentage of embryoid bodies
initially plated which had given rise to a CFU-A positive colony.
It is already known that wild-type embryoid bodies, regardless of their ES
cell line of origin, follow a specific temporal pattern in the CFU-A assay (Hole et
al., 1996). Very few colonies are produced from EBs which have been differentiated
for less than four days. After this, the proportion of CFU-A positive colonies rises to
a peak of approximately 40-60% somewhere between days six and eight, which then
tails off. The exact percentage of positive colonies at the peak of the graph and the
timing of this peak vary between experimental runs and cell lines, but the basic
pattern remains the same. This pattern suggests that it takes at least four days of
culture in the absence ofLIF to produce cells of haematopoietic lineages, or at least
to produce haematopoietic cells of sufficient maturity to respond to the growth
factors present in the assay and produce a colony. The average length of time taken
to produce such cells, however, is six to eight days. The fact that the proportion of
positive colonies decreases after the peak suggests that there is a limited temporal
window for the production of haematopoietic progenitors leading to CFU-A
colonies. After this time, the haematopoietic cells present in the EBs are too mature
to produce CFU-A colonies, and either produce smaller, CFU-GM-like, colonies, or
none at all (Hole et al., 1996).
Wild-type ES cells used in this experiment came from both the CGR8 and
E14 cell lines. A single experiment using the CGR8 cell line and mutants derived
from it is shown in figure 5.5, and summary data for all CGR8 experiments
presented in table 5.2. The CGR8 EBs were consistently shown to peak on days 6 to






Figure 5.5 CFU-A activity in CGR8 embryoid bodies
Cell aggregates were prepared using hanging-drop culture, then differentiated in
the absence of LIF for times ranging from 2 to 14 days. The resulting embryoid bodies
were then plated into semi- solid agar containing the growth factors GM-CSF, CSF-1 and
SCF and incubated for 7 days. Colonies over 1mm in diameter were scored as being
CFU-A positive. This is presented as a proportion of the total embryoid bodies plated.
Both DDS heterozygous and DDS compound heterozygous embryoid bodies are seen
here to take longer than the wild-types to reach their maximum colony production.
Data from experiment 4 presented in table 5.1.
Error bars show standard errors.
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peaks in El4 experiments varied from day 6 to day 12, with a tendency towards the
later time points (table 5.3).
In all experiments, the DDS compound heterozygous CGR8 EBs took longer
than the wild-type EBs to reach their peak haematopoietic activity (figure 5.5, table
5.2). This delay varied from two to more than four days relative to the wild-type
cells. DDS heterozygous CGR8 cells also showed a delay, ranging from two to four
days later than the wild-type cells (table 5.2). This peak was usually seen to coincide
with the peak in the compound heterozygous cells, but on occasion fell between the
wild-type and compound heterozygous peaks. As time points in this study are two
days apart, there is not sufficient resolution to detect the difference, if any, between
these two genotypes.
The height of the peak (maximum proportion of embryoid bodies producing a
CFU-A positive colony) varies considerably between the different experimental
runs. There is no consistent difference between the different genotypes regarding the
height of this peak, suggesting that, once Wtl mutant embryoid bodies begin
producing CFU-A progenitors, this occurs at the same frequency as it does in wild-
type embryoid bodies.
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Day of differentiation at which CFU-A peak reached, with
height of peak in brackets
+/+ +/- -/-
1 8 (24%) 10 (36%) 14+ (37%+)
2 8-10 (33%+) 12 (5%) 12 (3%)
3 8 (40%) No colonies 12 (15%)
4 6 (20%) 8+ (40%+) 8 (22%)
A second heterozygous clone was also used in each experiment as a control
for passage number, as the compound heterozygous cells have been through many
more passages than the wild-type cells, due to two targeting and selection
procedures. These control clones were heterozygous cells that had undergone the
second electroporation and survived the selection, but were found to have not
undergone homologous recombination at the wild-type Wtl allele. These cells had
undergone approximately the same number of passages as the compound
heterozygous cells, but had the same genotype as the heterozygotes, so could be
used as a control to determine whether any effects seen were due to genotype or just
to increased passage number. Unfortunately, these cells failed to produce more than
a handful of colonies in most of the experiments, so it is hard to say when they
actually peak. However, as the heterozygote and compound heterozygote usually
peaked at the same time anyway, it is unlikely that passage number had any effect
here, making the control unnecessary.
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The E14 ES cells used in this study generally formed fewer CFU-A positive
colonies than the CGR8 cells. Three genotypes were used: wild-type, DDS
heterozygote, and DDS homozygote (made by high G418 selection). The results
obtained from the CFU-A assay comparison of the E14 cells were consistent with
those obtained from the CGR8 cells (table 5.3). The results for only wild-type and
DDS homozygous cells are summarised in table 5.3, as DDS heterozygous cells
failed to produce colonies in most of the experiments. The height of the peak in
DDS homozygous embryoid bodies is considerably lower than that in wild-type
embryoid bodies, but as this effect was not seen in CGR8 experiments, it is unlikely
to be an effect of the Wtl mutation.
Table 5.3: Summary of CFU-A assay results for wild-type E14 cell line (+/+)
and its DDS homozygous derivative (-/-)
Experiment number Day of differentiation at which CFU-A peak
reached, with height of peak in brackets
+/+ -/-
1 8-10 (13%) 12(21%)
2 12 (26%) 12 (7%)
3 6-8 (27%) 12+ (5%+)
4 8-10 (81%) 12+ (26%+)
5 10 (59%) 10 (21%)
An in vitro assay such as this can only provide an indication of the potential
of cells to undergo haematopoietic development. The precise natures of the cell
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types capable of forming a colony in this assay are unknown, as are other factors,
such as the relationship of in vivo primitive and definitive haematopoiesis (see
section 1.3) to the results seen here. Are both of these represented in the typical
CFU-A curve, or only one? If both are represented, how would the graph change if
the effects of one of these processes were removed? It could be the case that
absence ofWT1 completely blocks all primitive haematopoiesis, for example, and it
is this lack which causes the observed delay on the graph. As previously mentioned,
the definitive test for the potential of cells from embryoid bodies of different stages
to form haematopoietic lineages is to examine their ability to achieve long-term
repopulation of the haematopoietic system of a lethally-irradiated mouse (Moore
andMetcalf, 1970).
5.3.2 Staining of embryoid bodies produced from wild-type, DDS
heterozygous and DDS compound heterozygous ES cells for the presence
of haem
Another drawback to the use of the CFU-A assay in the study of
haematopoietic potential is that it relies on the response of haematopoietic cells
within the embryoid bodies to specific growth factors in the conditioned medium.
This means that a failure to produce colonies in the assay could be due to a blocked
response to the growth factors, rather than a failure of haematopoiesis itself. So, the
effect observed in the Wtl mutant embryoid bodies could be due to a failure of the
cells to respond to GM-CSF, CSF-1 and SCF, not to a failure to differentiate along
this pathway. This can be tested using an independent method to assess
haematopoietic differentiation, one that is not reliant on growth factors.
Primitive erythropoiesis is the first haematopoietic activity seen in the yolk
sac of the developing embryo (Moore and Metcalf, 1970). This being the case,
markers for erythropoiesis should be detectable in a time course of embryoid bodies
produced as described above. Blood islands are often observed during embryoid
body development (Wiles and Keller, 1991), however none were seen here in either
wild-type or Wtl mutant ES cells.
Cells of erythroid lineage contain haemoglobin, which can be visualised by
staining with o-dianisidine, an analogue of benzidine (figure 5.6). This enables the
proportion of EBs containing erythroid cells to be determined easily, and a
comparison of erythropoietic activity between wild-type and mutant EBs over a time
course could be performed. This is a method of assessing haematopoietic activity
completely independent from the CFU-A assay, and the results could therefore reveal
whether Wtl mutation has a genuine effect on haematopoiesis, or if the CFU-A
results are simply due to a failure of the growth factors in the assay to act on
haematopoietic cells which are actually present.
A time-course of embryoid bodies was produced, which were differentiated
from 2 to 18 days. This consisted of CGR8 ES cells of two genotypes: wild-type and
DDS compound heterozygote. Embryoid bodies from the time-course were plated
into the CFU-A assay as usual. Excess embryoid bodies that were not required for
the assay were stained for the presence of haem using o-dianisidine.
The proportion of embryoid bodies that stained positive for haem produced a
graph very similar in appearance to that for the CFU-A assay for the same time-
course (figure 5.7). The peak of the curve is again seen later for the DDS compound




Figure 5.6 An embryoid body stained with o-dianisidine to reveal the
presence of haem.
Embryoid bodies made by hanging drop culture were stained with o-dianisidine to
reveal the presence of haem, an indicator of erythroid differentiation (see section
2.1.12). The staining can seen as red-brown spots on this embryoid body.
Magnification = x200.
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Legend to figure 5.7:
a. The embryoid body time course was produced as described in section 3.1.11, th
approximately 150 embryoid bodies were plated into CFU-A dishes (section 3.1.13}
b. Excess embryoid bodies were stained using o-dianisidine to reveal the presence
haem (section 3.1.12). The proportion of embryoid bodies showing any staining w
scored.
Error bars show standard errors.
Figure 5.7 CFU-A and haem formation in the same populations of wild-type






CFU-A assay is a real effect of the mutation on the haematopoietic differentiation
pathway, rather than an interaction between the mutation and the assay. In other
words, the later presence of CFU-A positive colonies in the mutant cell line is not
due to an effect of the mutation on the ability of cells to react to the growth factors
present in the assay, thus preventing the appearance of colonies from embryoid
bodies containing haematopoietic cells at the appropriate stage ofmaturity.
In the wild-type EBs, the peak of erythropoietic activity, as measured by o-
dianisidine staining, occurs 2 days later than the peak seen in the CFU-A graph for
the same EBs. This is as expected, as the haematopoietic cells detected by o-
dianisidine are more mature than CFU-A, and would therefore be expected to take
longer to appear. The peaks seen in the compound heterozygous graphs, however,
appear to coincide. This could suggest that once haematopoietic differentiation does
begin in the mutant cells, it proceeds more rapidly than in wild-type cells, but there
is evidence from the CFU-A assays that refutes this. Many of the CFU-A assays
performed were scored at more than one time point. An increase in the proportion of
positive colonies was seen between the earlier and later scorings (figure 5.8). This is
to be expected, as more primitive precursors will take longer to produce a positive
colony, and these will be detected at the later time, but not the earlier. No differences
were seen in the size of this increase between mutant and wild-type embryoid bodies,
indicating that there is no difference in the rate at which the haematopoietic
precursors appear between the mutant and wild-type EBs.
It is interesting to note how similar the proportions of embryoid bodies
displaying haematopoietic activity are when measured by two separate methods. The
CFU-A assay gave proportions of 40 and 15% at the peak for the wild-type and
Legend to figure 5.8:
Embryo id bodies were plated into the CFU-A assay as before. The proportion
of positive colonies for each genotype was counted after 7 days of incubation. The
dishes were then replaced into the incubator and left for another 7 days before being
scored again.
a. Wild-type embryoid bodies
b. DDS compound heterozygous embryo id bodies
Error bars represent standard errors.
Figure 5.8 Comparison of maturity of haematopoietic progenitor cells in
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compound heterozygote respectively, while o-dianisidine staining revealed 54 and
21%. This does confirm that these two methods are measuring related effects, albeit
by different approaches
The observation that the proportion of EBs containing erythroid cells peaks
then falls is possibly unexpected, as erythrocytes continue to contain haem
throughout their life span. The life span of an enucleated definitive mouse
erythrocyte is 42-56 days (Loeffler et al., 1989), but as the stage of erythropoiesis
represented here is likely to occur very early in development, the erythroid cells
produced here may be nucleated cells, of the type produced during primitive
haematopoiesis, about which little is known. This loss of erythroid cells is consistent
with that found by Wiles and Keller (1991), however, who observed formation of
blood islands in embryoid bodies, followed by their disappearance after 10 days of
culture. This may reflect a one-off, rather than continuous, pattern of erythroid
differentiation, in which differentiation only commences up to a certain time, then
cells mature and die and are no longer observed.
5.3.3 Replating of CFU-A colonies from wild-type and DDS compound
heterozygous embryoid bodies
In order to gain a better understanding of the mechanisms by which the Wtl
mutations exert their effects, it was decided to replate primary CFU-A colonies to
examine any effects of these mutations on the self-renewal potential of individual
colonies.
An embryoid body plated into the CFU-A assay will produce a positive
colony whether it contains one CFU-A cell or several. Replating dissociated colonies
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from the CFU-A assay will reveal how many CFU-A cells were present in the
primary colony. This could be important, as it could give an insight into the
mechanism by which Wtl mutations cause a delay in differentiation in this pathway.
If the lack of WT1 causes cells to be held at an early stage of haematopoietic
differentiation (see figure 5.9), leading to increased self-replication, rather than
differentiation, primary colonies from the earlier stages of the time-course should
contain a higher proportion of cells capable of producing secondary colonies after
disaggregation. Thus, more secondary colonies would be produced per primary
colony replated. If, however, the lack of WT1 prevents the cells from entering the
haematopoietic differentiation pathway altogether for a time (see figure 5.9), there
would be no apparent increase in self-renewal in the early stages, and the graph for
the mutant secondary colonies would resemble that for the wild-type colonies, but
shifted to the right due to the delay.
A short time-course of embryoid bodies was produced from wild-type and
DDS compound heterozygous ES cells, with EBs differentiated for 4, 6 and 8 days.
These were plated into a CFU-A assay, as described previously. After 7 days in the
assay, the proportion of embryoid bodies producing CFU-A positive colonies was
scored. The next day, individual positive colonies were picked out of the CFU-A
plates, dissociated into single cells, then plated back into CFU-A dishes, each
primary colony into its own dish. These dishes were replaced in the low oxygen
incubator for a further 10 days, then the number of positive colonies on each dish
was scored.
The initial CFU-A graph suggests that the wild-type peaks on day 4, and the
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Legend to figure 5.10:
A time course of embryoid bodies was plated into the CFU-A assay as befc
After 8 days of incubation, the colonies formed were picked, disaggregated and repla
into the CFU-A assay in separate dishes.
a. Initial CFU-A assay.
b. Secondary CFU-A assay.
Error bars show standard errors.
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Figure 5.10 Comparison of primary CFU-A positive colony formation with








earlier than has been found in previous experiments, but the time taken to reach the
peak proportion of positive colonies is subject to variation between runs. In the wild-
type embryoid bodies, the highest level of self-renewal is observed when the
percentage of primary CFU-A positive colonies is highest, at 4 days of
differentiation, when a large number of haematopoietic progenitors have appeared.
By day 6, both the level ofCFU-A positive colonies and the number of progenitors in
each colony have diminished. This indicates that many of the progenitors present at
day 4 have differentiated into something not detected by the assay, for example
erythroid lineages, by day 6, or have matured into a myeloid cell not capable of
producing a colony in this assay. The amount of self-renewal per primary colony
does not alter between days 6 and 8 in wild-type cells.
In the mutant, very few CFU-A positive colonies are present at day 4, and
each of these has low self-renewal ability. Both the number of primary colonies and
the self-renewal potential of each colony increase by day 6, indicating an increase in
both self-renewal and differentiation of progenitors into myeloid lineages. Between
days 6 and 8, there is a large increase in self-renewal capacity, yet no significant
change in the number of primary colonies produced.
A comparison of this pattern with that seen in the wild-type suggests that Wtl
mutation blocks entry into the haematopoietic differentiation pathway.
Unfortunately, no data were obtained from wild-type embryoid bodies before the
peak level of primary colonies was reached. Even so, it is possible to see that the
amount of self-renewal present in the mutant primary colonies is low at the time
when the primary wild-type level is high, suggesting that these mutant embryoid
bodies do not contain primitive haematopoietic cells retarded at an early stage of
haematopoietic differentiation and undergoing self-renewal rather than
differentiation. It is more likely that these embryoid bodies contain cells that have
not yet begun to undergo haematopoietic differentiation, as the self-renewal level is
low.
5.3.4 Examination of gene expression during haematopoietic differentiation
using semi-quantitative RT-PCR analysis
An examination of gene expression in these embryoid bodies could indicate
when haematopoietic differentiation actually begins, and help discover at what
developmental stage the mutation introduces a delay.
A time course of embryoid bodies was set up from CGR8 ES cells of the
various DDS genotypes as previously described, then total RNA was extracted after
4, 8 and 12 days of differentiation. A CFU-A assay was also performed on embryoid
bodies from the same time course (figure 5.5). The RNA was used to examine the
expression patterns of genes which had previously been shown to alter their
expression during embryoid body differentiation (Schmitt et al., 1991; McClanahan
el al., 1993; Hole et al., 1996). The genes chosen for analysis were adult bl and
foetal y (3-globin and G-CSF-R. The (3-globin genes are believed to be very early
indicators of the initiation of haematopoietic differentiation (J. Ansell, A.
Cunningham, personal communication). Expression of the receptor for G-CSF has
been suggested to be a marker for commitment of cells to myeloid lineages
(McClanahan et al., 1993). It was considered interesting to look for changes in
expression patterns, attributable to the Wtl mutations, related to the observed delay
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in haematopoiesis found using the CFU-A assay. These results are summarised in
table 5.4 and illustrated in figure 5.11.
Previous studies have found the expression of foetal and adult P-globin to be
an indicator of initiation of haematopoietic development. In a time course of wild-
type embryoid bodies, expression of both types of p-globin are first detected by RT-
PCR analysis at around days 3 to 5 of differentiation (Hole et al., 1996). This is
consistent with the results found here in CGR8 embryoid bodies, where adult p-
globin is expressed at a high level at all the time points examined. Foetal P-globin
expression is also seen at all time points in CGR8 wild-type EBs. In contrast, neither
adult nor foetal P-globin expression is seen at the earliest time point in any of the
mutant EBs. If p-globin expression is indeed a marker of the very earliest
haematopoietic differentiation, this is consistent with the idea that the Wtl mutations
present in these cells prevent the cells from entering the haematopoietic pathway for
a time.
The G-CSF receptor is expressed mainly in precursor and mature neutrophils
and myeloid cell lines (Park et al., 1989). Performing a similar experiment with RT-
PCR analysis of a time course of embryoid bodies, McClanahan et al. (1993) found
significant induction of G-CSF-R during in vitro development, and suggested that
this gene is a good candidate as a marker ofmyeloid lineage commitment. Schmitt et
al. (1991) and Hole et al. (1996) also found its induction during an in vitro EB time
course at days 12 and 8 of differentiation, respectively. As shown in figure 5.11 and
table 5.4, CGR8 wild-type EBs show only a small increase in G-CSF-R expression
from day 4 to day 8, followed by a large increase in expression between days 8 and
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Figure 5.11 Autoradiographs of semi-quantitative RT-PCRs on cDNA from a
CGR8 embryoid body time course
PCRs were performed on cDNA extracted from CGR8 embiyoid bodies
having undergone 4, 8 and 12 days of differentiation, taken from the same time
course as those used for the CFU-A assay shown in figure 5.5.
a. Adult [3-globin b. Foetal (3-globin c. G-CSF receptor
Differentiation time (days)
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12. Very little expression was seen in any of the mutant embryoid bodies, including
no expression after 4 days of differentiation in any mutant. This lack of expression at
day 4 would be as expected if a delay in haematopoietic induction is occurring in the
mutant EBs. The very low level of G-CSF-R is surprising, though, if this is indeed a
marker ofmyeloid commitment, as CFU-A positive colonies are believed to consist
of mixed myeloid lineages, especially macrophages, and no difference in colony
morphology has been observed between those produced from mutant and wild-type
embryoid bodies. It could be that once the mutant embryoid bodies begin producing
haematopoietic cells, these remain in a fairly primitive state until plated into the
assay, as opposed to haematopoietic cells arising within wild-type EBs, which begin
to mature before encountering the growth factors in the assay. Two lines of evidence
refute this hypothesis, however. Firstly, the shape of the curve on a CFU-A graph
indicates that CFU-A cells are produced within embryoid bodies, then their numbers
begin to fall away as they mature into cells unable to produce a colony in the assay.
This falling off of CFU-A numbers is detected in all mutant genotypes as well as
wild-types, suggesting that the haematopoietic precursors in all EBs are maturing
over time. Secondly, the evidence from scoring CFU-A assays at different times (see
figure 5.8) revealed no difference in the rate of CFU-A production in mutant and
wild-type cultures. If the mutant embryoid bodies contained a population of more
primitive cells, a higher proportion of positive colonies would be expected to appear
later, and this is not seen.
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5.4 Discussion of chapter 5
It has been demonstrated here that cells predicted to contain no functional
WT1 protein (ie not capable of normal DNA binding - Borel et al., 1996; Pavletich
and Pabo, 1991) are able to form embryoid bodies in vitro. These embryoid bodies
are morphologically similar to those produced from wild-type ES cells and appear to
contain a diverse range of cell types. Evidence that lineages derived from all three
primitive germ layers are present in Wtl mutant embryoid bodies could be obtained
by examining the expression of genes known to be markers for some of these
lineages, using RT-PCR, Western analysis, or in situ hybridisation.
From the more specific studies of the effects of this mutation on
haematopoietic development in vitro, some evidence has been obtained for a role for
Wtl in this process. Embryoid bodies produced from cells with DDS-type truncations
in either one or both Wtl alleles were found to take longer to differentiate into
haematopoietic precursors than wild-type embryoid bodies. This was demonstrated
using two independent methods for measuring haematopoietic differentiation: a
direct stain for the presence of haem to reveal embryoid bodies in which
erythropoiesis was occurring, and the CFU-A assay which indicates the presence of
early haematopoietic precursors.
Examination of the self-renewal potential of the mutant and wild-type CFU-A
colonies suggested that the Wtl mutation either prevents the cells from entering the
haematopoietic differentiation process for a time or slows down the early stages of
this process. Further evidence to support this came from looking at the expression of
foetal and adult (3-globin in these embryoid body time courses. Initiation of (3-globin
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expression is believed to occur at a very early stage of haematopoietic
differentiation. This expression was seen to begin at a later time point in mutant
compared with wild-type embryoid bodies. However, as the cells do go on to
produce haematopoietic cells eventually, it is shown that the presence of wild-type
WT1 is not an absolute requirement for haematopoietic differentiation to occur.
WT1 could stimulate a step in the differentiation process, causing it to occur more
rapidly in the presence of WT1 than without WT1. Alternatively, a completely
separate pathway could be responsible for the haematopoietic differentiation seen in
the Wtl mutant cells, either being activated later than the WT1-dependent pathway,
or operating throughout, but at a slower rate than the WT1-dependent pathway.
This evidence points to a role for WT1 at the very beginning of
haematopoietic differentiation. However, despite the occurrence of a phenotype due
to lack of functional WT1 during in vitro ES cell differentiation, no evidence for
haematopoietic defects has been reported in WT1 null mice (Kreidberg et al., 1993).
This may be because such defects have not yet been investigated, although the results
from the CFU-A assays suggest that it could be worth doing. Homozygous Wtl null
embryos die between day 13 and 15 of gestation (Kreidberg et al., 1993), however,
and such defects might not be apparent at this early stage. Also, a patient has been
reported who is a constitutional homozygote for a missense WT1 mutation (Kikuchi
et al., 1995), yet has no apparent haematopoietic defects. According to the results of
the in vitro CFU-A assay, despite a delay, haematopoietic development can proceed
in the absence of functional WT1, which may happen in vivo soon enough to prevent
disruption of haematopoietic development. This does not mean, however, that subtle
differences in the haematopoietic system do not result from lack ofWT1. The patient
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reported by Kikuchi et al. (1995) was only 13 months old, and could perhaps have
gone on to develop leukaemia in later life. Also, in neither the Kikuchi et al. study or
the Kreidberg et al. (1993) null mouse paper was any detailed examination made of
the haematopoietic system. This therefore does not rule out the possibility that subtle
differences, perhaps in the proportions of the different blood cell types, are present.
The results from the DDS heterozygous cells, which also showed a delay
relative to wild-type cells, are interesting, as the mutations found in AML cases have
been reported to resemble the mutation in the heterozygous cells, in that they are
usually found in a heterozygous state and lead to the disruption of the WT1 zinc
finger region (King-Underwood et al., 1996; King-Underwood and Pritchard-Jones,
1998). This is evidence for the idea that the observed delay in haematopoiesis caused
by the presence of Wtl mutations may be directly related to the mechanism by which
the heterozygous mutations found in AML lead to leukaemia.
How could a mutation that delays entry into haematopoiesis be involved in
leukaemogenesis? As the haematopoietic stem cells (HSCs) are produced during
prenatal development, the mutation would have to occur at this stage. It is possible
that a halt in the differentiation process of a cell, caused by a mutation like this,
could increase the chance of some other genetic event occurring. In other words, it
could make a 'second hit' in the same cell, or its progeny, more likely, perhaps in a
gene required for the regulation of proliferation. This cell could then become one of
the many quiescent HSCs which are found in a mature mammal. Only a small
proportion of the HSCs are active at any one time, and these few are responsible for
the maintenance of the cell population of the haematopoietic system (Lajtha, 1979).
If the mutant HSC became activated, as part of the normal haematopoietic
maintenance processes, it could then begin to proliferate out of control, as a
regulatory mechanism for this process would be non-functional.
Of course, it is ectopic expression of WT1 that is the predominant
observation in human leukaemias, so possibly examination of haematopoietic
differentiation in cells lacking functional WT1 is unlikely to elucidate matters. It
could be that this finding in leukaemias represents a separate, later, time point at
which WT1 acts, which is related to the observed down-regulation of WT1 during
early haematopoietic differentiation (Sekiya et al., 1994; Phelan et al., 1994).
Perhaps an examination of the performance in this assay of ES cells overexpressing
Wtl would give a better indication of the role ofWT1 in leukaemogenesis. Although
the presence of WT1 mutations (King-Underwood and Pritchard-Jones, 1998) in
leukaemias, possibly producing protein with reduced or altered WT1 function, and
the identification of leukaemias with overexpression of apparently wild-type WT1
(Miwa et al., 1992; Inoue et al., 1994) appears contradictory, it is possible that two
different routes to leukaemia can be achieved by opposite effects on the same gene.
There is evidence to suggest that WT1 overexpression or inappropriate expression
will maintain cells in, or return them to, a proliferative state, despite the presence of
differentiation-inducing stimuli (Svedberg et al., 1998; Inoue et al., 1998). It is
therefore easy to see how ectopic WT1 expression could cause leukaemia. As has
been demonstrated here, Wtl mutations which affect the zinc finger region of the
protein cause a delay in haematopoietic differentiation from ES cells. This delay
could increase the chance of a cancer-causing mutation occurring in a
haematopoietic precursor, resulting in leukaemia later in life when the resulting HSC
becomes activated.
It should be pointed out that the WT1 mutations detected in leukaemias have
been observed in a heterozygous form, leading to truncated proteins such as the ones
used here (King-Underwood and Pritchard-Jones, 1998). The embryoid bodies
produced from such heterozygous cells did reveal a delay in haematopoiesis similar
to that seen in the compound heterozygotes and homozygotes. These two results
would indicate that the role of WT1 in haematopoiesis could be a) sensitive to
dosage of the wild-type protein, b) the mutant forms are somehow affecting the wild-
type, or c) that the mutant forms have a novel, dominant function. The second
suggestion is unlikely, as there is no wild-type protein in the compound
heterozygotes or homozygotes, which show the same effect. The extremely low level
ofmutant protein present in these genotypes also makes the last hypothesis doubtful,
although as some mutant protein is present, it could be possible.
The CFU-A assay has shown that a DDS-type mutation in only one Wtl allele
is sufficient to cause a delay in haematopoiesis, yet DDS patients are constitutional
heterozygotes for this type of mutation, and leukaemia has not been reported as a
common secondary malignancy in DDS, nor are defects of the haematopoietic
system a feature of DDS. However, subtle haematopoietic abnormalities have not
been investigated.
It could be that Wtl expression in early haematopoietic precursors is
important not only to maintain the cells in a proliferative state, but also fulfils an
important role in the maturation process, enabling further haematopoietic
differentiation to then occur. WT1, in its role as a transcription factor, may trigger
the expression of certain genes required for further differentiation along the
haematopoietic pathway. In Wtl mutants, expression of these genes is not induced,
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so differentiation cannot proceed. However, haematopoiesis does eventually occur,
and no defects of the haematopoietic system have been reported in Wtl null mice, so
transcription of these genes must eventually occur via some other mechanism. The
results reported here, however, suggest that it could be worthwhile to make a
detailed examination of the haematopoietic system in Wtl null embryos and
heterozygous null mice. It is possible that the haematopoietic microenvironment
within the embryoid bodies alters at some point in the differentiation process and
begins to produce something which overrides the requirement for WT1 and triggers
an alternative pathway.
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6. Use of cDNA expression arrays to investigate gene expression in Wt1
mutant and wild-type ES cells
As already discussed in section 1.5.2, many genes have been suggested as
transcriptional targets of WT1. A list of these is found in table 1.1. Such genes were
linked with WT1 either because their expression was found to alter in Wilms'
tumours compared with normal kidney, or because the suggested WT1 consensus
sequence was found in their promoter regions. In vitro experiments using promoter
constructs provided further evidence for these genes being direct WT1 targets
(Drummond et al., 1992; Gashler et al., 1992). However, more recent work suggests
that at least some of these results may be artifacts, as the examination of endogenous
target gene expression rather than constructs found no evidence for an effect ofWT1
on some of these genes (Englert et al., 1995a). These experiments still used
transfection, often transient, ofWT1 cDNA into the cell, meaning that only one of a
possible 16 WT1 isoforms was represented. This obviously does not reflect the
normal situation either in vivo or in vitro, so the production of ES cells with Wtl
mutations has provided a useful tool for the examination of endogenous target gene
expression in cells where the expressed WT1 is also endogenous and under the
control of its own promoter. In an attempt to identify genes that are genuinely under
the transcriptional control ofWT1, cDNA from RA-differentiated ES cell progeny of
wild-type cells and cells harbouring Wtl mutations in the zinc finger domain was
used to probe cDNA arrays fixed on membranes. Macroarray technology allows the
expression ofmany, in this case 588, genes to be studied simultaneously. The arrays
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used have cDNA spots arranged into functional groups on a nylon membrane (figure
6.1), and the full list of genes represented can be found at:
http://www.clontech.com/archive/JAN98UPD/Atlaslist.html
A cDNA probe was made from polyA+ RNA, with the incorporation of dNTPs
containing 32P-dATP to radioactively label the transcripts. The resulting labelled,
mixed, cDNA population was used to probe the Mouse Atlas™ expression array
(Clontech). Hybridisation occurred between species represented in the cDNA probe
and cDNA spots fixed to the membrane, giving a signal on an autoradiograph, or
using a phosphorimager, the intensity of the signal produced being proportional to
the abundance of the specific cDNA in the probe (Kelly and Rizzino, 2000). The
resulting pattern of signals from two different genotypes or from differentiated and
undifferentiated cells of the same genotype could be compared, revealing the
expression levels of the various genes represented on the membrane. The results
were analysed using Clontech's Atlaslmage™ software, which compares the
intensities of each spot on the membrane between two different membranes.
6.1 Comparison of gene expression in retinoic acid-differentiated and
undifferentiated wild-type ES cells
The comparison between undifferentiated wild-type CGR8 ES cells and their
RA-differentiated progeny was performed to provide information about some of the
cell lineages that are produced when ES cells are induced to differentiate using all-
trans retinoic acid (figure 6.2). This continues the work described in section 4.3.4,
191
4 5 6
• 0 ♦ # f» •
1 2
3 0 « » «
b Q -3 0 0 00 9 © # • © ©




d © S> * ■
| 0 <|
i at « •
, ■ Oncogenes
h a o * Tumor suppressors
i • • • Cell-cycle regulators •
j » 9 •







ma# « # * + •# • • ♦ »
no# © # © © © « © • «#
1 2 3 4 5 6
a## ## • © •« •• « ♦
bo# # © • » «# a# # •
C © © • • #8 • I •# « ♦
da# »













9# 0 # #1# a (3 o#
ao mm # & 03 ©a
© © ♦ » #e a# a#




•a » a 9




* 0 0 »


















1 2 3 4 5 6 7
a#© ©• ©• » • •• • • #o
b## • ♦ • ♦ ♦ © ♦ » #9 39
C ♦ © ©9 ©• • © ©© 9© ©9
(J « * «
e © B *
1 " ' Stress response *
® * elon channels & transport '*
,
„ • Intracellular signal , „
transduction modulators
I • & effectors
k • • •
I © «# mm mm mm mm mm mm
m • • •© • ♦ •© •• ♦©
n©» ♦» #» «• •• •© #©
1 2 3 4 5 6 7
3 • « ft# •© •© «© «• ©a
b«# ©# #© 99 ©« 9# »9
C • # mm mm mm mm mm mm
d « i •
• « * > •
i < 'Receptors ••
g , - Growth (actor & chemokme, „
h - Interleukin & interferon
! ' -Hormone
\ * - Neurotransmittei * •
k ' • Cell-surface antigens | *
i , • Cell adhesion , 4
m » js
n • • a» * % > • *• « # e «
S 3 10 11 12 13 14
G • a 0 0 •• 0 0 9 • 0 0 » »
1 2 3 4 5 6 7
a a* •» •• a* •• ««
b •• «e «a a 9 a * •* 0000
C •• *0 00 00 09 •» ® -a # 9
0 # s 9 a • ■
*00 C
' * * * Apoptosis • • • •
® * * ° DNA synthesis, repair "n • • & recombination • • • •
fa* 0000
1*0 0300
k 00 00 00 00 00 00 0 0 0*
1 #0 00 00 00 00 00 0000
m 0 0 00 00 00 00 »0 00 ••
n 00 00 00 00 90 00 0000
12 3 4 5 6 7
a 90 00 0 9 90 00 00 00 00
b»« 00 0* 90 SO 00 0000
do '0 00
• 0 F 0 0#
t 0 • Cell-cell communication * • •
9 *
- Growth factors, cytokines " • •
ho j, chemokines 000
! » - Interfeukins & interferons 000
i • -Hormones 000
k a 000
I a* 00 99 90 00 o a a a 0 0
m a a 00 09 90 00 a» *0 00
n 00 00 09 00 00 00 0000
15 16 17 18 19 20 21
Gil 0 0 00 09 09 00 9000
00 00 00 00 00 00 00 00
Figure 6.1 Layout of the Clontech Atlas™ mouse version I expression array
Regions A-F contain 200-500bp cDNA fragments placed into functional
groupings. Region G (at the bottom of the array) consists ofnegative control plasmid
and bacteriophage cDNAs, plus nine housekeeping control cDNAs which are used to
normalise mRNA abundance. The darker spots at the very bottom and far right of the
array are genomic DNA, which are intended for use in orientation of the hybridised
array, enabling identification of the coordinates of signals of interest.
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b.
Figure 6.2 Comparison of gene expression in CGR8 wild-type retinoic acid-
differentiated and undifferentiated ES cells using mouse Atlas expression arrays.
a. Undifferentiated wild-type
b. Differentiated wild-type
Circles indicate the positions of some differentially expressed genes.
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where it was shown that the majority of cells express WT1 protein after 96 hours of
5pM RA-differentiation. It was hoped that the genes found to be expressed in the
differentiated cells would include some markers of cell lineage, enabling an
impression to be obtained of the cell types present in a differentiated cell population.
The results from this experiment were not compared using the Atlaslmage™
software, but by visual assessment, so they are not quantitative. Genes were
identified whose expression was seen to be substantially higher on one membrane
than the other, relative to the other signals present on each membrane. The results
are displayed in table 6.1.
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Table 6.1 Genes that were either substantially upregulated or downregulated
after four days of RA differentiation of wild-type CGR8 ES cells
Higher in undifferentiated cells Higher in differentiated cells
B-myb proto-oncogene Tight junction protein ZO-1
p53 tumour suppressor Protein kinase C theta
c-kit proto-oncogene Zyxin
Cyclin B1 (G2/M specific) Plasma glutathione peroxidase
IGFBP2 TDAG51
Heat shock protein 84 (Hsp90j3) Pre-adipocyte factor 1 (.Pref-1)
Heat shock protein 86 (Hsp90a) Homeobox protein 2.1 (Hoxb5)
BAG-1 BCL-2 binding protein Homeobox protein 2.4 (Hoxb8)
Glutathione S-transferase mu 1 IGFBP-4
Glutathione S-transferase pi 1 Insulin-like growth factor 2 (Ig/2)
MSH2 DNA mismatch repair protein Butyrate response factor 1
Lung Kruppel-like factor (LKLF) Serine protease inhibitor homologue J6
GTP-binding protein Cdc42
Fibroblast growth factor 4 (FGF-4)
Laminin receptor 1
Although it had already been determined from the evidence provided by
Northern, Western and immunofluorescence analysis that Wtl expression occurs in
the differentiated cells at a higher level than it does in the undifferentiated cells
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(section 4.3.4), this expression was not high enough even in the differentiated cells to
be detected by this method.
6.2Comparison of gene expression in retinoic acid-differentiated wild-
type and DDS compound heterozygous CGR8 and wild-type and
DDS homozygous E14 ES cell progeny
Comparisons between gene expression in CGR8 wild-type and DDS compound
heterozygous (figure 6.3) and between E14 wild-type and DDS homozygous (figure
6.4) differentiated ES cell progeny were made using Clontech mouse Atlas™ macro-
arrays. The cells had first been induced to differentiate for 96 hours using 5p.M all-
trans retinoic acid (section 3.1.8), as it was necessary to achieve WT1 expression in
the cells before making comparisons between the different genotypes. These results
were then compared to identify differences that were consistent between the two cell
lines, indicating effects attributable to Wtl mutation, rather than genetic changes
elsewhere in the genome.
Results were analysed using Atlaslmage™ software, which normalises spot
intensities relative to other spots on the same membrane, including those for house¬
keeping genes, before making comparisons between membranes, to account for
differences in overall hybridisation efficiency and probe labelling. The difference
between the normalised intensities was determined, as was the ratio of the
normalised intensities of the mutant to wild-type spots. Threshold values for the ratio
b.
Figure 6.3 Comparison of gene expression in CGR8 wild-type and DDS
compound heterozygous (Wt1tmT396/Wt1tmT403) retinoic acid-differentiated ES cells
using mouse Atlas expression arrays.
a. Differentiated wild-type
b. Differentiated DDS compound heterozygote








Figure 6.4 Comparison of gene expression in E14 wild-type and high G418 DDS
homozygous (Wt1tmT396/Wt1tmT396) retinoic acid-differentiated ES cells using
mouse Atlas expression arrays.
a. Differentiated wild-type
b. Differentiated DDS homozygote
Circles indicate the positions of some differentially-expressed genes.
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between the mutant and wild-type intensities outside which the value was considered
to be significant were determined by the software from the data, as were actual
values for this difference above which the results were considered to be significant.
Spots were considered to be significantly different from one another if the difference
exceeded a certain value and if the ratio fell outside the range 0.59-1.69. To be
considered significant, for the CGR8 comparison, the difference had to exceed 9335
normalised intensity units and for the E14 comparison, the difference had to exceed
225 normalised intensity units. Table 6.2 shows the genes that were considered to be
significantly different for at least one of the cell lines, and for which the results from
the other cell line are also significant, or nearly so.
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Table 6.2 Genes showing altered expression relative to wild-type cells in both
CGR8 DDS compound heterozygous and E14 DDS homozygous cells
Gene CGR8 E14
Diff. Ratio Diff. Ratio
G2/M specific cyclin (cyclin Gl) -13034 0.43 -207 0.47
Plasma glutathione peroxidase precursor 23910 2.04 778 6.85
RAD23 UV excision repair protein B -11932 0.54 -308 0.42
Insulin-like growth factor binding protein 3 -12975 0.15 -240 <0.15
Insulin-like growth factor binding protein 4 -35966 0.21 -299 <0.15
Heat shock 86 kDa protein (Hsp86) -22349 0.48 -283 0.55
T-cell death-associated protein (Tdag51) 14193 1.68 620 8.75
RAD21 DNA repair protein 8136 1.98 335 3.38
14-3-3 protein zeta/delta -15357 0.69 -476 0.58
Diff. - difference between normalised intensities of the two spots.
Cyclin Gl, RAD21 and 14-3-3 protein zeta/delta are included in the table
because the results are significant for one cell line, and very near to the thresholds
for significance in the other.
Several genes have been suggested to be transcriptional targets of the WT1
protein (section 1.5.2). As some of these are present on the expression arrays, it was
decided to examine the results obtained for these in the comparisons between wild-
type cells and those with two Wtl mutations. The results are presented in table 6.3.
The values of difference in spot intensity and ratios corresponding to significant
changes in gene expression are the same as for table 6.2.
Table 6.3 Expression of putative WT1 target genes relative to wild-type cells
in CGR8 DDS compound heterozygous and E14 DDS homozygous cells
Gene CGR8 E14
Diff. Ratio Diff. Ratio
Early growth response protein 1 {Egrl) -16315 0.40 228 2.98
Insulin-like growth factor 2 (Igf2) 708 1.01 -1312 0.15
Insulin-like growth factor 1 receptor alpha -1568 <0.21 118 6.13
Platelet-derived growth factor A chain -956 <0.21 148 9.22
Transforming growth factor beta 1 (Tgf-J31) -2622 <0.21 13 1.87
Colony-stimulating factor 1 (Csf-1) -1886 <0.21 89 6.93
c-myb proto-oncogene -2041 0.7 28 6.6
Inhibin a -3398 0.26 -28 0.15
Ornithine decarboxylase -720 0.96 -280 0.58
c-myc proto-oncogene -6022 0.48 -26 0.73
B-cell lymphoma protein 2 (bcl-2) -3816 <0.21 27 3.38
Insulin receptor {IR) -940 <0.21 40 6.00
Cyclin-dependent kinase inhibitor 1 (p21) 7135 6.4 26 2.04
Expression of none of these genes was significantly affected in the same
direction by the presence of the Wtl mutations in both CGR8 and E14 cells. Egrl
was significantly altered in both cell lines, but expression is much lower in the
mutant than the wild-type in the CGR8 cell line and higher in the mutant than the
wild-type in the El4 line. Ornithine decarboxylase and Ig/2 are significantly altered
in the E14 mutant compared to the wild-type, but as this difference is not also found
in the CGR8 cells, it cannot be attributed to the Wtl mutation.
6.3Comparison of gene expression in retinoic acid-differentiated wild-
type and DDS heterozygous CGR8 ES cells
A comparison between gene expression in wild-type and DDS heterozygous ES
cells was only made for the CGR8 line (figure 6.5). This means that any results
which differ from those obtained with the compound heterozygotes and homozygotes
may be due to unknown genetic changes which have occurred in this clone, and may
be unrelated to the Wtl mutation present. This is particularly true as the
heterozygous cells used here are from clone 10, while the compound heterozygous
CGR8 clone used was derived from heterozygous clone 15.
It was considered important to look at gene expression in the DDS heterozygous
cells, as it is in a heterozygous form that DDS mutations occur in affected
individuals, and because this mutation has already been demonstrated to produce a
phenotype in vivo. Patek el al. (1999) found that this same mutation induced
symptoms of DDS in chimaeric and heterozygous mice, so any changes in gene
expression levels which are responsible for this pathology may be detectable in vitro
using this method.
Regarding the heterozygous cells, the data can be divided into three categories:
(1) Genes whose expression altered in both the heterozygotes and compound
heterozygotes/homozygotes (table 6.4a); (2) Genes whose expression altered in the
b.
Figure 6.5 Comparison of gene expression in CGR8 wild-type and DDS
heterozygous (Wt1/Wt1tmT396) retinoic acid-differentiated ES cells using mouse
Atlas expression arrays.
a. Differentiated wild-type
b. Differentiated DDS heterozygote
Circles indicate the positions of some differentially-expressed genes.
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compound heterozygotes/homozygotes but not the heterozygotes (table 6.4b) and (3)
Genes whose expression altered in the heterozygotes only (table 6.4c). This last
group of results is that most likely to have been affected by changes specific to the
one heterozygous clone. To be significant in this comparison, the ratio between the
two intensities must lie outside the range 0.59-1.69, and the difference between the
two intensities must exceed 10,069.
Table 6.4 Comparison of gene expression in CGR8 wild-type and DDS
heterozygous RA-differentiated ES cell progeny
a. Genes showing altered expression relative to that in wild-type cells in DDS
heterozygotes as well as DDS compound heterozygotes/ homozygotes
Gene Diff. Ratio
Insulin-like growth factor binding protein 3 -15344 <0.17
Insulin-like growth factor binding protein 4 -30070 0.34
T cell death-associated protein (TdagSl) 30572 2.47
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b. Genes showing altered expression relative to wild-type cells in DDS
compound heterozygous/homozygous cells, but not DDS heterozygous cells
Gene Diff. Ratio
Plasma glutathione peroxidase precursor 2784 1.12
RAD23 UV excision repair protein B 5976 1.23
Heat shock 86kDa protein (Hsp86) 8803 1.20
G2/M specific cyclin (cyclin Gl) -6095 0.73
14-3-3 protein zeta/delta -8750 0.82
c. Genes showing altered expression relative to that in wild-type cells in DDS
heterozygous cells, but not DDS compound heterozygous/ homozygous cells
(showing comparison with results for CGR8 compound heterozygote)
Gene +/- -/-
Diff. Ratio Diff. Ratio
Insulin-like growth factor binding protein 2 23309 2.00 2574 1.11
Golgi 4-transmembrane spanning
transporter
15354 2.18 -631 0.95
BAX membrane isoform alpha 22943 3.49 2909 1.32
Laminin receptor 1 (LAMR1) -30828 <0.17 2821 1.09
CDC42 GTP-binding protein 19535 3.67 -1508 0.79
Cathepsin B1 (CTSB) 13728 3.24 -4369 0.28
+/- CGR8 heterozygous (WtllWtlT""m) cells
-/- CGR8 compound heterozygous (WtlT""396/Wtl7""403) cells
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An interesting point to note here is that there are approximately the same
numbers of genes in the mutant cells showing increased as decreased expression in
the first two parts of the table. In the third part, which contains genes whose
expression altered in the heterozygous but not compound heterozygous/homozygous
cells, most of the genes showed increased expression in the mutant, suggesting that
this mutation in a heterozygous form either prevents a repressive effect of the WT1
protein or produces a novel activating effect. This will be discussed in section 6.5.
6.4Confirmation of expression array results using RT-PCR analysis
Some of the genes identified by the Atlas™ expression arrays as being
differentially expressed between Wtl mutant and wild-type ES cells were examined
further using RT-PCR to confirm the results. The genes chosen were some of those
that showed consistent differences between double mutant and wild-type in both
CGR8 and El4 cells. Primer pairs, each of which spanned an intron, were designed
for cyclin Gl, Hsp86 and IGFBP-4 so that any contaminating genomic DNA
sequences would probably not be amplified due to their size, and would produce a
PCR product of a larger size even if amplification did occur. Despite not knowing
the actual cDNA sequences bound to the Atlas™ membranes, it is certain that at
least part of the sequence amplified here was not represented on the membrane, as
the expected PCR products were all in the region of 800bp, whereas those bound to
the membrane were 200-500bp. This means that this PCR amplification will include
a different part of the gene of interest, and so constitutes an independent method that
can therefore be used to confirm the macroarray results.
Cyclin Gl was thought to be an interesting gene for study as it is required for the
cell cycle transition from G2 to M, a transition at which WT1 is also believed to be
important (Yamagami et al., 1996). WT1 is already known to interact with HSP70,
leading to transcriptional upregulation of the Hsp70 gene (Maheswaran et al., 1998).
Unfortunately this gene is not represented on the expression array, but a related gene,
Hsp86, was found to be expressed at lower levels in the DDS compound
heterozygous and homozygous cells, so expression levels of this gene were
confirmed by RT-PCR. IGFBP-4 was also examined, as it had previously been
suggested as a familial Wilms' tumour gene (Rahman et al., 1996).
Total RNA was extracted from RA-differentiated wild-type, heterozygous and
compound heterozygous/homozygous CGR8 and E14 ES cells. This was treated with
DNasel to remove any genomic DNA contamination, then underwent first strand
cDNA synthesis. RT-PCR was performed on this cDNA, and also control samples
made with no reverse transcriptase (no RT), using primers for cyclin Gl, Hsp86 and
IGFBP-4, with the number of PCR cycles chosen to ensure that the intensity of the
band produced was proportional to the amount of template. A glyceraldehyde
phosphate dehydrogenase (GAPDH) PCR was used as a measure for the cDNA
concentration, to standardise the other PCR results (figure 6.6). PCR products of the
expected size only were obtained in each reaction, and no product was obtained in
any no RT control. PCR primers, conditions and band sizes can be found in appendix
H.
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Figure 6.6 GAPDH RT-PCR used to standardise amount of template for
differentially-expressed gene RT-PCRs
a. Autoradiograph ofGAPDH RT-PCR, showing intensities of bands produced.
b. Standard curve to show that after 16 cycles of PCR, intensity of signal produced
is proportional to amount of template added.
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IGFBP4 was seen to be far more highly expressed in the differentiated than
undifferentiated cells (figure 6.7), which agrees with the result from this comparison
performed on wild-type cells (section 6.1). The RT-PCR analysis shows expression
to be low in undifferentiated cells within the other genotypes as well, which would
be expected, as these cells express WT1 at an extremely low level, so genotype
should have no effect. In the differentiated cells, IGFBP-4 expression is
approximately twice as high in the wild-type cells as in the Wtl mutant cells. This
difference is slightly lower than predicted from the expression array results, as the
ratios between wild-type and mutant expression levels for the DDS heterozygote and
DDS compound heterozygote were 0.34 and 0.21, respectively. However, this
analysis was performed on different clones than those used in the expression array
analysis, so some variability could be expected, and the levels in the mutant cells are
substantially lower than in the wild-type, thus confirming the result from the
expression arrays.
Cyclin G1 expression is detected at a much higher level in the differentiated than
undifferentiated wild-type cells by RT-PCR (figure 6.8), although this was not seen
on the expression array results (section 6.1). As the comparison between
differentiated and undifferentiated images was only by visual assessment, only the
most obvious differences between the two membranes were regarded as being real
results, so a less dramatic difference in cyclin Gl levels would have been discounted.
Again, the fact that different clones were used for the expression arrays as for RT-
PCR could partly explain the difference. The variation in cyclin Gl levels in
undifferentiated cells between the different DDS genotypes was not examined by
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Legend to figure 6.7:
a. Autoradiograph of quantitative RT-PCR, showing intensity of bands produce
with IGFBP-4 primers.
b. Standard curve to show that after 16 cycles of PCR, intensity of band produced
proportional to amount oftemplate added.
c. Results corrected for amount of template using GAPDH PCR results. The ban
intensities produced by all the undifferentiated cells fell below the range c
template concentrations for which linearity had been established, so could not b
estimated accurately.
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Figure 6.7 Comparison of IGFBP-4 expression in CGR8 mutant and wild-type
ES cells using cDNA expression arrays and RT-PCR analysis.
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Legend to figure 6.8:
a. Autoradiograph of quantitative RT-PCR, showing intensity of bands produced1
with cyclin G1 primers.
b. Standard curve to show that after 12 cycles of PCR, intensity of band produced is>
proportional to amount of template added.
c. Results corrected for amount of template using GAPDH PCR results. The band
intensity produced by the undifferentiated compound heterozygous cells fell
below the range of template concentrations for which linearity had beer-
established, so could not be estimated accurately.
Figure 6.8 Comparison of cyclin G1 expression in CGR8 mutant and wild-
type ES cells using cDNA expression arrays and RT-PCR analysis.
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expression array, and the results from the RT-PCR analysis do not show them to be
greatly different from one another. In the differentiated cells, the RT-PCR results do
not completely agree with those from the expression arrays, as the level of cyclin G1
RNA did not vary significantly between the wild-type and DDS heterozygous cells
according to the expression array (although a small difference was seen), but is seen
by RT-PCR analysis to be significantly reduced. This can again be explained by
differences in the clones used for the different analyses. The appreciably lower level
of cyclin Gl expression detected in the DDS compound heterozygous cells by
expression array is reflected in the results obtained by RT-PCR. Although cyclins are
so named due to their varying levels at different points in the cell cycle, this cyclic
behaviour is controlled at the protein, rather than RNA, level, so the differences seen
here can not be attributed to an indirect effect of the mutations on the proliferative
state of these cells.
The gene for heat shock protein 86 (Hsp86 - also called Hsp90a) was seen to be
expressed at a higher level in undifferentiated than differentiated wild-type cells
using the expression array. This is confirmed in the wild-type by the RT-PCR results
(figure 6.9). However, the levels ofHsp86 RNA seen in undifferentiated mutant cells
are far lower, according to RT-PCR. As very little WT1 protein was detected in
undifferentiated ES cells (section 4.2.4), it seems likely that these differences in
Hsp86 levels are due to some other factor. If this is the case, then the results from the
differentiated cells, from both types of analysis, must also be suspect. Expression of
heat shock proteins is notoriously sensitive to slight changes in pH, temperature and
other environmental factors (Santoro, 2000), and by chance this could have produced
an apparently consistent effect in the mutant cells. This is supported by the fact that
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Legend to figure 6.9:
a. Autoradiograph of quantitative RT-PCR, showing intensity of bands produce
with Hsp 86 primers.
b. Standard curve to show that after 16 cycles of PCR, intensity of band produced
proportional to amount oftemplate added.
c. Results corrected for amount of template using GAPDH PCR results.
Figure 6.9 Comparison of HSP 86 expression in CGR8 mutant and wild-type
ES cells using cDNA expression arrays and RT-PCR analysis.
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Hsp86 RNA levels are actually higher in the DDS heterozygous cells than the
wild-types according to the expression array, and yet found to be far lower using RT-
PCR.This demonstrates exactly why it is important to confirm results obtained by
expression arrays using another, independent, method.
Discussion of chapter 6
The comparison of gene expression in retinoic acid-differentiated and
undifferentiated ES cells was performed to determine which cell types are being
produced by this differentiation process. This was considered interesting, as the vast
majority of cells express WT1 after differentiation (section 4.3.4), which is
surprising, bearing in mind that WT1 expression is extremely limited during
development and adult life (Pritchard-Jones et al., 1990; Buckler et al., 1991;
Armstrong et al., 1992). Visual examination of the differentiated cell cultures by
light microscope revealed a very morphologically heterogeneous population, so it is
unlikely that the uniformity ofWT1 expression is due to all the cells differentiating
along the same pathway.
Most of the genes seen to be at a higher level in undifferentiated ES cells (see
table 6.1) are associated with proliferating cells, or known to be downregulated upon
differentiation, whether spontaneous or RA-mediated. For example, there is a strong
link between B-myb expression and high proliferative ability (Sitzmann et al., 1996)
and cyclins such as B1 would be expected to be expressed at lower levels in more
differentiated cells which are not cycling as rapidly (Hanley-Hyde et al., 1992). The
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reduction in B-myb expression may also be due to transcriptional repression,
mediated through E2F (Lee et al., 1998a). Fibroblast growth factor 4 (FGF-4) has
previously been shown to be downregulated upon differentiation of F9 embryonic
carcinoma (EC) cells (Velcich et al., 1989) and RA-induced differentiation of ES
cells (Kelly and Rizzino, 2000). Expression of p53 is known to decrease upon
differentiation of ES cells (Sabapathy et al., 1997). Levels ofMSH2 expression have
been found to decrease upon retinoic acid-mediated differentiation of human
neuroblastoma cell line SH-SY5Y (Belloni et al., 1999) and both Hsp 90a and (3 are
downregulated upon differentiation of human EC cells with all-trans retinoic acid
(Yamada et al., 2000), as are levels of glutathione S-transferases (Faria et al., 1998).
Expression of c-kit was found in undifferentiated ES cells by RT-PCR (McClanahan
et al., 1993; Schmitt et al., 1991). All-trans retinoic acid has been found to have
different effects on haematopoietic cells of different stages (Purton et al., 1999),
with an enhancing effect on the differentiation of committed haematopoietic
progenitors, but a preventative effect on haematopoietic differentiation in primitive
haematopoietic precursors. There is also evidence to suggest that RA suppresses
haematopoietic differentiation in ES cells (Menzel, 1999), so, although
undifferentiated ES cells express c-kit, treatment with RA may bias differentiation
away from haematopoietic lineages, and thus away from cells which normally
express c-kit, leading to the observed lowering of expression in differentiated cells.
IGFBP-2 expression is inversely correlated with degree of differentiation in
hepatoblastoma (Akmal et al., 1995), and in the SK-N-BE(2) human neuroblastoma
cell line, IGFBP-2 expression levels decrease after induction of differentiation with
retinoic acid (Bernardini et al., 1994).
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Some of the genes which appear to be upregulated upon differentiation of ES
cells with RA are markers of particular cell lineages. ZO-1 expression is commonly
used as a marker for epithelial lineages (Stevenson et al., 1986), and Pref-1 for pre-
adipocytes (Smas and Sul, 1993). Retinoic acid-mediated differentiation of F9 EC
cells has been found to be rapidly followed by an increase in the level of Hox 2.1
mRNA (Ura and Hirose, 1991) and retinoic acid is known in vivo to be necessary for
the expression of Hox 2.4 and establishment of a zone of polarising acitivity (ZPA)
during development (Lu et al., 1997). Protein kinase C theta (PKC-theta) is
predominantly expressed in haematopoietic cell lines (Baier et al., 1994), although if
RA does indeed inhibit haematopoietic differentiation, it may be another cell
lineage, such as muscle, which is also known to express PKC-theta (Mischak et al.,
1993) that is responsible for the expression seen here. Support for the presence of
muscle lineages comes from the upregulation of Igf2 in the differentiated cells. Igf-2
is an important modulator ofmuscle growth and differentiation (Pedone et al., 1994)
and has been found to rise to high levels during myogenic differentiation from ES
cells (McKarney et al., 1997). The zyxin protein contains a LIM motif, a common
feature of many proteins playing roles in the regulation of cellular differentiation
(Beckerle, 1997). Glutathione peroxidase levels are seen to increase upon
differentiation in several cell lines, including a 4-5 fold increase when cultured
myotubes are induced to differentiate into skeletal muscle (Franco et al., 1999). This
is probably not a cell type-specific phenomenon, but a general response of cells to
differentiation. As has already been mentioned, IGFBP-4 expression is seen in the
human foetus in regions where differentiation is occurring (Delhanty et al., 1993).
To examine more precisely the nature of the cells which are being produced by this
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differentiation protocol, the expression of specific markers for cell lineage could be
examined, perhaps through RT-PCR or a technique such as immunofluorescence.
This study of RA differentiation of wild-type ES cells by macroarray analysis has
suggested that epithelial cells, preadipocytes and muscle cells are produced upon
such differentiation.
Since this work was carried out, a study has been published which describes
changes in gene expression in D3 ES cells upon differentiation with RA (Kelly and
Rizzino, 2000). This work involved the use of the same type of cDNA expression
array as used here. Although many similarities were seen between the genes found to
be differentially expressed, some differences were also evident. Table 6.5 indicates
the similarities in gene expression patterns between the two studies. Many genes,
particularly those encoding cytoskeletal and extracellular matrix proteins, were
found to alter expression by Kelly and Rizzino but not by myself. This is most likely
due to the fact that my analysis of these membranes was performed purely on a
visual basis, rather than using image analysis software.
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Table 6.5 Genes found to alter expression upon RA-mediated differentiation
of ES cells in two independent studies
Higher in undifferentiated cells Higher in differentiated cells
B-myb proto-oncogene Tight junction protein ZO-1
Heat shock protein 86 (Hsp90a) Zyxin
Lung Kruppel-like factor (LKLF) Plasma glutathione peroxidase
Fibroblast growth factor 4 {FGF-4) TDAG51
Laminin receptor 1 Pre-adipocyte factor 1 (Pref-1)
Homeobox protein 2.1 (Hoxb5)
Homeobox protein 2.4 (Hoxb8)
Serine protease inhibitor homologue J6
Insulin-like growth factor 2 (Ig/2)
The paper does not state which carrier was used for the retinoic acid, which
is usually DMSO, as used here, or ethanol. A difference in carrier could account for
differences in the results obtained, as could the continued use of LIF during
differentiation in the study by Kelly and Rizzino. The use of a different ES cell line,
D3 as opposed to CGR8, most likely explains the majority of the differences, though,
as different genes are found to be expressed in the undifferentiated cells. Any genes
whose expression changes were detected by Kelly and Rizzino (2000) but not myself
are likely to be due to the increased sensitivity of their image analysis method, which
utilised image analysis software, as opposed to the method used by myself, which
consisted of a comparison of the two images solely by visual assessment.
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Both studies found a downregulation in FGF-4 expression levels during
differentiation, which Kelly and Rizzino (2000) link to Oct-3 (also called Oct-4)
downregulation {FGF-4 is a known target of Oct-3/4 during early mouse
development - reviewed in Lamb and Rizzino, 1998), whereas no Oct-3/4 expression
was seen by myself in either undifferentiated or differentiated cells. This in itself is
an indication that my detection method lacks sensitivity, as the expression of Oct-3/4
in undifferentiated ES cells and its downregulation upon differentiation is a well-
established fact (Nichols et al., 1998). The higher level of sensitivity of Kelly and
Rizzino's study, may also be attributable to the fact that the hybridisation signals
were generally stronger, suggesting that I may have missed some expressed genes.
This may also account for the fact that Kelly and Rizzino found many more genes
upregulated than downregulated upon differentiation (61 compared with 18),
whereas my numbers were approximately equal (12 and 15). Thus, differences in
probe strength, cell line and analysis techniques probably account for most of the
discrepancies between the two studies.
Comparison by cDNA array of gene expression between RA-differentiated
ES cell progeny with DDS mutations in both alleles ofWtl and wild-type cells of the
same line revealed nine genes that may be transcriptional targets ofWT1 (cyclin Gl,
PGPx, RAD23 UV excision repair protein B, IGFBP-3, IGFBP-4, Hsp86, Tdag51,
RAD21, 14-3-3 protein zeta/delta). Some of these showed increased expression in
Wtl mutant cells {PGPx, Tdag51, RAD21) others decreased expression compared to
wild-type cells {cyclin Gl, RAD23 UV excision repair protein B, IGFBP-3, IGFBP-
4, Hsp86, 14-3-3 protein zeta/delta), providing further evidence that WT1 may act as
both an activator and a repressor of transcription.
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Cyclin Gl was seen to be expressed at a very low level in both CGR8 and
E14 mutant cells, relative to wild-type cells, suggesting that WT1 protein is required,
either directly or indirectly, for its transcription. This cyclin is known to be involved
in the transition between the G2 and M phases of the cell cycle and has been shown
to be transcriptionally activated by p53 (Okamoto and Beach, 1994). Cyclin G1 RNA
levels have been shown to increase after p53 induction by DNA damage, which does
not occur in p53 -/- cells (Reimer et al., 1999). It may have a role in the facilitation
of p53-dependent apoptosis in response to DNA damage (Okamoto and Prives,
1999). Cyclin Gl has been seen to be overexpressed in breast and prostate cancer
cell lines, in which the cell cycle-dependency of its expression is lost (Reimer et al.,
1999). In humans, the cyclin Gl gene is located at chromosome 5q32-q34. In this
region, translocations have been detected in human haematopoietic tumours,
including CML and ALL, suggesting a possible connection between cyclin Gl and
leukaemogenesis (Endo et al., 1996). As well as this possible link with WT1, cyclin
Gl expression is also seen to be high in ovary and kidney, regions in which WT1
expression is detected (Home et al., 1996). It is known that some cells require WTl
expression to get past the G2/M cell cycle checkpoint, as WTl antisense
oligonucleotides cause G2/M arrest in K562 cells (Yamagami et al., 1996). This
could be effected through cyclin Gl, with WTl being necessary for cyclin Gl
expression in these cells.
Glutathione peroxidases interact with selenium to remove reactive oxygen
species from the body, thus preventing DNA damage (Reviewed in Yu, 1994).
Plasma glutathione peroxidase (PGPx) is expressed in tissues that are in contact with
body fluids, the kidney for example (Brigelius-Flohe, 1999). Unlike WTl, however,
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expression is much higher in the adult kidney than the foetal (Maser et al., 1994). It
is localised to the proximal tubules, where it is secreted by the epithelial cells (Maser
et al., 1994). Obviously, genes that affect the synthesis of proteins like this one will
ultimately affect the amount of DNA damage caused to cells by free radicals.
Surprisingly, the level of PGPx RNA is increased in the Wtl mutant cells, which
would have a protective effect against DNA damage, and therefore against possible
cancer-causing mutations. This would suggest that part of the normal function of
WT1 protein is the transcriptional repression of the PGPx gene.
The murine B homologue of the yeast RAD23 UV excision repair protein
gene is expressed at a reduced level in CGR8 and El4 Wtl mutant cells, so is a
candidate for being transcriptionally activated by WT1. This protein is ubiquitously
expressed, with elevated levels in the testis (van der Spek et al., 1996). A reduction
in the level of such a DNA repair protein would lead to more DNA damage going
uncorrected, increasing the chance of a cancer-causing mutation persisting and
undergoing replication. No evidence for a deficiency in WT1 causing an increased
frequency of mutations in other genes has ever been published, however. A possible
link with Wilms' tumour lies in the fact that the human RAD23 homologue B gene
lies on chromosome 3p25, and translocations of chromosome 3p occur in sporadic
Wilms' tumours (Walton et al., 1992).
The genes for two members of the insulin-like growth factor binding protein
family (IGFBP-3 and -4) have reduced expression in the Wtl mutant cells, so may be
genes which are transcriptionally activated by WTl. These proteins have growth
suppressive functions, as they are responsible for controlling the levels of free
insulin-like growth factors (IGF-I & IGF-II), which have mitogenic activity
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(Clemmons et al., 1995). Indeed, lower than normal levels of circulating IGFBP-3
are seen in breast cancer patients (Stoll et al., 1997). Expression of IGFBP-3 is low
in the foetus, then increases after birth (Lindenberg-Kortleve et al., 1997). This is the
main carrier protein for circulating IGFs in the adult, and is mostly synthesised by
the liver, but also in vascular endothelial cells, such as those of the renal capillary
system (Lee et al., 1999). Expression is also seen in human granulosa cells, as is
WT1 expression (Barreca et al., 1996). In the human foetus, IGFBP-4 is highly
expressed in the kidney, stomach, intestine and lung (Delhanty et al., 1993). In the
adult, expression is mainly seen in differentiating cells, but also the proximal tubules
of the mature kidney (Lindenberg-Kortleve et al., 1997). IGFBPs 1-6 have been
found to be expressed in the mesangial cells of the glomerulus, where they may
control IGF-I availability, which has been implicated in glomerular hypertrophy and
matrix expansion (Grellier, et al., 1996). Strong IGFBP-4 expression is seen in the
stromal cells of the bone marrow, where it may modulate the haematopoietic
response to IGFs (Grellier et al., 1995). IGFBPs also are believed to have IGF-
independent effects on growth and apoptosis (Grimberg and Cohen, 2000). As well
as being expressed in many similar locations to WT1 and being apparently involved
in some of the same processes, a connection between Wilms' tumour and IGFBP-4
has already been established by the finding that chromosomal region 17ql2-q21.1,
where this gene is located, is linked to the disease in a Wilms' tumour family
(Rahman et al., 1996).
The RAD21 gene is a homologue of a Saccharomyces pombe gene known to
be involved in the repair of DNA double strand breaks caused by ionising radiation
(Yu et al., 1995). Its expression is ubiquitous, but seen at higher levels in the thymus
and testis, in which it may play roles in V(D)J and meiotic recombination,
respectively. Apart from expression in the testis, the only connection with WT1 or
Wilms' tumour is that the RAD21 gene is situated on chromosome 8, gains of which
have been detected in familial Wilms' tumours (Altura et al., 1996). RAD21
expression is seen to be raised in both the CGR8 and E14 mutants, and so may
normally be repressed by WT1 protein.
Heat shock protein 86, also referred to as 90 alpha (Hsp90a), is a molecular
chaperone, involved with the folding and intracellular transport of proteins such as
steroid receptors (Pratt et al., 1992). This folding machinery also plays a role in
signal transduction, regulating the folding, assembly and disassembly of signalling
molecules between active and inactive states, modulating the activity of kinases,
receptors and transcription factors (Rutherford and Zuker, 1994). In the adult kidney,
Hsp90 is expressed in the glomerular podocytes, Bowman's epithelia and epithelial
cells from the distal tubules to the collecting ducts (Kamatsuda et al., 1996).
Expression of Hsp90a has been found to be higher in breast cancer tissues than in
normal cells, and may play a role in cellular proliferation (Yano et al., 1996). High
Hsp90a expression has also been found in other cancers, including those of the
endometrium and gastro-intestinal tract, and has been discovered to be the target to
which anti-cancer drug geldanamycin binds (Whitesell et al., 1994). Expression of
all heat shock protein genes, including 90a, has been found to be higher in AML
cells than those from CML or normal peripheral blood. This may relate to the
differentiation state or proliferative potential of the cells (Chant et al., 1995).
Hsp90a expression was found to be higher in wild-type cells than those with DDS
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mutations in both Wtl alleles, suggesting that WT1 protein may be involved in the
transcriptional activation of this gene.
14-3-3 proteins participate in signal transduction and checkpoint control
pathways. Their expression in Xenopus oocytes has been found to enhance the
activity of Raf-1, leading to DNA synthesis and cell division (Fantl et al., 1994).
They are ubiquitously expressed, with their highest concentrations found in the brain,
and are mainly located in the cytosol (Martin et al., 1994). 14-3-3 zeta occurs in a
posttranslationally modified form in the brain called 14-3-3 delta. This modification
enhances the protein's protein kinase C inhibition around two-fold (Aitken et al.,
1995). Expression of the 14-3-3 zeta/delta gene was found to be lower in cells with
DDS mutations in both alleles of Wtl than in wild-type cells, so WT1 may play a
role in the transcriptional activation of this gene.
Cross-linking of the T-cell receptor (TCR), followed by activation of this
receptor, leads to apoptosis in T-cell hybridomas. TDAG51 is responsible for fas
expression, and links the TCR stimulation to the fas-mediated apoptotic pathway
(Park et al., 1996). The TDAG51 gene is known to be expressed in multiple foetal
and adult tissues (Frank et al., 1999). This gene has significant homology with a gene
called IPL/TSSC3, which is expressed exclusively from the maternal allele and
located in the imprinted gene cluster on human chromosome 11pi5.5 (mouse
chromosome 7), associated with Beckwith-Wiedemann syndrome (Lee and Feinberg,
1998). Although these genes are very closely related, it cannot be assumed from the
expression array evidence that Wtl mutation would also lead to changes in
expression of TSSC3, although if the TDAG51 cDNA bound to the expression array
membrane was from a region very homologous to TSSC3, there could be some cross-
hybridisation occurring, so at least part of the signal might come from TSSC3. The
manufacturers of the expression array used, Clontech, were unable to rule out the
possibility that the cDNA sequence representing TDAG51 on the membrane could
also hybridise to TSSC3 RNA. An examination of TSSC3 expression by a method
such as RT-PCR in Wtl mutant cells could therefore be an interesting experiment. If
alterations in the expression of this gene were discovered, a link would be provided
between T77-related Wilms' tumours and those found in Beckwith-Wiedemann
syndrome, which have no genetic alterations of WT1. Expression of TDAG51 is
higher in the cells with mutations in both Wtl alleles than in the wild-type cells,
suggesting that this gene is repressed by WT1, which is surprising, as a gene such as
this, which is involved in the promotion of apoptosis, would have a tumour
suppressive function.
Of course, the fact that expression of these particular genes is altered in Wtl
mutants relative to wild-type cells does not necessarily mean that they are all under
the direct transcriptional control of WT1, as they could be further downstream in
pathways in which WT1 is involved. Also, any of these genes could be strictly
regulated at the protein level, making these observed changes in mRNA levels
physiologically irrelevant.
Expression of three of these genes (cyclin Gl, IGFBP-4, and Hsp86) was
subsequently examined using RT-PCR analysis, and two of them, cyclin Gl and
IGFBP-4, were confirmed as being affected by the Wtl mutation. Both showed
lowered expression in cells lacking wild-type WT1 protein, suggesting that WT1
plays a role in the transcriptional activation of these genes. The third, Hsp 86, was
shown to vary its expression in a pattern inconsistent with transcriptional regulation
by WT1. Heat shock protein expression is extremely sensitive to environmental
effects (Santoro, 2000), and the apparent consistency of changes in expression
between wild-type and homozygous/compound heterozygous cells found by
microarray analysis can be attributed to chance. This emphasises the importance of
checking results obtained from expression arrays using independent experimental
samples. Obviously, this finding calls into question whether the remaining seven
genes suggested by the expression array are genuine targets ofWT1. These cannot be
assumed to be correct until confirmed, although none of these types of genes are as
susceptible to environmental effects as those for heat shock proteins.
The finding that none of the previously suggested putative WT1 target genes
(table 1.1) which were present on the expression array showed significant alteration
of expression levels in both mutant cell lines was unexpected (table 6.1). Although
some of these genes show significant differences between the mutant and wild-type
cells in one direction or the other, none of these differences are consistent between
the two cell lines. In fact, Egrl expression is significantly altered in both CGR8 and
E14 mutant cells, but this is seen as a down-regulation in the CGR8 mutants and an
upregulation in the E14 cells. Such differences cannot be accounted for by the Wtl
mutations present, otherwise they would show consistency between the two cell
lines. As only one clone was examined from each cell line, these results can be
explained by other differences specific to the individual clone tested, perhaps due to
the high G418 selection used to produce the E14 DDS homozygotes. High G418
selection selects for clones in which the introduced sequences have been duplicated,
presumably through mitotic recombination (see section 1.1). This is likely to affect
other coding sequences in the region, with unknown effects. No evidence has
therefore been obtained here for any of these genes being genuine transcriptional
targets forWT1.
Many of these genes, including IGF2 and PDGF-A, were originally suggested
to be targets of WT1 as they were found to be overexpressed in Wilms' tumours
(Fraizer et al., 1987; Reeve et al., 1985; Scott et al., 1985). Putative WT1 binding
sites were identified in their 5' and 3' regulatory sequences, and studies involving
co-transfection of WT1 expression vectors with reporter constructs indicated that
WT1 was indeed capable of repressing transcription from their promoters
(Drummond et al., 1992; Gashler et al., 1993). However, there is much evidence to
suggest that such experiments do not reflect the in vivo transcriptional activity of the
WT1 protein. The magnitude, and even whether WT1 appeared to be acting as an
activator or repressor of transcription has been seen to depend on the cell type used,
the promoter used to drive WT1 expression (Reddy and Licht, 1995) and the isoforms
of WT1 expressed (Reviewed in Little et al., 1999). These involved transient
transfection, in which the WT1 protein is produced at far higher than physiological
levels for a short space of time, rather than the continuous, lower levels that would
result from the WT1 promoter. These experiments were also often performed in cells
that do not normally express WT1, which calls into question their validity as a test
system. Indeed, as all of these experiments involved the expression of only one of the
16 WT1 isoforms (section 1.5.2.1), and WT1 function is believed to be affected by
isoform ratio, as seen in Frasier syndrome (Barbaux et al., 1997; Klamt et al., 1998),
it is hardly surprising that the results are inconsistent.
Examination of the effects of WT1 on transcription of endogenous genes,
rather than promoter constructs, found a repressive effect of WT1 on EGF-R
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transcription, but no effect on the transcription of EGR1 or IGF1-R (Englert et al.,
1995). Two that were found to be affected, EGF-R (Englert et al, 1995) and
syndecan-l (Cook et al., 1996), are unfortunately not represented on the expression
array, so cannot be examined here. Again, however, although endogenous target gene
expression was used, the WT1 was from an expression vector, therefore not all
isoforms were represented and expression was not driven by the Wtl promoter. The
fact that both the WT1 and the target genes are endogenously expressed may make
the present examination of target gene expression in Wtl mutant cells a more
physiologically valid reflection of the in vivo situation than any of those previously
reported. The fact that none of the genes widely believed to be regulated by WT1
have their expression altered in the mutant cells does not, however, necessarily mean
that these are not true transcriptional targets of WT1. It is suggested that
transcriptional activation of a target gene by the WT1 protein involves the binding of
WT1 to a specific DNA region, as well as interaction with other proteins, basal
transcription factors, for example (Reddy and Licht, 1996). This would necessarily
involve both the N- and C-tenninal regions of WT1, and would be affected by the
truncations present in the mutant cells. Transcriptional repression, on the other hand,
may not always involve DNA binding at all, but can occur through protein-protein
interaction, either by preventing a specific transcription factor binding to DNA, or by
interacting with a bound transcription factor and preventing it binding to other
proteins. If this were the case, the mutations present in these cells, affecting only the
C-terminal region of WT1, would do nothing to prevent repression, as protein-
protein interaction is believed to occur via the N-terminus ofWT1. This is supported
by evidence that found more transcriptional repressor activity in the N-terminal
region ofWT1 than in the C-terminal region including the KTS insert (Tajinda et al.,
1994). It would also explain why many more genes are shown to be down-regulated
in the mutants than are shown to be upregulated. It could be that the WT1 putative
target genes shown here to be unaffected by this mutation are real WT1 targets for
which the presence of a functional WT1 C-terminal region is unimportant. Although
the compound heterozygous cells express very little WT1 mutant protein, some can
be detected (figure 4.13), and may be sufficient to affect transcription of some genes.
Obviously many genes on the expression array do appear to be repressed by WT1
and there is no reason why WT1 could not effect transcriptional repression in two
different ways, only one of which involves DNA binding by the WT1 zinc fingers.
An obvious experiment to try to determine the relative importance of the WT1 bl¬
and C-terminal regions would be to compare expression patterns in wild-type cells
and the cells with two DDS mutations used here with WT1 null cells. Any gene
whose expression is affected by the true null mutations, but not the DDS mutations,
may be influenced by the WT1 N-terminal region and not need a functional C-
terminus for transcriptional effects.
A comparison of gene expression between wild-type and DDS heterozygous
cells was made for the CGR8 line. This comparison was important, as it had
previously been shown that the Wtl""T396 mutation can induce symptoms of DDS in
mice (Patek et al., 1999). The results of this analysis were divided into three groups:
(1) Genes whose expression altered in heterozygous, compound heterozygous and
homozygous cells (table 6.4a) are those whose levels are affected when the cell
contains less than the full amount of intact WT1 protein made from both copies of
the gene. These genes, which include IGFBP-3, IGFBP-4 and TdagSl, are unlikely
to be those involved in Wilms' tumourigenesis, as evidence points to a requirement
for the second allele of WT1 to be lost before a Wilms' tumour is produced. This was
demonstrated by the genotype of the Wilms' tumour found in one DDS heterozygous
chimaera in which an exon 9 skipping event had occurred in the remaining allele of
Wtl (Patek et al., 1999). On the other hand, heterozygous DDS-type mutations have
been identified in human leukaemias (King-Underwood and Pritchard-Jones, 1998),
so any genes whose expression is affected in both heterozygotes and cells with DDS
mutations in both alleles of Wtl could be relevant to leukaemogenesis. Such genes
could also be involved in the other, non-malignant, symptoms of DDS, such as the
mesangial sclerosis or genitourinary abnormalities. IGFBPs, as previously
mentioned, control levels of IGFs, suppressing their mitogenic activity. As the effect
seen in heterozygous cells is so large, it may be that IGFBP downregulation is not a
causative step in Wilms' tumour development.
(2) Genes shown to be affected by two Wtl mutations only (table 6.4b) could
possibly be important for Wilms' tumourigenesis. Expression of the RAD23 UV
excision repair protein B is downregulated in the cells with two Wtl mutations, but
not those with one. This is consistent with it being a gene involved in WT1-related
tumourigenesis, and lowered expression of a DNA repair protein will obviously
allow possible cancer-causing mutations to go unrepaired.
Expression of the 14-3-3 zeta/delta gene is very low in both E14
homozygotes and CGR8 compound heterozygotes, yet the change in expression in
the heterozygote compared with the wild-type is small. These proteins are involved
in signal transduction and checkpoint control pathways (Xing et al., 2000), having an
inhibitory effect on protein kinase C (Aitken et al., 1995), so the downregulation in
the homozygote and compound heterozygote could remove this inhibition, allowing
cells to progress through checkpoints, and again could lead to the perpetuation of
cancer-causing mutations.
(3) Genes which are found to be affected in the heterozygotes only (IGFBP-2, Golgi
4-transmembrane spanning transporter, BAX membrane isoform alpha, LAMR1,
CDC42, CTSB) could be spurious results due to the use of only one clone for this
study (table 6.4c). Alternatively, these could be important genes involved in the
aetiology of Denys-Drash syndrome, as they are very good candidates for being
genes affected by dominant-negative WT1 mutations. Such mutant proteins exert a
dominant effect on gene expression by interacting with the wild-type protein present
in the cell (Reddy et al., 1995b). Obviously, as no wild-type protein is present in the
compound heterozygous or homozygous cells, these effects will not occur. If
interaction between the DDS mutant and wild-type WT1 proteins leads to the
binding of the wild-type protein to novel DNA sequences, these genes may not be
normal transcriptional targets ofWT1, which is why they would appear only in this
group.
The majority of genes in this latter group show increased expression in the
mutant relative to the wild-type. This would fit in with the above suggestion that the
zinc finger region of WT1 is more important for activation than repression of
transcription. The mutant protein could bind to and interact with the wild-type
protein in such a way that the zinc finger region of the wild-type protein binds to
inappropriate target sequences, leading to expression from genes which would not be
usual wild-type WT1 targets. It could be inappropriate expression of such genes at
particular developmental stages which leads to the genitourinary abnormalities
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observed in DDS, and in the mature kidney that leads to extra-cellular matrix
deposition and mesangial sclerosis. This would not be through a dominant-negative
mechanism, but suggests that the DDS mutation confers a type of gain of function
activity which requires the presence of the wild-type protein within the same cell.
IGFBP-2, which is expressed at higher levels in the DDS heterozygote than
the wild-type, is found at high levels in the foetus, where expression is localised to
differentiating cells (Lindenbergh-Kortleve et al., 1997). Like the other insulin-like
growth factor binding proteins previously mentioned, IGFBP-2 is responsible for
regulating the levels of IGFs.
Golgi 4-transmembrane spanning transporter (MTP), which is also
upregulated in heterozygous cells relative to wild-type cells, is a component of
intracellular membranes (Cabrita et al., 1999). It is believed to be involved in the
transport of nucleosides and related molecules across such membranes. In yeast it
can alter the sub-cellular localisation of certain drugs, such as antimetabolites,
antibiotics and steroid hormones, thus changing the sensitivity of the cell to such
substances (Hogue et al., 1996).
Box is a homologue of the apoptosis gene bcl-2, and the protein products of
these two genes form heterodimers together (Oltvai et al., 1993). Bax suppresses
tumourigenesis and stimulates apoptosis in vivo (Yin et al., 1997). Interestingly, Bax
expression is shown to be increased in kidneys following acute renal failure, and in
stressed renal tubular epithelial cells in culture (Ortiz et al., 2000). Its expression is
also higher in DDS heterozygous than wild-type cells.
Laminin molecules are matrix proteins that anchor the basal lamina to the
cell surface. Basal laminae surround cells such as epithelial cells, fat cells and
smooth and striated muscle, and the structure of the lamina will vary according to
cell type. This may be due to the different laminin receptors present on the different
cell types. The basal lamina in the glomerulus of the kidney is of double thickness,
due to being secreted by both epithelial and endothelial cells (McCarthy, 1997). It is
continuous with both the blood and urinary space and acts as a filter. Lack of laminin
receptor (LAMR1), as is seen in these heterozygous cells, could prevent anchorage of
the basal lamina to the cells, and secreted matrix proteins would remain unattached.
Unfortunately, the podocyte cells in the glomerulus where WT1 is expressed possess
a different laminin receptor, one from the integrin family (a3 (31). The laminin
receptor whose expression is seen to be affected here (LAMR1) is expressed in
tubule epithelial cells, mainly in the distal tubules (Baraldi et al., 1994).
As the results from table 6.4 only rely on the study of expression of one
heterozygous clone, a study of other clones, ideally from a different cell line, would
enable spurious results, caused by other, unknown, genetic changes unique to this
clone to be distinguished, and the genes which are genuinely affected by Wtl
mutation to be determined.
In conclusion, the use of expression arrays combined with RT-PCR has
identified two genes, eyeIin G1 and IGFBP-4, which are likely direct or indirect
transcriptional targets of WTL Expression array analysis alone has identified six
other genes (PGPx, RAD23 UV excision repair protein B, IGFBP-3, IGFBP-4,
Tdag51, RAD21, 14-3-3 protein zeta/delta) which are possible WT1 targets but
remain to be confirmed using an independent technique.
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7. Results of in vivo studies
7.1 Production of chimaeric mice using DDS compound heterozygous
cells
One of the initial aims of the project was to sequentially target ES cells to
generate DDS-type mutations in both alleles of Wtl and use these to produce
chimaeric mice. Achieving germ-line transmission of these mutations was not the
object, as Kreidberg et al (1993) had demonstrated that Wtl null mice died in utero,
and it was assumed that this mutation, removing the ability of the WT1 protein to
bind to DNA, would have a similarly severe effect. It was intended to use a
'chimaeric rescue' approach, which can help elucidate gene function in two ways.
Firstly, a high contribution of mutant cells to a particular tissue in which WT1 is
essential could lead to developmental abnormalities of that tissue, enabling the pin¬
pointing ofmore specific regions within the genitourinary system and other systems
in which Wtl is expressed during later development. An alternative possibility is that
Wtl mutant cells would be so poorly suited for colonisation of these tissues, due to a
requirement for WT1 in these areas, that the mutant ES cells would be outcompeted
by wild-type cells. In this case, the tissues in question would develop normally, but
consistently show failure of colonisation by mutant cells.
Unfortunately, despite repeated attempts at micro-injection of the mutant ES
cells, no chimaeric offspring were produced. Despite a lack of any coat-colour
chimaerism, all offspring (n =20)were tested for chimaerism using glucose phosphate
isomerase (GPI) analysis, and none was found in pancreas, spleen, brain, blood,
237
kidney, gonads, large or small intestine, or lung. Although it is tempting to suggest
that the Wtl mutations present in the ES cells had such a severe effect that they were
totally out-competed by the wild-type cells present and could not colonise any tissue,
this is extremely unlikely, as the expression of Wtl during development is confined
to very specific areas (see section 1.5.3). It is more likely that the lack of chimaeras
was due to technical problems. Thus, no information on the role of Wtl in murine
development was obtained from this experiment.
7.2Comparison of teratomas produced from DDS mutant and wild-type
ES cells
An experimental teratoma is a type of germ cell-derived benign tumour that
can be produced by subcutaneous injection of ES cells into a mouse. As teratomas
contain derivatives of all three primitive germ layers, experimental teratoma analysis
is a useful tool for determining the developmental potential of ES cells in vivo. For
example, Reubinoff et al (2000) used this method to demonstrate the pluripotency of
the ES cells that they had derived from human blastocysts. Human ES cells were
grafted into SCID mice and produced teratomas containing tissues derived from all
three embryonic germ layers. Teratomas have the advantage over chimaeric rescue
experiments in that they assess the innate ability of the ES cells to differentiate,
without the presence of wild-type cells, which may act in a paracrine manner to
prevent effects of the mutation from being apparent. Disadvantages of the
experimental teratoma method include the possibility that differences seen between
different genotypes of teratoma could be due to genetic changes at loci other than the
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locus of interest, although use of different clones of each genotype should make this
unlikely. Also, the tumour can grow from a small subset of the injected cells, perhaps
ones which have a growth advantage.
Teratomas have also been used to examine gene function by comparison of
mutant and wild-type ES cells, particularly in cases where the effect of the null
mutation is embryonic lethal. This is true of embryos lacking either N-cadherin
alone, or both N- and P-cadherin (Radice et al., 1997). Production of teratomas from
ES cells with these genotypes revealed that some differentiation had occurred, with
epithelial differentiation being unaffected in the mutant teratomas (Moore et al,
1999b). More striated muscle than controls, but no neural tube-like structures were
found in the cadherin null teratomas (Moore et al, 1999b). More dramatically, when
this method was used to examine the potential of (31 integrin null cells to
differentiate into various tissues, null cells either did not grow at all, or only
produced small teratomas (Bloch et al, 1997). This was attributed to a failure of
angiogenesis caused by the lack of P1 integrin.
As can been seen from the above examples, teratoma analysis can be used to
identify specific developmental processes in which a gene of interest is involved, and
is particularly useful in cases of embiyonic lethality due to a null mutation. It was
therefore decided to utilise this method to compare wild-type, DDS heterozygous and
DDS compound heterozygous/ homozygous ES cells, from both CGR8 and E14 cell
lines. Cells were injected subcutaneously into both flanks of a mouse from an
isogenic strain (129/Ola), with a different genotype of cells being injected into each
flank, enabling direct comparisons between tumours to be made. Teratomas were
allowed to develop for up to 70 days before being dissected out and analysed, with
the tumours from the same mouse being removed at the same time. Weights of
teratomas were compared, then histological analysis was performed on sections
stained with haematoxylin and eosin.
No difference was seen between the average weights of teratomas from the
different ES cell genotypes (see table 7.1), suggesting that no failure of angiogenesis
occurred in any genotype.
Table 7.1: Weights of teratomas produced by ES cells of different genotypes






1.7 (s.e.m. = 0.35) 34.3 (s.e.m. = 1.60
Heterozygote
(ii =9)
1.8 (s.e.m. = 0.49) 37.2 (s.e.m. =4.3)
Homozygote/ Compound
heterozygote (n =16)
1.8 (s.e.m. = 0.39) 36.9 (s.e.m. =3.3)
Histology revealed that derivatives of all three germ layers were present in
teratomas produced from ES cells of all three genotypes, with no difference
consistent with genotype found between teratomas of different genotype (table 7.2,
figure 7.1). From the endoderm, glandular epithelium was found in most of the
teratomas; squamous epithelium and neural tissue, from the ectoderm, were also seen
in many teratomas. Some mesodermally-derived components, such as muscle, fat,
cartilage and bone were also present. Of particular interest is the observation that no
difference was found between the three genotypes with regard to formation of
muscle. It has been suggested that loss of functional WT1 promotes myogenesis
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Figure 7.1 Sections of teratomas
All are from teratomas made using CGR8 DDS compound heterozygous cells,
which were representative of teratomas produced from cells of all genotypes.
x200
GE - glandular epithelium
SE - squamous epithelium
SM - skeletal muscle
C - cartilage
B - bone
EC - embryonal carcinoma
(Miyagawa et al, 1998), but there was no greater prevalence of myogenic
differentiation in the teratomas produced from Wtl mutant cells.
The results from the teratoma experiment and analysis of embryoid bodies
produced from ES cells of the different DDS genotypes (section 5.1), reveal that Wtl
mutations of this nature do not prevent early differentiation of the three primitive
germ layers. This is consistent with the findings of Kreidberg et al (1993) when
studying Wtl null mice. These developed normally except for very specific
abnormalities, of the genitourinary system, thoracic cavity, diaphragm, heart and
lungs. It is perhaps as expected that mutations in a gene which is not expressed until
mouse E9 do not affect embryoid body and teratoma differentiation, which probably
reflect the very earliest stages ofmouse development. The results of this experiment
reveal very little about the role ofWT1 in developmental processes, except that it is
not required for the differentiation of endoderm, ectoderm and mesodermper se.
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Table 7.2 Composition of teratomas




EC Epith. Muscle Fat Neuro Cartilage Bone
CGR8 wt 31 2.1 Y G N N Y Y N
CGR8 wt 31 1.7 Y N N Y Y Y Y
CGR8 wt 42 3.3 Y G,S N N N N N
CGR8 wt 36 2.7 Y G N N Y Y N
CGR8 wt 36 1.6 Y G N N Y Y N
CGR8 wt 32 2.8 Y G,S Y N Y Y N
CGR8 wt 32 1.3 Y G N N N N N
CGR8 wt 43 0.2 Y G N N N N N
CGR8 het 31 3.8 Y G,S N N N Y N
CGR8 het 31 1.2 Y G,S N N N N N
CGR8 het 36 0.1 N G N N Y N N
CGR8 het 32 1.6 Y G,S N N Y N N
CGR8 het 70 0.1 N G N N Y N N
CGR8 het 43 0.2 Y N N N N N N
CGR8 ch 42 0.4 Y G,S N N N N N
CGR8 ch 36 0.1 Y G N N Y Y N
CGR8 ch 66 3.3 Y G N N N N N
CGR8 ch 66 1.9 Y G,S N N Y N N
CGR8 ch 70 0.1 N G Y N Y N N
E14 wt 28 0.5 Y G,S N N Y N N
E14 wt 32 0.2 Y G Y N Y Y N
E14 het 28 2.2 Y G N N N Y N
E14 het 32 3.4 Y G Y N Y Y N
E14 het 32 3.1 Y G,S Y N Y N N
E14 horn 28 1.1 Y G,S N N N Y N
E14 hom 28 2.2 Y G,S Y N N Y N
E14 horn 28 0.6 Y G N N N Y N
E14 hom 28 0.5 Y G,S N N Y Y N
E14 hom 28 1.1 Y G,S N N Y Y N
E14 hom 28 1.7 Y G,S N N Y N N
E14 hom 26 2.9 Y G,S N N Y Y Y
E14 hom 26 4.8 Y G,S N N Y N N
E14 hom 26 2.6 Y G,S N N Y N N
E14 hom 32 4.7 Y G,S Y N Y Y N
E14 hom 32 0.4 Y G Y Y Y N N
Age - time for which tumour grown
Y - tissue present Genotypes:
N - tissue absent wt - wild-type
Epith. - epithelium: G- glandular, S - squamous het - DDS heterozygous
EC - embryonal carcinoma ch - DDS compound heterozygous
Neuro - neural tissue horn - DDS homozygous
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8. Conclusions and future directions
1. Wtl is only expressed at very low levels in undifferentiated ES cells.
Differentiation with all-trans retinoic acid causes Wtl expression levels to
increase. Evidence is presented here that suggests that this expression is due to
the differentiation status of the cells, rather than a direct effect of the RA on Wtl
expression. The induction of Wtl expression by retinoic acid provides a useful
tool for studying Wtl using techniques which require high levels of RNA or
protein. To fully understand the mechanism through which Wtl is expressed,
however, the cell types produced during this differentiation process need to be
determined. This could be carried out in situ, using antibodies against cell surface
markers known to be specific to particular cell lineages.
2. WT1 protein is found at lower levels in DDS compound heterozygous
differentiated ES cells than in wild-type or DDS heterozygous cells of the same
line, differentiated in the same manner. To determine whether the situation is the
same as had previously been found in DDS homozygous cells, in which the
levels of Wtl mRNA were higher than would be expected from the level ofWT1
protein detected, Northern analysis must successfully be performed on these
cells.
3. From the comparison of WT1 protein subnuclear localisation in differentiated
wild-type and DDS heterozygous cells, it can be concluded that this mutation
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does not lead to the sequestration of wild-type WT1 protein into the splicing
domains.
4. The ratios of the Wtl isoforms possessing and lacking the first alternatively
spliced region cover the same range in differentiated ES cells as in other murine
tissues. Ratios of the different KTS isoforms, on the other hand, are different in
ES cells than in tissues previously examined, with an excess of isoforms lacking
the KTS insert found in ES cell progeny. An examination of these isoforms in
foetal mouse tissues would be interesting to determine whether this phenomenon
is unique to ES cell progeny, or a property of foetal mouse tissue in general.
5. The presence of a DDS-type truncation mutation in one or both alleles of Wtl
does not significantly affect the ability of ES cells to form embryoid bodies in
vitro, or the range of cell types produced upon their differentiation. This could be
examined in closer detail using lineage-specific markers.
6. The DDS-type truncation mutation studied here exerts an effect on
haematopoietic differentiation in vitro when present in either one or both Wtl
alleles in an ES cell. Closer examination of the haematopoietic lineages present
in the CFU-A colonies produced by mutant and wild-type cells would indicate
whether the observed delay in differentiation is accompanied by either a lack or
an excess of a particular lineage at later stages. An in vivo study of the ability of
dissociated mutant and wild-type embryoid bodies different time-points to
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achieve long-term repopulation of lethally irradiated mice could provide further
evidence for the existence of a delay caused by Wtl mutation.
7. Expression of the genes for cyclin G1 and IGFBP4 is affected by the presence of
DDS-type mutations in both alleles of Wtl. These genes could be direct
transcriptional targets of the WT1 protein, or lie further downstream in a pathway
involving WT1. The relevance of these genes as transcriptional targets of WT1
can be examined by looking for potential WT1 binding sites in their control
regions, and by the use of reporter constructs to assess the ability of WT1 to
repress transcription from their promoters. This last method, however, would
require careful thought, to ensure that conditions are as physiological as possible.
A comparison of expression levels in these two genes in Wilms' tumours with
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Appendix I - solutions
A. Solutions for embryonic stem cell culture
Medium CM





0. ImM L-aspartic acid
0. ImM L-asparagine




5% (v/v) foetal calf serum
5% (v/v) newborn calf serum
Medium CMP
Medium CM, with the addition of:
O.lmM P-mercaptoethanol
Medium EFNB
Medium CMP, without the addition of sodium pyruvate and non-essential amino
acids.
Standard tissue culture medium
Medium CMP, with the addition of sufficient LIF to prevent ES cell differentiation.




1% chick serum (Life Technologies)
in PBS
Fixative for metaphase spreads
2:1 methanol: acetic acid (v:v)
















Stir to dissolve, autoclave, then cool to room temperature. Then add:
2M Mg+ " stock (1M MgCl2* 6H20 + 1M MgS04* 7H20, filter sterilised) 1ml
2M glucose stock 1ml







1 litre L-Amp broth
12g Bacto-Agar (Difco)
TE buffer









0.25% mg bromophenol blue
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40% 19:1 acylamide/bisacrylamide 75ml
10X TBE 50ml
8M urea






D. Solutions for RNA analysis
DEPC-treated water
0.01% (v/v) diethylpyrocarbonate




0.25% mg bromophenol blue


















400mM Tris-HCl (pH 7.5)
lOOmMNACl
60mM MgCl2




E. Solutions for protein analysis






Dilute 1/10 for xl stock, then add 300mM sucrose, and 1 complete protease inhibitor
cocktail tablet.
Resolving_geL(20ml) 10% gel 8% gel
ddw 11.9ml 13.9ml
29:1 30% acrylamide/bisacrylamide 10.0ml 8.0ml
1.5M Tris pH 8.8 7.5ml 7.5ml
10% SDS 0.3ml 0.3ml
10% APS 0.3ml 0.3ml
TEMED 21pi 18pl
Stacking gel (20ml 5% gel)
ddw 13.6ml
29:1 30% acrylamide/bisacrylamide 3.4ml






























F. Solutions for in vivo methods
GPI sample buffer
1.9g Triethanolamine hydrochloride
(in 200ml) pH 7.6
60mg DTT (Sigma)




3% glacial acetic acid
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Appendix II - PCR primer sequences and conditions
1. Primers for sequencing WTV2
5' 3'
Forward (WTV2F/DS26393) TGA AAC CAT TCC AGT GTA AAA C






2. GAPDH primers for standardisation of RT-PCRs
Product size: 570bp
Forward (GAPDH1) AGT CAG CCG CAT CTT CTT







3. WT1 primers for examination of isoform ratios
a. +/- exon 5 (Moore et aj 1999)
Product sizes: 192, 243bp
Forward (K447) GAC GCC CTA CAG CAG TGA CAA






b. +/-KTS (Moore et aL 1999)
Product sizes: 106, 115bp
Forward (J421) CCA CAC CAG GAC TCA TAC AG







c. +/- KTS primers to confirm genotype of targeted cells
Product sizes 173, 164bp
Forward (DDS1) GTG TAA AAC TTG TCA GCG AAA G






4. Primers for haematopoiesis RT-PCRs
a. c-kit (Schmitt et al, 1991)
Product size: 1069bp
Forward (SCFRS) CAA CAG CAA TGG CCT CAC GAG T






b. G-CSF receptor (Schmitt et aL 1991)
Product size: 567bp
Forward (GCSFRS) CCC CTC AAA CCT ATC CTG CCT C







c. Foetal B-globin (Schmitt et a!, 1991)
Product size: 415bp
Forward (GLOBFS) AAC CCT CAT CAA TGG CCT GTG G






d. Adult B-globin (Schmitt et al, 19911
Product size: 444bp
Forward (GLOBAS) ATG GTG CAC CTG ACT GAT GCT G







5. Primers for RT-PCRs to confirm mouse Atlas expression results
( numbers of cycles represent where PCR was found to be in log phase for amount of
template used)
a. Insulin-like growth factor binding protein 4
Product size: 735bp
Forward (IGFBP4S) TGG GTT GCG AGG AGT TGG T






b. Heat shock protein 86
Product size: 830bp
Forward (HSP86S) CCA GTT AAT GTC CTT GAT CA









Forward (CYCG1S) ACT GAC AAC TGA CTC TCA GA
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